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Macrophages within atherosclerotic plaques are heterogeneous, with macrophage-colony stimulating 
factor (M-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) demonstrated to 
generate two different macrophage subsets (termed M-Mac and GM-Mac respectively). M-Macs 
display an elongated shape and are considered anti-inflammatory, due to their proposed roles in 
immune response suppression and induction of tissue repair. However, GM-Macs exhibit a rounded 
morphology and are regarded as pro-inflammatory. The actin cytoskeleton modulates cell shape and 
regulates cellular functions, which in macrophages includes the engulfment of apoptotic cells 
(efferocytosis), and phagocytosis of modified lipoproteins and subsequent foam cell formation, a 
hallmark of advanced atherosclerosis.  
The key findings within this thesis demonstrate that the actin-perturbing drugs fasudil and pravastatin 
reduced the F-actin content of human M-Macs and GM-Macs, which was associated with shifting 
macrophages towards an anti-inflammatory phenotype (increased TGFBI and decreased MMP-12), 
suggesting actin cytoskeleton remodelling regulates macrophage polarisation. In addition, fasudil or 
pravastatin decreased oxLDL-induced foam cell formation in human GM-Macs, which was associated 
with decreased protein expression of the scavenger receptors OLR1 and CD36, alongside increased 
levels of the cholesterol efflux molecules NCOR1, NCOR2, and PPARα suggesting actin cytoskeleton 
remodelling regulates foam cell formation. Relatedly, human GM-Macs displayed impaired 
efferocytosis capacity compared to human M-Macs, which could be restored to M-Mac levels through 
the addition of fasudil or pravastatin. However, discrepancies were observed between mRNA and 
protein levels of some key molecules, suggesting the involvement of a post-transcriptional regulatory 
mechanism, such as SUMOylation. Analysis of advanced human atherosclerotic plaques revealed 
increased pSTAT5 expression and decreased SUMO protein levels within foam cell macrophage-rich 
regions, suggesting reduced STAT5 SUMOylation in advanced plaques. Confirmatory in vitro studies 
showed that blocking STAT5 SUMOylation augmented foam cell formation and efferocytosis capacity 
in human GM-Mac foam cells while reducing their F-actin content. Preliminary mechanistic studies 
suggest that sustained STAT5 activation (afforded by blocking its SUMOylation) within human GM-
Macs upregulated OLR1 expression and its accumulation at the cell membrane, permitting enhanced 
efferocytosis effects dependent on actin cytoskeleton remodelling. 
Taken together, our results imply an essential role for the actin cytoskeleton in regulating the 
inflammatory phenotype of macrophages, including the novel regulation by STAT5 SUMOylation, 
suggesting that targeting actin cytoskeleton remodelling in GM-Macs, may have therapeutic potential 
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vvvvincreased foam cell formation compared to M-Macs derived from THP-1 cells 
4.5        Fasudil or pravastatin did not change the ability of intermediate M-Macs derived from 




4.6        Fasudil or pravastatin did not change the ability of mature M-Macs derived from THP-
vvv1 cells to accumulate oxLDL and form foam cells 
4.7        Fasudil or pravastatin reduced the ability of intermediate GM-Macs derived from THP-
vvv1 cells to accumulate oxLDL and form foam cells 
4.8        Fasudil or pravastatin reduced the ability of mature GM-Macs derived from THP-1 cells 
vvvvto accumulate ox-LDL and form foam cells 
4.9       GM-Macs derived from human blood-derived monocytes displayed increased foam 
mmcell formation compared to M-Macs 
4.10 Fasudil or pravastatin reduced the ability of GM-Macs derived from human blood-
mmderived monocytes to accumulate oxLDL and form foam cells 
4.11 Fasudil or pravastatin co-incubation reduced OLR1 protein expression in GM-Macs 
bbbderived from human blood-derived monocytes treated with oxLDL 
4.12 Fasudil or pravastatin co-incubation reduced CD36 protein expression in GM-Macs 
vvvderived from human blood-derived monocytes treated with oxLDL 
4.13 Fasudil and pravastatin co-incubation increased the percentage of NCOR1 positive 
mmGM-Macs derived from human blood-derived monocytes 
4.14 Fasudil and pravastatin co-incubation increased the percentage of NCOR2 positive 
mmGM-Macs derived from human blood-derived monocytes 
4.15 Fasudil and pravastatin co-incubation increased the percentage of PPARα positive   
mmGM-Macs derived from human blood-derived monocytes 
4.16 GM-Macs derived from human blood-derived monocytes display decreased 
vvvvefferocytosis capacity compared to M-Macs 
4.17 Fasudil and pravastatin increased the efferocytosis capacity of GM-Macs derived from 
vvvhuman blood-derived monocytes 
 
5. EFFECT OF SUMOYLATION ON MACROPHAGE SUBSET BEHAVIOUR AND VALIDATIVE 
STUDIES IN HUMAN ATHEROSCLEROTIC PLAQUES 
5.1        Summary of SUMOylation pathway 
5.2        The percentage of pTAT5A positive cells is increased in both stable and unstable 
mmhuman plaques 
5.3        The percentage of SUMO1 positive cells is increased in stable plaques and 
mmdecreased in unstable human plaques 




5.5        The percentage of SENP3 positive cells is increased in both stable and unstable human 
nnnplaques 
5.6        Effect of topotecan on M-Mac and GM-Mac cell viability 
5.7        Topotecan reduced the ability of early M-Mac and GM-Mac subsets derived from 
mmhuman PBMCs to accumulate oxLDL and form foam cells 
5.8        Topotecan reduced the ability of mature M-Mac and GM-Mac subsets derived from 
mmhuman PBMCs to accumulate oxLDL and form foam cells 
5.9        Topotecan addition alters the mRNA expression of select key lipoprotein-related        
mmscavenger receptors and lipid transporters in M-Macs and GM-Macs derived from 
nnnhuman PBMCs 
5.10 Topotecan reduced MSR1 and OLR1 protein levels in early and mature M-Macs 
mmderived from human PBMCs 
5.11 Topotecan significantly reduced the protein expression of scavenger receptors CD36 
nnnin GM-Macs derived from human blood monocytes 
5.12 Topotecan increased the efferocytosis capacity of GM-Macs  
5.13 Topotecan increased pSTAT5A levels in GM-Macs co-incubated with oxLDL  
5.14 Topotecan increased pSTAT5A expression in GM-Macs co-incubated with oxLDL  
5.15 HODHBt increased pSTAT5A expression in GM-Macs co-incubated with oxLDL 
5.16 HODHBt treatment reduced GM-Mac foam cell F-actin content 
5.17 HODHBt increased the ability of GM-Macs to accumulate oxLDL and form foam cells 
5.18 HODHBt addition upregulated the mRNA expression of OLR1 and MMP12 in GM-Mac 
nnnfoam cells 
5.19 HODHBt increased GM-Mac foam cell OLR1 protein expression  
5.20 HODHBt increased GM-Mac MMP-12 protein expression 
5.21 Predicted transcription factor binding sites within the promoter of human OLR1 
5.22 HODHBt increased GM-Mac foam cell co-expression of POU2F1 and pSTAT5A  
5.23 HODHBt increased the efferocytosis capacity of GM-Mac foam cells, but not non-
mmfoamy GM-Macs 
5.24 Fasudil co-incubation reduced the HODHBt-induced efferocytosis capacity of GM-Mac 
nnnfoam cells 
5.25 Nifepidine co-incubation did not alter the HODHBt-induced efferocytosis capacity of GM-
nnnMac foam cells  




5.27 Fasudil blunts HODHBt-mediated OLR1 membrane protein levels in GM-Mac foam 
nnncells 
 
6 GENERAL DISCUSSION 














List of Tables 
1.  
2. MATERIALS AND METHODS 
2.1.              Media composition for RPMI Reagent 
2.2.              Media composition for 10% FBS/RPMI Reagent 
2.3.              Program used qPCR on the LightCycler 480 system 
2.4.              List of primer used for qPCR 
2.5.              List of primary antibodies for Western Blotting 
2.6.              List of secondary antibodies for Western Blotting 
2.7.              List of primary antibodies for ICC 
2.8.              List of secondary antibodies for ICC 
2.9.              List of primary antibodies for IHC 
2.10. List of secondary antibodies for IHC 
 
3. EFFECT OF ACTIN-PERTURBING DRUGS ON THE POLARISATION OF DIVERGENT MACROPHAGE 
SUBSETS 
3.1.              Table summarising mRNA expression changes between THP-1 derived M-Mac and 
VVVVVGM-Mac subsets 
 
4. EFFECT OF ACTIN-PERTURBING GRUGS ON FOAM CELL FORMATION IN DIVERGENT 
MACROPHAGE SUBSETS 
4.1.             Table summarising mRNA expression changes between human monocyte-derived 
bbbbbearly, intermediate, and mature GM-Macs 
4.2.             Table summarising mRNA expression changes between human monocyte-derived    
hhhhhearly GM-Macs exposed to oxLDL, with and without fasudil or pravastatin treatment  
4.3.             Table summarising mRNA expression changes between human monocyte-derived 
hhhhhintermediate GM-Macs exposed to oxLDL, with and without fasudil or pravastatin 
bbbbbtreatment 
4.4.             Table summarising mRNA expression changes between human monocyte-derived 





















1.1 Epidemiology and aetiology of atherosclerosis 
Atherosclerosis is the major cause for the development of multiple cardiovascular diseases (CVD), such 
as coronary heart disease (CHD) and stroke. Although studies from the Global Burden of Disease (GBD) 
show a significant reduction in CVD mortality rates comparing the period from 1990 to 2013, it is still 
considered as a primary cause of fatality in the UK and worldwide with approximately 17 million 
deaths throughout the world, and 233,000 deaths in the UK yearly (Bhatnagar, Wickramasinghe et al. 
2016). The rate of development of atherosclerosis depends on different factors increasing its risk in 
certain patient groups more than others. The typical risk factors can be divided into two groups. The 
first group are non-modifiable risk factors including increasing age, male gender, genetic abnormalities 
for example, genetic defects that affects the plasma lipoprotein levels in the body (such as, familiar 
hypercholesterolemia), and family history of previous coronary artery disease (Kim and Han 2013). 
The second group are modifiable risk factors including cigarette smoking (Doll, Peto et al. 2005), 
hypertension, diabetes mellitus, hyperlipidaemia, and obesity (Guilbert 2003, Insull 2009) 
Atherosclerosis is now considered a chronic inflammatory disease, precipitated by endothelial cell 
dysfunction, which is focal and gradually develops over decades. It occurs at susceptible areas of large 
arteries (Insull 2009) and medium-sized arteries (Ross 1999), especially at curvatures or bifurcations. 
Atherosclerosis is characterised by the accumulation of extracellular lipid within the arterial wall 
accompanied by inflammatory cells (Libby, Ridker et al. 2002). The initial steps in the development of 
atherosclerosis can regress spontaneously while the later stages will progress continuously (Insull 
2009). The structure of a normal blood vessel consists of three layers, the intima, media, and the 
adventitia (as illustrated in Figure 1.1). The first layer that abuts the lumen of the vessel is called the 
tunica intima. The tunica intima (or intimal layer) is the thinnest layer consisting of one layer of 
endothelial cells located upon a basement membrane. Following the intimal layer is a dense elastic 
sheet called the internal elastic lamina (IEL) that separates the tunica intima from tunica media. The 
tunica media (or medial layer) is the thickest layer of all. The tunica media has an essential role in 
providing elasticity and to support the function of the vessel due to its composition of elastic fibres, 
vascular smooth muscle cells (VSMCs), and connective tissue. Beneath the medial layer is the external 
elastic lamina (EEL). Finally, the outermost layer is the tunica adventitia (or adventitial layer), which 






















Figure 1.1 Organisation of normal blood vessel 
Histology of a normal blood vessel composed of three layers. The innermost layer abutting the lumen 
is the tunica intima that consists of a monolayer of endothelial cells. Beneath it is the internal elastic 
lamina separating the intima from the media. The tunica media, which is the thickest layer consisting 
of vascular smooth muscle cells. And finally, Tunica adventitia that is separated from the media by the 













1.2 Pathogenesis of atherosclerosis 
Atherosclerosis is a disease that primarily affects the coronary and carotid arteries to precipitate 
myocardial infarction and stroke, respectively. During its inception, pre-atherosclerotic arteries are 
characterised by the presence of intimal thickenings accompanied by the accumulation of extracellular 
lipids. The lipoproteins which initially accumulate within the arterial wall (such as low-density 
lipoprotein (LDL)) become modified and finally oxidized. Oxidized LDL (oxLDL) can provoke an 
inflammatory reaction that triggers the recruitment of inflammatory cells and the development of 
atherosclerosis (Insull 2009). 
In 1990, Russel Ross proposed that the pathogenesis of atherosclerosis is initiated due to increased 
cholesterol concentrations within the plasma, predominantly LDL (Ross 1999). With the prolonged 
exposure to other risk factors that were mentioned earlier, such as smoking, hypertension, and 
diabetes mellitus, endothelial cells become dysfunctional at atherosclerosis-prone areas, a hypothesis 
referred to as response to injury (Ross 1999). These athero-prone sites are located mainly at branch 
points or curvatures within the arterial tree, where blood flow is disturbed and oscillatory in nature 
and accompanied by low shear stress (VanderLaan Paul, Reardon Catherine et al. 2004). Endothelial 
cells are able to sense changes in blood flow, and are relatedly termed as mechanosensitive and 
therefore play a major role in blood flow regulation through the release of different mediators such 
as endothelin (Chiu and Chien 2011). Endothelial cells also produce nitric oxide (NO) in an endothelial 
nitric oxide synthase (eNOS)-dependent manner and is a powerful oxidant that has athero-protective 
properties. NO exerts essential homeostatic actions that include vasodilation, decreasing the adhesion 
of leukocytes (Singh, Mengi et al. 2002), inhibiting the uptake of lipids, suppressing the proliferation 
of VSMCs (Ross 1999), and reducing platelet aggregation (Cooke and Tsao 1994). Disturbed low shear 
stress leads to the activation of different signalling pathways and causes widening of the junctions 
between the cells that resulting in increased permeability of endothelial cells (Li, Haga et al. 2005). 
Therefore, dysfunctional endothelial cells decrease their production of eNOS and increase their 
permeability (Smith, Trogan et al. 1995). Firstly, reduced eNOS levels permit medial VSMC migration 
and proliferation within the intimal area, fostering the development of an adaptive intimal thickening, 
the precursor to atherosclerotic plaque formation in humans. Therefore, these newly recruited VSMCs 
secrete and lay down specific extracellular matrix (ECM) proteins which have an increased affinity for 
the binding and retention of LDL (Stary , Nakashima, Fujii et al. 2007). Secondly, this causes increased 
insudation and accumulation of LDL within the adaptive intimal thickening of the arterial wall (Smith, 




















Figure 1.2 Endothelial dysfunction in the arterial wall 
Endothelial dysfunction due to different risk factors including hyperlipidaemia, cigarette smoking, and 
hypertension, alongside alterations in shear stress, permits the accumulation and modification of LDL 
via oxidation. OxLDL activates endothelial cells and increases the expression of adhesion molecules 





Atherosclerosis develops gradually over decades. Each stage of atherosclerotic development is 
characterised by specific pathological changes which permits the differentiation of each stage in 
pathogenesis from the other (Insull 2009). 
 
1.2.1 Fatty streaks/pathological intimal thickening 
As mentioned above, adaptive intimal thickenings at athero-prone sites serve as a soil-bed for the 
accumulation of lipids and ensuing inflammatory cell recruitment. This transition into an early pre-
atherosclerotic lesion is historically termed as a fatty streak, and more recently pathological intimal 
thickening (PIT) (Kolodgie Frank, Burke Allen et al. 2007). PIT is defined as an early stage of 
atherosclerosis, PIT identifies a lesion formed by extracellular accumulation of lipids with VSMCs are 
abundantly present in the thickened tunica intima and macrophages are infiltrated and become foam 
cells (Nakagawa and Nakashima 2018). Fatty streaks/PITs are the initial step in the development of 
atherosclerosis (Glass and Witztum 2001). The development of fatty streaks begins in early years of 
life (Insull 2009) and can be visible microscopically (Stary, Chandler et al. 1994, Insull 2009) due to 
streaks or patches that appear yellow in colour (Stary, Chandler et al. 1994). Even though fatty streaks 
can be visible grossly, not all initial lesions of atherosclerosis show changes in their appearance. On 
the other hand, all early lesions display similar histological changes within the intimal region of the 
arterial wall (Stary, Chandler et al. 1994). Microscopically, fatty streaks consist of droplets of lipid 
accumulated within a VSMC and ECM-rich intimal thickening, alongside accumulation of T cells, mast 
cells, and most dominantly macrophages, most of which exist as foam cell macrophages (lipid-laden 
macrophages) and are responsible for the yellow appearance on the vessel luminal surface (Hansson, 
Robertson et al. 2006) (as illustrated in Figure 1.3). Although within fatty streaks most of the 
accumulated lipids are engulfed by macrophages, recent evidence has proposed that VSMCs can also 
accrue modified lipoproteins and therefore contribute to foam cell numbers (Allahverdian, Chehroudi 
Ali et al. 2014, Maguire, Pearce et al. 2019). Demonstrating the efficient clearance of modified 
lipoproteins within these early lesions, only small amounts of lipids accumulate within the 
extracellular area which mainly consists of cholesterol esters (Stary, Chandler et al. 1994).  
Fatty streak development has multiple steps. It starts with increased levels of LDL-cholesterol (LDL-C) 
within the blood alongside the presence of different risk factors such as hypertension and smoking, 
facilitating the accumulation and subsequent trapping of LDL-C within the adaptive intimal thickenings 
located at athero-prone areas. At the lesion site, the homeostatic balance between different matrix 
components will be altered, increasing the content of proteoglycans such as heparan sulphate. As 




proteoglycan-rich adaptive intimal thickenings (Tavafi 2013). As a result of its accumulation alongside 
the prevalence of reactive oxygen species (ROS), LDL can be modified by oxidation (Glass and Witztum 
2001). OxLDL induces an inflammatory reaction through the activation of endothelial cells which 
subsequently upregulate and express cell adhesion molecules such as vascular cell adhesion protein-
1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), P-selectin, and E-selectin (Cybulsky and 
Gimbrone 1991). P-selectin and E-selectin have a pivotal role in the development of atherosclerosis 
since the deletion of both genes in Apolipoprotein E (Apoe)-deficient mice inhibited monocyte entry 
into athero-susceptible regions and decreased the formation of atherosclerosis by 60% (Dong, 
Chapman et al. 1998). Moreover, studies showed that Apoe-deficient mice lacking the ICAM-1 gene 
had significantly reduced formation of atherosclerosis (Collins, Velji et al. 2000). Subsequently, cell 
adhesion molecules have an important role in the recruitment of inflammatory cells to athero-prone 
areas during atherogenesis. Additionally, oxLDL can provoke the recruitment of monocytes to early 
atherosclerotic lesions by increasing the expression of monocyte chemoattractant protein-1 (MCP-1) 
(Navab, Berliner et al. 1996). Studies showed that deletion of MCP-1 gene or its receptor C-C 
Chemokine receptor 2 (CCR2) leads to a decrease in the development of atherosclerosis (Boring, 
Gosling et al. 1998). Monocytes within intimal thickenings are exposed to growth factors such as 
macrophage-colony stimulating factor (M-CSF) which will induce their differentiation into 
macrophages (Hansson, Robertson et al. 2006). Differentiation of monocytes into macrophages has 
an essential role in atherogenesis (Smith, Trogan et al. 1995). Macrophages upregulate the expression 
of different cell-surface receptors such as scavenger receptors (Hansson, Robertson et al. 2006). 
Scavenger receptors are important for the engulfment of oxLDL by phagocytosis and the formation of 
















Figure 1.3 Development of fatty streaks/PITs 
Fatty streaks/PITs within the arterial wall consists mainly of foam cell macrophages that give the 
yellow appearance of the affected area, as well as small amounts of extracellular lipid and T cells, 















1.2.2 Formation of atherosclerotic plaque 
Mature atherosclerotic plaques display distinct pathological characteristics. This includes the 
formation of a necrotic/lipid-rich core with a thick VSMC and ECM-rich fibrous cap, as a result of the 
core forming within a pre-existing intimal thickening (Stary, Chandler et al. 1994, Virmani, Kolodgie et 
al. 2000, Insull 2009, Bentzon, Otsuka et al. 2014). If the necrotic/lipid-rich core is extensive, it can 
force the fibrous cap to protrude into the vessel lumen affecting the normal blood flow within the 










Figure 1.4 Pathological changes associated with established atherosclerotic plaque formation. 
Established atherosclerotic plaques are characterised by the presence of a necrotic/lipid-rich core 
formed from cell debris, extracellular lipid, and cholesterol crystals, overlain by a VSMC and ECM-rich 
fibrous cap. Inflammatory cells, including foam cell macrophages and occasional T lymphocytes are 
located around the core, particularly between the core periphery and the fibrous cap. In the absence 
of expansive remodelling, established atherosclerotic plaques can markedly protrude into the vessel 
lumen and compromise blood flow. SMC, smooth muscle cell; ECM, extracellular matrix; TGFβ, 
transforming growth factor β; PDGF, platelet-derived growth factor Figure is taken from (Linton, 
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Under physiological conditions and in the presence of high-density lipoprotein (HDL), macrophages 
efflux lipoproteins to extracellular HDL through reverse cholesterol transport, preventing foam cell 
formation (Nissen, Tsunoda et al. 2003). During atherosclerosis, foam cell macrophages continue to 
accrue modified lipoproteins which ultimately results in their death (Falk 2006). Mechanistically, foam 
cell macrophages do not downregulate scavenger receptor expression and therefore, continually 
accumulate lipoproteins (Falk 2006), resulting in lysosomal dysfunction due to decreased levels of 
lysosomal acid lipase (Jerome 2006). Lysosomal acid lipase is an enzyme essential for the destruction 
of cholesterol within lysosomes (Griffin, Ullery et al. 2005). Accordingly, cholesterol esters amass 
within lysosomes and induce apoptosis of foam cell macrophages (Linton, Yancey et al. 2000). In 
addition, adjacent foam cell macrophages become defective in their efferocytosis capacity 
(engulfment and clearance of apoptotic cells), causing apoptotic foam cell macrophages to undergo 
secondary necrosis further perpetuating inflammation alongside the release of modified cholesterol 
(Badimon and Vilahur 2014). Consequently, death of foam cell macrophages leads to the formation of 
a lipid-rich necrotic core, that is characterized by being soft (gruel-like), lacking collagen support, 
avascular, and containing minimal cell numbers (Falk 2006). Unlike macrophages, VSMCs have 
incompetent functional lysosomes (which are necessary for the hydrolysis of cholesterol) (Jerome, 
Minor et al. 1991) along with low expression of ATP-binding cassette transporter (ABCA1), leading to 
the accumulation of lipids within the cells, and eventually death of VSMCs (Allahverdian, Chehroudi 
et al. 2014). Death of VSMCs has a destructive effect on atherosclerotic plaques, since VSMCs are the 
main source for the production of collagens, which are important for the stability of the fibrous cap 
(van der Wal and Becker 1999). Moreover, death of foam cell macrophages increases the expression 
and activity of matrix metalloproteinases (MMPs) (Libby, Ridker et al. 2002). Altogether, this causes 
destruction and weakening of the fibrous cap, and the development of a vulnerable plaque (van der 
Wal and Becker 1999). 
Advanced atherosclerotic plaques are classified into stable and unstable phenotypes according to their 
composition (van der Wal and Becker 1999). Stable plaques are featured by the presence of a thick 
fibrous cap composed of multi-layered VSMCs embedded within abundant fibrillar collagens. The thick 
fibrous cap forms a protective barrier between flowing blood and the highly-thrombogenic 
necrotic/lipid-rich core, and prevents bio-mechanical rupture of the plaque, and subsequent clinical 
consequences (Linton, Yancey et al. 2000). The fibrous cap is preserved by the regulation of athero-
protective growth factors and cytokines such as, transforming growth factor β (TGFβ) and interleukin 
10 (IL-10). Both TGFβ and IL-10 are released from anti-inflammatory cells including protective 
macrophage subsets and T-regulatory cells (Letterio and Roberts 1998). In support, studies showed 




development of advanced atherosclerotic plaques (Robertson, Rudling et al. 2003). Other studies 
showed that global deficiency of IL-10 in Apoe-deficient mice increases plaque development (Mallat, 
Besnard et al. 1999). IL-10 has also been proposed to enhance the stability of plaques by reducing the 
activation of MMPs and inhibiting thrombogenicity. It has been reported that IL-10 promotes the 
release of TGFβ and vice versa (Potteaux, Esposito et al. 2004). Alongside, T-regulatory cells inhibit the 
release of interferon γ (IFNγ) from pro-inflammatory macrophage subsets (Linton, Yancey et al. 2000).  
Accordingly, in the presence of sufficient efferocytosis capacity, inhibition of IFNγ, and the secretion 
of athero-protective cytokines (IL-10, and TGFβ) plaques are maintained as a stable phenotype and 
less prone to rupture. It has also been reported that stable plaques can undergo expansive/adaptive 
remodelling of their vessel wall to compensate for plaque volume, and therefore limit the 
encroachment into the lumen and prevent deleterious effects on blood flow and potential occlusion 
of the vessel (Falk 2006) (as illustrated in Figure 1.5). As such, stable plaques within coronary arteries 
are usually asymptomatic, but in the long-term can cause some clinical symptoms such as stable 























Figure 1.5 Pathological changes associated with the development of stable plaques. 
Stable plaques are characterised by the presence of a thick fibrous cap composed of several layers of 
vascular smooth muscle cells within collagenous extracellular matrix, small necrotic core containing 
cell debris, droplets of lipid and sparse cholesterol crystals. The stability of the plaque is preserved by 
increased secretion of TGFβ and IL-10 from T-regulatory cells and macrophages. A partially-occluded 
lumen can be seen due to the increase in the cellular contents within the vessel wall. TGFβ, 
transforming growth factor β; T-reg, T regulatory cell; IFNγ, interferon-γ; Th1, T helper cell type 1. 
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Conversely, unstable plaques (also termed vulnerable plaques) are the plaques with highest risk to 
rupture. They are characterised by the presence of an enlarged necrotic core (Rauch, Osende et al. 
2001). Enlargement of necrotic core is associated with increasing accumulation of extra-cellular lipids 
and free cholesterol. It has been reported that T cells within vulnerable plaques release IFNγ, which 
can polarise macrophages towards a pro-inflammatory phenotype (Linton, Yancey et al. 2000). Pro-
inflammatory macrophages increase the release of inflammatory chemokines, MMPs, and inhibit the 
release of anti-atherogenic cytokines including TGFβ and IL-10 (Linton, Yancey et al. 2000). Moreover, 
pro-inflammatory macrophages have inefficient efferocytosis capacity that will lead to the inability for 
these macrophages to engulf apoptotic macrophages (Dickhout, Basseri et al. 2008). The inability to 
eliminate the apoptotic macrophages leads to secondary necrosis of apoptotic macrophages and 
subsequent release of all their cellular contents, which will cause further enlargement of the necrotic 
core and perpetuate the inflammatory response (Thorp, Li et al. 2009). Necrotic core enlargement is 
also associated with intra-plaque haemorrhage (Rauch, Osende et al. 2001), and most importantly, 
with increased VSMC death (Badimon and Vilahur 2014). The death of VSMCs leads to decreased 
support within the fibrous cap due to the reduced collagen production and diminished cellular content 
(Felton, Crook et al. 1997). Indeed, it has been demonstrated that patients suffering from symptomatic 
unstable angina have a higher percentage of apoptotic VSMCs compared to patients with stable 
angina (Bauriedel, Hutter et al. 1999). Furthermore, the increased expression of MMPs 
(predominantly from focal aggregates of foam cell macrophage) leads to further fibrous cap 
destruction (Hansson, Robertson et al. 2006). Pathological studies of human ruptured coronary 
plaques showed that the main characteristics for a vulnerable plaque include a thin fibrous cap (<65 
µM), presence of haemorrhage, hyper-cellular content of foam cell macrophages and T cells within 
the plaque, as well as hypo-cellular content of VSMCs within the fibrous cap, and finally, an enlarged 
necrotic core accounting for more than 30% of atherosclerotic plaque area (Virmani, Burke et al. 2006) 
(as illustrated in Figure 1.6). Lipidomic studies demonstrated that the lipid fractions within plaques are 
different between stable and unstable lesions, indicating that stable plaques have more cholesterol 
esters, whereas unstable plaques have increased lysophosphatidylcholine content, indicative of 
increased oxidation levels within unstable plaques (Stegemann, Drozdov et al. 2011). Rupture of the 
plaque causes the release of pro-thrombotic factors and pro-coagulant factors, especially the release 
of tissue factor (TF), which is abundant within the necrotic core (Toschi, Gallo et al. 1997). TF is 
affiliated with the activated macrophages and initiates the coagulation process and thrombin 
formation (Toschi, Gallo et al. 1997). When TF is exposed to blood flow in the lumen, it interacts with 
factor VII which causes the activation of factor X. Factor X is important in the conversion of 




increasing the risk for thrombus formation (Gentry, Ye et al. 1995). Consequently, the formation of a 
thrombus at the site of plaque rupture is responsible for most of the related clinical events in CVD 
















Figure 1.6 Pathological changes associated with the development of unstable plaques. 
Unstable plaques are characterised by the presence of a thin fibrous cap, enlarged necrotic core with 
abundant extra-cellular lipid and cholesterol crystals, focal accumulations of foam cell macrophages 
at the shoulder regions, and diminished fibrous cap, VSMC, and collagen content. T cells within the 
vulnerable plaque release IFNγ generating pro-inflammatory macrophages. Pro-inflammatory 
macrophages inhibit the secretion of TGFβ and IL-10 and increase the release of MMPs, precipitating 
fibrous cap degradation and thinning. In addition, pro-inflammatory macrophages display inefficient 
efferocytosis, resulting in secondary necrosis. Altogether, these processes increase the susceptibility of 
plaque rupture and succeeding potential of thrombus formation. IFNγ, interferon-γ; MMP, matrix 
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Monocytes are the largest cell-type within the leukocyte/white blood cells (WBC) class. They display 
an amoeboid morphology with a unilobed nucleus and a non-granulated cytoplasm (Nichols, Bainton 
et al. 1971). Monocytes are the main effector cells during innate immune responses in the body 
(Nikiforov, Wetzker et al. 2019). Monocytes originate from pluripotent stem cells within the bone 
marrow. The monoblasts form pro-monocytes that are the direct progenitor cells of monocytes 
(Figure 1.7) (van Furth and Beekhuizen 1998). Within the bone marrow, monoblasts divide to form 
monocytes that remain within the bone marrow for around a day before entering the circulation. 
Within the circulation, monocytes’ half-life is up to 71 hours in humans (van Furth and Beekhuizen 
1998). Several factors and cytokines determine the formation of monocytes such as M-CSF, 
granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-3, as well as inflammatory factors 
such as factor increasing monocytopoiesis (FIM), which can double the number of circulating 
monocytes compared to under normal conditions, with the majority of them migrating toward the 
source of inflammation (van Furth and Beekhuizen 1998). Circulating monocytes in the blood do not 
proliferate, their role involves the removal of toxic substances and cellular debris (Auffray, Sieweke et 
al. 2009). It has been postulated that circulating monocytes can facilitate the renewal of tissue-
resident macrophages, such as Kupfer cells within the liver (Geissmann, Auffray et al. 2008). 
 
 
Figure 1.7 Origin of monocytes 
Monocytes originate from myeloid stem cells within the bone marrow. Pro-monocytes originate from 
monoblasts and are the direct precursor for monocyte production. Monocytes most commonly 











Flow cytometry and microscopy analysis of mouse monocytes have demonstrated the existence of 
different subsets that can be delineated according to their expression of different cell-surface markers 
(Johnson and Newby 2009). Monocytes which display high levels of lymphocyte antigen 6C, high levels 
of C-C chemokine receptor 2, and low levels of CX3C chemokine receptor 1 (Ly6ChighCCR2+CX3CR1low) 
expression are known as inflammatory monocytes, and can differentiate into dendritic cells and 
inflammatory macrophages (Kratofil Rachel, Kubes et al. 2017). Conversely, Ly6ClowCCR2-CX3CR1high 
monocytes are termed as patrolling monocytes, and are thought to survey the endothelium and 
underlying tissues for signs of damage. This action is mediated by binding of C-X3-C motif chemokine 
receptor 1 (CX3CR1) on the monocyte surface with β2-integrins on endothelial cells within small 
arteries, therefore, their role is associated with the processes of wound repair (Audoy-Rémus, Richard 
et al. 2008, Woollard and Geissmann 2010). Underlying their patrolling function, Ly6Clow monocytes 
stay for a longer time in the circulation compared to Ly6Chigh monocytes. On the other hand, their 
recruitment to inflammatory sites such as atherosclerosis is delayed and depends on the expression 
of C-X3-C motif ligand 1 (CX3CL1) (Johnson and Newby 2009). In contrast, although Ly6Chigh monocytes 
reside for a shorter time in the circulation, they can move to the inflammation site rapidly (Johnson 
and Newby 2009). Accordingly, studies showed the presence of Ly6Chighmonocytes within early 
atherosclerotic plaque lesions in mice (Swirski, Libby et al. 2007). The chemokines responsible for the 
recruitment of Ly6Chigh monocytes into atherosclerotic plaques are CX3CL1 and C-C motif ligand 2 
(CCL2). Indeed, it has been reported that the gene-deletion of CX3CL1 and CCL2 has an anti-
atherosclerotic effect on lesions in mouse models (Johnson and Newby 2009). Studies showed that 
the involvement of C-C chemokine receptor type 5 (CCR5) is also important for the migration of 
Ly6Chigh monocytes (Tacke, Alvarez et al. 2007). Therefore, these three chemokines and their receptors 
(CX3CL1/CX3CR1, CCL2/CCR2, and CCL5/CCR5) have a pivotal role in the recruitment and the entry of 
monocytes into mouse atherosclerotic plaques (Johnson and Newby 2009). While monocyte subsets 
have also been identified in humans, they are differentiated according to their cell-surface expression 
of Fc Fragment Of IgG IIIA (FCGR3A) which is more commonly termed CD16, and CD14 (Ziegler-
Heitbrock, Ancuta et al. 2010). Accordingly, three monocyte subsets have been identified in humans 
termed classical (CD14++CD16-), intermediate (CD14++CD16+), and non-classical (CD14+CD16++) 
(Thomas, Hamers et al. 2017). The Ly6Chigh monocytes in mice are considered the equivalent to 
CD14++CD16-population, while Ly6Clow monocytes in mice are thought similar to the CD14+CD16++ 
population in humans, based upon similar expression patterns of CCR2 (Johnson and Newby 2009). 
The CD14++CD16- population are more abundant compared to the CD14+CD16++ population and are 
considered anti-inflammatory due their production of anti-inflammatory cytokines such as IL-10 in 




deemed to have a pro-inflammatory effect as their numbers are increased during inflammatory 
responses and they are able to release pro-inflammatory cytokines and chemokines such as IL-8, IL-6, 
and CCL2 (Schlitt, Heine et al. 2004). However, the circulating numbers of classical CD14++CD16- 
monocyte subset have been shown to predict future cardiovascular risk, independent of their 
expression of chemokine receptors (Berg Katarina, Ljungcrantz et al. 2012). A study showed that 
primary human monocytes, isolated from the blood of patients suffering from atherosclerosis, can 
react to the presence of lipopolysaccharide (LPS) in a stronger manner which was demonstrated by 
the increase in the expression and the release of pro-inflammatory cytokines. This finding may suggest 
that monocytes in atherosclerotic patients obtained trained immunity (Bekkering, Blok et al. 2016). 
Furthermore, human monocytes subsets display differences in their responses to oxLDL, as 
CD14++CD16+ monocytes more readily phagocytose modified lipoproteins compared to 
CD14++CD16−monocytes (Mosig, Rennert et al. 2009). Moreover, the intermediate CD14++ CD16+ 
monocytes also show differences in their phagocytic capacity, while also displaying reduced ability to 
adhere to the substratum, alongside increased release of IL-12 compared to the CD14++CD16- 







1.4.1 Macrophage subsets in atherosclerosis. 
Macrophages within atherosclerotic plaques can originate from different sources, with some 
macrophages already residing in the adventitia and therefore called resident macrophages 
(Nagenborg, Goossens et al. 2017). Such macrophages are activated in the presence of inflammation 
and are considered as the first line of protection within tissues. Study in mice showed that adventitial 
resident-macrophages are embryonically originated from CX3CR1 positive precursors which express 
lymphatic vessel endothelial hyaluronan receptor 1 (Lyve1) (Ensan, Li et al. 2016). It has been reported 
that resident macrophages also express mannose receptor 1 (MRC1) known as CD206 alongside folate 
receptor β (Folr2) similar to anti-inflammatory macrophages, suggesting that the resident 
macrophages exert anti-inflammatory effects in the tissue (Kim, Shim et al. 2018).  
In addition to bone marrow-derived monocytes giving rise to macrophages, monocytes can originate 
from spleen, and together with bone marrow-derived monocytes, are known as the mononuclear 
phagocyte system (MPS). Monocytes from both reservoirs are released into the circulation and are 
recruited to tissues such as atherosclerotic plaques, during an inflammatory response (Xu, Jiang et al. 
2019). Within the same atherosclerotic plaque, it has been demonstrated that macrophages are 
heterogeneous and exist as different phenotypes. Macrophage subsets are highly dependent on the 
stimuli from the microenvironment such as cytokines, lipids, and haemorrhage (Xu, Jiang et al. 2019), 
and can be classified into anti-inflammatory and pro-inflammatory macrophage subsets (Mantovani, 
Sica et al. 2004). The pro-atherogenic stimuli such as oxLDL, not only effects macrophage polarisation, 
but also stimulates monocytes and precursor cells within the bone marrow (Murphy, Akhtari et al. 
2011). Recent controversial mouse studies have postulated that VSMCs can differentiate into 
macrophage-like foam cells in the atherosclerotic plaques due to their high proliferative capacity 
(Chappell, Harman et al. 2016). However, studies in human showed that these VSMC-derived 
macrophage-like cells are different from classical macrophages in salient functions such as 
efferocytosis and phagocytosis, as well as their transcriptional profile (Vengrenyuk, Nishi et al. 2015). 
The classically activated M1 and alternatively activated M2 macrophage subsets (and others) have 
been identified predominantly through in vitro studies. M1 macrophages are polarised in response to 
interferons, toll-like receptor ligand, lipoproteins, and lipopolysaccharides (Barrett Tessa 2020). They 
secrete pro-inflammatory mediators such tumour necrosis factor α (TNFα), IL-1β, and IL-6, 
contributing to tissue destruction (Martinez, Gordon et al. 2006, Wolfs, Donners et al. 2011). Pro-




light-chain-enhancer of activated B cells (NFĸB) and signal transducer and activator of transcription 
(STAT) (Barrett Tessa 2020). On the other hand, M2 macrophages display anti-inflammatory 
properties, they are polarised in response to IL-4, IL-10 and IL-13 (Wolfs, Donners et al. 2011). M2 
macrophages secrete anti-inflammatory mediators such as collagen and IL-10, and they are 
characterised by expressing high levels of arginase-1, and MRC1 (Barrett Tessa 2020). 
Colony stimulating factors (CSFs) are secreted glycoproteins that attach to receptors on the cell 
surface of hemopoietic stem cells, and have also been assigned an essential role in the regulation of 
macrophage heterogeneity (Di Gregoli and Johnson 2012). It has been reported that M-CSF and GM-
CSF can generate two different macrophage phenotypes in vitro, referred from hereon as M-Mac and 
GM-Mac, respectively. M-Mac and GM-Mac differ in their morphology, function, phagocytic capacity, 
and transcriptome (Di Gregoli and Johnson 2012). Under physiological conditions, M-CSF is expressed 
by numerous cell types including macrophages, VSMCs, and endothelial cells. On the other hand, GM-
CSF is weakly expressed by these cell types and requires stimulation by inflammatory cytokines such 
as TNFα or exposure to modified lipoproteins, in order to be upregulated (Di Gregoli and Johnson 
2012). During pathological conditions such as atherosclerosis, the expression of GM-CSF and the 
polarisation of macrophages toward a pro-inflammatory macrophages become dominant (Di Gregoli, 
Jenkins et al. 2014). Advanced human plaque is associated with high expression of GM-CSF, while cell 
surface expression of the M-CSF receptor is compromised, favouring macrophage polarisation to a 
GM-Mac phenotype (Di Gregoli, Jenkins et al. 2014). This can be reversed during the resolution of an 
inflammatory response where GM-CSF concentrations diminish (Hamilton 2008), suggesting that 
polarisation of macrophages is not terminal in the presence of a single CSF (Hamilton 2008) and there 
is a competition between different CSFs in macrophage differentiation and polarisation (Di Gregoli 
and Johnson 2012). Regarding cell morphology, M-Macs display an elongated shape compared to GM-
Macs which have a more rounded shape (Waldo, Li et al. 2008). During inflammation, GM-Macs 
release pro-inflammatory cytokines and proteases such as IL-23, TNFα, MMP-12, and MMP-14. In 
contrast, M-Macs secrete anti-inflammatory cytokines and factors such as, CD206, IL-10, arginase 1 
(ARG1), and selenoprotein 1 (SEPP1) (Verreck, de Boer et al. 2004). Accordingly, M-Macs are 








Figure1.8 Macrophage heterogeneity 
Macrophages can be differentiated into different subsets by stimulation with distinct colony 
stimulating factors (CSFs). The pro-inflammatory macrophages (on the left-hand side) are polarised by 
GM-CSF, giving rise to a phenotype displaying a rounded shape, and responds to tissue injury and 
cytotoxicity through the release of ROS, TNFα, MCP-1, MMP-12, and IL-23. 
Anti-inflammatory macrophages (on the right-hand side) are polarised by the presence of M-CSF, are 
elongated in shape, and proposed to play an essential role in the suppression of immune responses 
and induce tissue repair during healing, by the release of IL-10, TGFβ, PDGF, arginase 1, and SEPP1.  
GM-CSF, granulocyte macrophage colony-stimulating factor; INFγ, interferon gamma; TNFα, tumour 
necrosis factor alpha; M-CSF, macrophage colony-stimulating factor; IL, interlukein; TGFβ, 
transforming growth factor β; ROS, reactive oxygen species; MCP-1, monocyte chemoattractant 
protein-1; MMP, matrix metalloproteinase; PDGF, platelet-derived growth factor; SEPP1, 





1.4.2 Foam cell formation in macrophages 
Macrophages are well known for their ability to uptake oxLDL and transform into foam cell 
macrophages during atherogenesis and plaque progression. Unchecked uptake of oxLDL increases the 
esterification of cholesterol, while suppressed efflux of cholesterol leads to its accumulation within 
the cytoplasm as droplets, giving rise to foam cell formation and their distinguishable appearance 
under the microscope (Yu, Fu et al. 2013). The uptake of oxLDL is mediated by specific receptors known 
as scavenger receptors such as CD36 and macrophage scavenger receptor-1 (MSR1, also known as SR-
AI).It has been reported in mice that the inhibition of MSR1 decreases the ability of macrophages to 
engulf modified lipoproteins and transform into foam cells, subsequently preventing the further 
accumulation of macrophages within atherosclerotic lesions (Robbins, Hilgendorf et al. 2013). Studies 
in primary human macrophages showed that M-Mac and GM-Mac subsets differentially express genes 
related to cholesterol homeostasis (Waldo, Li et al. 2008). Both M-Mac and GM-Mac subsets are able 
to uptake lipids and form foam cells, but M-Macs capability to accumulate oxLDL is more rapid 
compared to GM-Macs, attributed to their increased expression of scavenger receptors (Irvine, 
Andrews et al. 2009). In addition, the M-Mac subsets have markedly lower expression of mediators 
for reverse cholesterol transport such as ABCG1, in comparison to GM-Macs (Irvine, Andrews et al. 
2009). Furthermore, the increased uptake of lipids by M-Macs causes changes in their behaviour, 
indicating a shift towards a pro-inflammatory phenotype as evidenced by reduced IL-10 expression 
and increased levels of MCP-1 and IL-6 (Di Gregoli and Johnson 2012). It has been postulated that this 
phenotypic change in M-Mac occurs in order for them to increase their ability to efflux cholesterol 
and lessen the formation of foam cells (Di Gregoli and Johnson 2012). Foam cell macrophages release 
several pro-inflammatory mediators inducing further recruitment of monocytes and associated 
accumulation of macrophages. 
 
  Scavenger receptors and toll-like receptors in macrophages 
CD36 and MSR1 are the most prevalent macrophage scavenger receptors and are responsible for 75-
90% of macrophage oxLDL internalisation (Kunjathoor, Febbraio et al. 2002). CD36 is a cell surface 
glycoprotein that is 88 kDa in size, and is expressed by multiple cell types other than macrophages, 
including VSMCs, platelets, and endothelial cells (Collot-Teixeira, Martin et al. 2007). CD36 was first 
discovered as a glycoprotein III b/IV in platelets (Yu, Fu et al. 2013), but subsequent studies with MSR1-
specific monoclonal antibody, identified its expression by monocytes (Talle, Rao et al. 1983). According 
to its structure and function, CD36 was classified as a member of class B scavenger receptor family. It 
is composed of two transmembrane extracellular regions and two cytoplasmic areas and has high-




(sn-2 acyl group) forming a specific characteristic in its structure that is essential for its high-affinity 
binding to CD36 (Kunjathoor, Febbraio et al. 2002). The expression of CD36 by macrophages is 
upregulated by the endocytosis of oxLDL and subsequent signalling through protein kinase C (PKC)- or 
PKB-dependent activation of the peroxisome proliferator-activated receptor gamma (PPARγ) pathway 
(Feng, Han et al. 2000, Munteanu, Taddei et al. 2006). It has been reported that deficiency in the 
expression of CD36 in old and young Apoe-deficient knockout mice leads to a decrease in the size of 
atherosclerotic plaques (Collot-Teixeira, Martin et al. 2007). On the other hand, studies showed that 
mice deficient for Apoe and CD36 showed increased atherosclerosis with heightened foam cells 
formation within aortic sinus lesions, suggesting that lipid uptake by plaque macrophages occurs in 
the absence of CD36 (Moore, Kunjathoor et al. 2005). Another study showed that patients with CD36 
deficiency are more prone to develop advanced atherosclerosis (Yuasa-Kawase, Masuda et al. 
2012).Taken together, the role of CD36 in the development of foam cell macrophages and 
atherosclerotic plaques requires further elucidation.  
MSR1 is a membrane glycoprotein that is about 77 kDa in size and represents another major 
macrophage scavenger receptor that has a vital role in the uptake of oxLDL. While under physiological 
conditions MSR1 expression is predominantly restricted to macrophages, specific growth factors and 
oxidative stress, can induce MSR1 expression by VSMCs and endothelial cells (Linton, Yancey et al. 
2000). Studies in Apoe knockout mice which were also deficient in MSR1 showed a significant 
reduction in the size of atherosclerotic plaques as alongside a 60% inhibition in macrophage foam cell 
formation (Babaev, Patel et al. 2000), supporting a pro-atherosclerotic role for MSR1. However, and 
similar to CD36, contrasting results have been reported with mice deficient for Apoe and CD36 
demonstrating increased atherosclerosis and macrophage foam cell formation within aortic sinus 
lesions, implicating alternative receptors can mediate lipid uptake by plaque macrophages in the 
absence of MSR1 and CD36 (Moore, Kunjathoor et al. 2005). Furthermore, it has been reported that 
MSR1 has other functions in macrophages such as mediating cell adhesion to ECM (Fraser, Hughes et 
al. 1993).  
The oxidized low-density lipoprotein receptor 1 (OLR-1), which is also known as lectin-like oxLDL 
receptor-1 (LOX-1), is a 50-kDa glycoprotein member of SR family class E. OLR1 was first identified in 
endothelial cells (Sawamura, Kume et al. 1997), but was later detected in several other cell types 
including macrophages, platelets, VSMCs, and fibroblasts (Kattoor, Goel et al. 2019). In addition to its 
role in oxLDL uptake, studies showed that OLR1 has an essential role in apoptosis, contribution to 
endothelial dysfunction, and macrophage foam cell formation (Kattoor, Goel et al. 2019). Expression 
of OLR1 is regulated by different mediators which includes oxLDL, TNFα, IFNγ, and IL-1 (Kattoor, Goel 




responses and conditions such as hypertension and diabetes mellitus upregulate the expression of 
OLR1 (Xu, Ogura et al. 2013). Studies in endothelial cells demonstrated that when bound to oxLDL, 
OLR1 induces an increase in the expression of MCP-1 and VCAM-1 (Aoyama, Sawamura et al. 1999). 
which in turn further increases OLR1 levels, revealing self-cycle activation between OLR1 and oxLDL 
(Feng, Cai et al. 2014). It has been demonstrated that OLR1 is able to bind MMP-14, triggering 
activation of Rac1 and Ras homolog family member A (RhoA) (Kattoor, Goel et al. 2019). Subsequently, 
RhoA reduces the production of eNOS while Rac1 increases the activity of nicotinamide adenine 
dinucleotide phosphate hydrogen (NADPH) oxidase, resulting in heightened production of oxidative 
stress and ROS (Sugimoto, Ishibashi et al. 2009).  
In addition to the scavenger receptor family, other types of receptor have the ability to identify and 
uptake oxLDL such as Toll-like receptors (TLRs) especially TLR2 (Kadl, Sharma et al. 2011), TLR4 (Choi, 
Harkewicz et al. 2009), and TLR9 (Karper, Ewing et al. 2012). TLRs are a family of proteins that have an 
essential role in the innate immune system and are expressed by multiple cell types including dendritic 
cells and macrophages. In mammals, 13 members of TLR family have been recognised and they are 
recognised as specialised receptors which identify pathogen-associated molecular patterns (PAMPs) 
(Cole, Georgiou et al. 2010). It has been demonstrated that TLRs and scavenger receptors can interact 
during atherosclerosis, resulting in activation of NFĸβ signalling pathway (Stewart, Stuart et al. 2010). 
Such activation leads to the release of pro-inflammatory mediators including TNFα and IL-12 (Cole, 
Georgiou et al. 2010). Studies showed that during atherosclerosis, the expression of TLRs especially 
TLR1, TLR2, and TLR4 is upregulated within inflammatory cells such as T and B lymphocytes, 
macrophages, VSMCs and endothelial cells (Xu, Shah et al. 2001). 
 
 Reverse cholesterol transport 
The removal of accumulated lipids within macrophages after the process of phagocytosis is known as 
cholesterol efflux. Cholesterol efflux is considered as the initial step of reverse cholesterol transport, 
which is the process where the cholesterol particles are transferred from peripheral tissues to the liver 
for biliary elimination (Yu, Fu et al. 2013). Lipids can be diffused passively through cell membranes or 
via an active mechanism through specific transporters such as SR-BI, ABCA1, and ABCG1 and then 
lipids are collected by ApoA1 and HDL (Yu, Fu et al. 2013). Mature HDL as well as lipid poor ApoA1 are 
considered as the main contributors in preventing the formation of foam cells by regulating the 
removal of cholesterol from macrophages. HDL transports cholesterol back to the liver via two 
different routes, either by binding to SR-BI (Acton, Rigotti et al. 1996) or through LDL and its receptors 




anti-atherogenic effect within atherosclerotic plaques (Nofer, Kehrel et al. 2002). Studies showed that 
injection of ApoA1 results in reduced expression of adhesion molecules on activated endothelial cells 
(Shaw, Bobik et al. 2008), through inactivation of the NFĸβ signalling pathway (Park, Park et al. 2003). 
Accordingly, HDL suppresses the recruitment of monocytes, the activation, proliferation, and 
accumulation of macrophages within atherosclerotic plaques by suppressing the expression of 
adhesion molecules in monocytes (Murphy, Woollard et al. 2008) through the inhibition of the PPARγ 
and NFĸβ signalling pathways (Bursill, Castro et al. 2010).  
ABCA1 is a member of the superfamily of ABC transporters which are expressed by macrophages and 
responsible for mediating cholesterol efflux via ApoA1 or Apoe (Fielding and Fielding 1995). It has 
been reported that ABCA1 has an essential role in the prevention of macrophage foam cell formation 
within atherosclerotic plaques. Studies showed that patients who carry a loss-of-function ABCA1 
mutation display low HDL-cholesterol levels accompanied with advanced atherosclerotic lesions when 
compared to controls (Bochem, van Wijk et al. 2013). Multiple pathways have been implicated in the 
regulation of ABCA1, with studies in THP-1 macrophages showing that agonism of the PPARγ and liver 
X receptor alpha (LXRα) signalling pathways increased ABCA1 expression, resulting in the enhanced 
cholesterol efflux (Lee, Moon et al. 2013). A further study noted that activation of the PKCα pathway 
enhanced expression of ABCA1 in macrophage foam cells differentiated from THP-1 cells (Liu, Lu et al. 
2013). Opposingly, it has been demonstrated that unsaturated fatty acids can inhibit the expression 
of ABCA1 in macrophages (Ku, Park et al. 2012). Furthermore, stimulation of THP-1 derived 
macrophages with IL-12 and IL-18 downregulated ABCA1 levels (Yu, Jiang et al. 2012).  
ABCG1 is another transporter that mediates the removal of cholesterol from macrophages through 
HDL particles via ApoA1. Supporting an athero-protective role for ABCG1 through facilitating 
macrophage cholesterol efflux, mice with bone marrow-restricted deficiency of ABCG1 expression 
displayed a significant increase in aortic root atherosclerotic plaque size (Out, Hoekstra et al. 2006). 
Regulation of the expression of ABCG1 is similar to ABCA1 since the activation of LXRα increases 
ABCG1 levels (Jun, Hoang et al. 2013). SR-BI also mediates the efflux of cholesterol via HDL, inferring 
an anti-atherosclerotic role. Indeed, bone marrow-restricted loss of SR-BI increased the development 
of atherosclerotic lesions in Apoe-deficient mice (Zhang, Yancey et al. 2003). However, although 
patients with deficiency in the expression of SR-BI suffer from blunted cholesterol efflux, they are at 







1.4.3 Efferocytosis in macrophages 
The process of efficient apoptotic cell removal is termed as efferocytosis (Yurdagul, Doran et al. 2018). 
Efferocytosis is important in maintaining homeostatic balance, resolution of inflammation, and 
allowing development of organs in the body (Arandjelovic and Ravichandran 2015). Efferocytosis is 
performed by professional cells (macrophages) and non-professional cells (neighbouring cells) 
depending on the setting. Macrophages rapidly migrate toward apoptotic cells and clear them through 
efferocytosis; accordingly, it is very rare to detect apoptotic cells in tissues (Hochreiter-Hufford and 
Ravichandran 2013). The migration of macrophages towards dying cells is regulated by specific 
mediators released from the apoptotic cells themselves such as ‘find me’ signals which includes 
chemokines such as CX3CL1, adenosine triphosphate (ATP) nucleotides, and lysophosphatidylcholine 
(Elliott, Chekeni et al. 2009). Accordingly, recruited macrophages are able to recognise specific signals 
known as ‘eat-me’ signals that are located on the surface of apoptotic cells and bind to specific 
macrophage receptors either directly or indirectly using bridging molecules (Yurdagul, Doran et al. 
2018). Internalisation of dead cells occurs in multiple steps. Initially, binding of dead cells to receptors. 
Therefore, after a proper binding between signals and receptors occur, reorganisation of the 
macrophage actin cytoskeleton takes place, which permits engulfment of dead cells to begin alongside 
triggering internalization of apoptotic cells in a process termed as ‘tether and tickle’ (Hoffmann , 
deCathelineau  et al. 2001). It has been reported that the formation of F-actin filaments within the 
phagocytic cup is promoted and regulated by Rho family of small GTPases such as RhoA, Cdc42, and 
Rac1 (Nakaya, Kitano et al. 2008). Internalised apoptotic cells are conjugated with microtubule-
associated protein 1A/1B-light chain 3 (LC3)-family of proteins that are specific autophagy proteins via 
a process known as LC3-associated phagocytosis (LAP) (Martinez, Malireddi et al. 2015). LAP enhances 
the fusion of phagosomes to lysosomes leading to degradation of the apoptotic cell via hydrolysis. 
Cholesterol particles resulting from the degradation process activates members of the PPAR and LXR 
signalling families, leading to upregulated expression of ABCG1 and ABCA1 in order to stimulate 
cholesterol efflux from macrophages (Kidani and Bensinger 2012).  
Efficient efferocytosis within the body is dependent on its rapidity and competence (Brown, Heinisch 
et al. 2002), with the recognition and targeting of apoptotic cells for efferocytosis occurring within 
minutes, explaining the low probability of detecting apoptotic cells in healthy and normal tissues 
(Ravichandran 2010). However, within advanced atherosclerotic plaques apoptotic corpses are readily 
detected, suggesting that the efferocytosis capacity in atherosclerotic lesions is markedly dysregulated 
in comparison to normal tissues (Schrijvers, De Meyer et al. 2005). Furthermore, impaired 
efferocytosis in macrophages is associated with suppression of reverse cholesterol transport (which is 




- a key driver of atherosclerotic plaque progression (Kojima, Downing et al. 2019). Whereas efficient 
efferocytosis suppresses pro-inflammatory responses by enhancing the release of anti-inflammatory 
mediators such as TGFβ and IL-10 from macrophages (Fadok, Bratton et al. 1998), impaired 
efferocytosis of apoptotic cells stimulates pro-inflammatory macrophage polarisation and propagates 
inflammation (Kojima, Downing et al. 2019). Finally, non-removed apoptotic cells undergo secondary 
necrosis (Ravichandran and Lorenz 2007), a process that involves the degradation of dead cell 
membranes and subsequent release of their contents, including multiple cytokines and chemokines, 
leading to enhanced inflammation and neovascularisation within the plaques, increasing their 
vulnerability to rupture (Mallat, Hugel et al. 1999). The mechanisms leading to impaired efferocytosis 
within atherosclerosis are poorly described (Schrijvers, De Meyer et al. 2005). It has been proposed 
that the marked increase in apoptosis overwhelms the efferocytosis capacity within advanced plaques 
(Thorp and Tabas 2009). However, a deficiency in efferocytosis is not exhibited during the early stages 
of atherosclerosis and data from studies suggested that the capacity of the efferocytosis system is 
sufficient to cope with the increased numbers of apoptotic cells seen in early plaques (Tabas 2010). It 
has also been suggested that during atherosclerosis, macrophage efferocytosis capacity is less efficient 
due to the number of efferocytosis-poor pro-inflammatory phenotypes outnumbering the content of 
efferocytosis-competent anti-inflammatory macrophages (Yamamoto, Yancey et al. 2011). Moreover, 
the increasing presence of ROS during plaque progression reduces the phagocytic capacity of 
macrophages (Schrijvers, De Meyer et al. 2005). Other studies noted that VSMCs, considered to 
display non-professional phagocytic capacity, lose their ability to uptake apoptotic cells when exposed 
to oxLDL (Clarke, Talib et al. 2010). Most importantly, it has been demonstrated that apoptotic cells 
within plaques are less ‘edible’ to macrophages compared to apoptotic cells in other parts of the body 
(Kojima, Weissman et al. 2017). Supportingly, it has been reported that expression of the ‘eat-me’ 
molecule calreticulin is decreased in dead intra-plaque cells making them more resistant for clearance 
by efferocytosis (Leeper, Raiesdana et al. 2013). Moreover, it has been reported that TNFα (which is 
upregulated in advanced atherosclerotic lesions) stimulates the expression of ‘don’t eat me’ molecules 
including CD47 on the membrane of apoptotic VSMCs (Kojima, Volkmer et al. 2016). This finding 
suggests the presence of a deleterious feedback loop where impaired efferocytosis stimulates the 
release of TNFα (Martinet, Schrijvers et al. 2011) and TNFα perpetuates the ineffective clearance of 
apoptotic cells by suppressing efferocytosis. Finally, oxLDL can trigger the generation of 
autoantibodies which mask the eat-me ligands upon the surface of apoptotic cells, preventing their 
recognition and clearance by macrophages (Shaw, Hörkkö et al. 2001). Furthermore, abundant oxLDL 
will compete with apoptotic corpses for the same scavenger receptors, further preventing the 




1.5 Actin cytoskeleton 
The cytoskeleton of eukaryotic cells has an essential role in maintaining and providing support to the 
intracellular components. The actin cytoskeleton is composed of three families of filamentous 
proteins which are subdivided according to their size; microtubules (which are the largest type of 
filaments); intermediate filaments; and the smaller actin filaments (Karp 2010). The actin cytoskeleton 
is a fundamental structure during biological functions such as morphogenesis during development, 
wound healing, and in immune defence (Dominguez 2014). It is well known that the actin cytoskeleton 
regulates cell shape and motility of cells through its ability to mediate the production of different 
cellular components such as filopodia, lamellipodia, and focal adhesions (Dominguez 2014). These 
elements have pivotal roles in maintaining the function of different cells, including immune cells such 
as macrophages, neutrophils, and monocytes. Pertinent to atherosclerosis (and as briefly mentioned 
in the previous section), reorganisation of the macrophage actin cytoskeleton facilitates their 
clearance of apoptotic cells (Hoffmann , deCathelineau  et al. 2001, Nakaya, Kitano et al. 2008). 
 
1.5.1 Structure of actin cytoskeleton 
The actin cytoskeleton of cells exists in two isoforms; polymeric filamentous actin (F-actin); and 
monomeric globular actin (G-actin). Actin is an ATP-ase and the hydrolysis of this nucleotide is crucial 
for the transition between filamentous and globular actin forms. The importance of the two actin 
isoforms arises from the fact that there must be a homeostatic balance between them for the stability 
of actin filaments (Hall 1994). As illustrated in Figure1.9, ATP-bound G-actin attaches to filaments at 
its so-called barbed (+) end, while the release of G-actin occurs from the pointed (-) end when in an 
adenosine diphosphate (ADP) bound state, a process that is known as actin filament treadmilling 
(Dominguez 2014). The polarity mentioned above controls the directional growth of actin filaments. 
The regulation of this procedure is tightly controlled by a family of proteins called actin binding 
proteins (ABP). It has been demonstrated that polymerisation of actin occurs at specific areas known 
as actin nucleation sites, which are located at the plasma membrane (Hall 1994). It has also been 
reported that the plasma membrane at these sites has numerous ABP located at the tips of 
lamellipodia and microspikes, for example, α-actinin, fimbrin, and talin. Other sites in the plasma 
membrane invested with actin filaments are focal adhesions alongside aggregations of integrins, and 
















Figure 1.9-Actin filament treadmilling 
Monomeric (globular) actin in an ATP-bound state attaches to the barbed (+) end of filaments while it 
is released from the pointed (-) end in ADP bound state. Figure is taken from (Lodish, Berk et al. 2008) 
 
 
The organisation of the actin cytoskeleton is controlled by a number of extracellular factors such as 
cytokines, chemokines and growth factors (Hall 1994). Signals received by the cell activate different 
types of receptors. For example, M-CSF stimulates the M-CSF receptors on macrophages and can lead 
to actin cytoskeleton remodelling (Pixley and Stanley 2004). Furthermore, signals transmitted through 
activated receptors trigger an arm of the Ras superfamily, the Rho family of small GTPases, including 
Rho, Rac, and Cdc42 (Hall 1994). Recent studies have identified a number of cytoskeleton effector 
proteins which interact with Rho GTPase family members. For example, Rho-associated kinase (ROCK) 
is activated by the small GTP-binding protein RhoA. ROCK exists in two isoforms, ROCK1 and ROCK2, 
which share 90% similarity in their kinase domains, and have vital roles in controlling functions of the 
cell such as regulating cell shape, migration, and proliferation (Zanin-Zhorov, Flynn et al. 2016)  
Another example of cytoskeleton effector proteins which can interact with Rho family of small 
GTPases (including Cdc42 and Rac) are the Cdc42/Rac interactive binding (CRIB) motif-containing 
proteins such as Wiskott-Aldrich syndrome Protein (WASP), and formins (Dominguez 2014). Moreover, 
these proteins are usually auto-inhibited by internal interactions, and can be activated by Rho family 
of small GTPases (Dominguez 2014). WASP is one of the most studied ABPs (Hall 1994) and is 
considered a nucleation promoting factor (NPF) as it attaches directly to the Actin related protein 2/3 
(Arp2/3) complex, an actin filament nucleation factor which promotes the assembly of new actin 
filaments (Jones 2000). The attachment between WASP and the Arp2/3 complex leads to activation of 
Arp2/3 protein and initiates nucleation of actin as both Arp2 and Arp3 form the initial subunits of new 




1.5.2 Role of the actin cytoskeleton in monocyte/macrophage migration and invasion 
During inflammatory responses, at the site of inflammation multiple pro-inflammatory and 
chemotactic mediators are released which are responsible for the recruitment of 
monocyte/macrophages (Iijima, Huang et al. 2002). The migration cycle of macrophages occurs in 
multiple steps that include briefly the protrusion of the plasma membrane due to actin cytoskeleton 
remodelling, attachment of integrins to adhesion sites, and finally the contraction of the cell toward 
the inflammatory site by actomyosin contraction (Lauffenburger and Horwitz 1996). Migration is 
initiated when macrophages sense pro-inflammatory chemokines and cytokines via specific receptors, 
this stimulates both Rho GTPase and phosphoinositide 3-kinase (PI3K) signalling pathways (Fukata, 
Nakagawa et al. 2003). These signalling pathways lead to rearrangement and remodelling of the 
macrophage actin cytoskeleton, forming cell protrusions at the leading edge toward the source of 
inflammation (Petrie, Doyle et al. 2009).  
It has been reported that polymerisation of the actin cytoskeleton leads to the formation of different 
types of protrusions depending on the type of migration needed for the cell such as, microspikes or 
filopodia (Ridley 2011). Microspikes are precursors of filopodia and are characterised as short in length 
(up to 20 µm) with a diameter around 0.1-0.2 µm and consist of bundles of F-actin. Filopodia are 
finger-like slender, tapering cytoplasmic projections that extend beyond the leading edge of 
lamellipodia in migrating cells (Jones 2000). It has been reported that filopodia have the ability to 
sense the external cytokines to provide the exact direction of migration for the cell (Yamaguchi and 
Condeelis 2007). The most common type of protrusions is pseudopodia and lamellipodia. Lamellipodia 
are characterised as flat, thin veil-like protrusions, which extend directly from the cell membrane, do 
not contain any organelles, and consists of networks of myosin II and F-actin filaments. Lamella, is a 
thick area located in between the cell and lamellipodia, which is described to have strong attachments 
to underlying substrates, and has organelles and networks of F-actin filaments (Chhabra and Higgs 
2007). The initiation of lamellipodia occurs through three different mechanisms that are responsible 
for the polymerisation of the actin filaments; the first mechanism is the generation of a new free 
positive end at the leading edge of an actin filament; second, is the uncapping of an actin filament that 
has a cap on it; and the third mechanism involves severing (and depolymerisation) of F-actin filament 
at the leading edge, by the ABP cofilin (Zigmond 2004).  
It has been reported that Arp 2/3 has pivotal role in mediating remodelling of the actin cytoskeleton 
and the formation of cell protrusions at the cell leading edge, in addition to its role in directing 
macrophage migration towards the site of inflammation (Suraneni, Rubinstein et al. 2012). Different 
cytokines and growth factors can stimulate chemotaxis in macrophages. M-CSF is the main growth 




Ohsawa et al. 2001). M-CSF is also considered as a chemoattractant for macrophages, at sites of 
infection and during atherosclerosis (Pixley 2012). Binding of M-CSF to its receptor leads to 
phosphorylation of this receptor tyrosine kinase and during downstream signalling, activates NPFs 
such as members of the WASP/WASP-family verprolin-homologous protein (WAVE) family via 
interaction with Rac and Cdc42, and eventually inducing actin cytoskeleton rearrangement 
(Mouchemore and Pixley 2012). Signalling through PI3K has an important role in chemotaxis, and can 
also stimulate Rho-GTPases, important regulators of the actin cytoskeleton. Moreover, it has been 
reported that there is an interaction between PI3K and CSF1R signalling via p85, and that CSF1R 
ligation with M-CSF interacts with multiple signalling pathways and complexes, which succeed in 
mediating cytoskeletal changes. SH2 domain-containing inositol phosphatase (SHIP) is an inhibitor of 
PI3K and bone marrow macrophages from SHIP-deficient mice show increased migratory capacity to 
M-CSF, and elevated levels of F-actin relative to wild-type control macrophages (Vedham, Phee et al. 
2005).  
The WASP family consists of five in members including WAVE1, WAVE2, WAVE3, N-WASP, and WASP. 
Members of the WAVE1-3 play an essential role in the formation of membrane ruffles and lamellipodia 
through the regulation of Rho-GTPase family members such as, Rac (Suetsugu, Kurisu et al. 2006), 
while N-WASP has a vital role in the formation of filopodia by the regulation of Cdc42 (Miki, Sasaki et 
al. 1998). It has been reported that WASP has an important role in guiding macrophages chemotaxis. 
Additionally, WASP has a pivotal role in the formation of podosomes in macrophages (Calle, Chou et 
al. 2004), which is a dynamic cell-ECM adhesive structures formed at the ventral surface of different 
cells such as macrophages, and composed of an actin rich core surrounded by adhesion proteins . 
Accordingly, WASP provides stability and support for lamellipodia by providing sufficient adhesion to 
the underlying substrate (Rougerie, Miskolci et al. 2013). Studies showed that the insufficient 
adhesion of lamellipodia causes the protrusion area to fold back, a process known as ruffling (Borm, 
Requardt et al. 2005). Forms of cell attachment to substrates are different, for example, focal 
adhesions use large contacts or attachments to the underlying substrate. On the other hand, 
macrophages use small point contacts to the substratum that are rich in phosphopaxillin, termed as 
focal complexes (Linder and Aepfelbacher 2003). Macrophages also use podosomes for their adhesion 
to ECM, and podosomes have larger contact surfaces than focal complexes. Podosomes are dynamic, 
located at the cell leading edge, and have a core rich with actin filaments mediated by the activation 
of Arp 2/3 and WASP family members. It has been demonstrated that podosomes have a ring of 
integrin receptors such as vinculin and talin that provide a link between the actin cytoskeleton (actin 




1 transmembrane heterodimeric glycoprotein receptors that mediate cell adhesion (Hood and 
Cheresh 2002).  
It has been demonstrated that during migration, cells are continuously breaking and forming contacts 
between integrins and ECM proteins. Integrins are able to stimulate intracellular signalling pathways 
to activate the Rho family of small GTPases (Rac and Cdc42) to control actin cytoskeleton 
reorganisation (Hood and Cheresh 2002). On the other hand, it has been reported that integrins may 
have a role in the release of MMPs such as MMP-2 and MMP-9, which can degrade and remodel the 
ECM (Mignatti and Rifkin 1993). Similar to other cytoskeletal characteristics, podosome formation is 
in part regulated by M-CSF via the PI3K signalling pathway (Wheeler, Smith et al. 2006). Moreover, 
podosomes are associated with remodelling of the ECM through the localised degradation of ECM 
proteins by matrix degrading enzymes (Burgstaller and Gimona 2005).  
It has been demonstrated that activation of Rac and Rho stimulates the formation of lamellipodia and 
stress fibres (Ridley and Hall 1992). Stress fibres are a cytoskeleton network consisting of F-actin 
bundles and myosin II, and are important for cell migration and adhesion due to their association with 
integrins and focal adhesions (Jones 2000). On the other hand, activation of Cdc42 stimulates the 
formation of filopodia, with a study revealing that Cdc42, Rho, and Rac can stimulate and activate each 
other to form different cellular protrusions (Ridley and Hall 1992). Another role for Rho family of small 
GTPases is to provide stability for cellular protrusions by regulating the formation of cell adhesion 
contacts. It has been reported that Cdc42 and Rac have key roles in the regulation of focal complexes 
while Rho is important for the regulation of focal adhesions (Jones 2000).  
For a cell to migrate it needs a specific level of force generated by the exterior adhesion and the 
interior tension (Palecek, Loftus et al. 1997). A study showed that the Rho family of small GTPases has 
an essential role in mediating the contractility of the cell. RhoB is important for the adhesion of the 
cell to the ECM via the regulation of integrin expression, and macrophages lacking RhoB have limited 
migratory capacity (Wheeler and Ridley 2007). On the other hand, RhoA mediates the retraction of 
the cell ‘tail’ during macrophage migration, through the regulation of myosin activity (Rougerie, 
Miskolci et al. 2013). Accordingly, the activity of myosin is connected to actin cytoskeleton dynamics.  
Interestingly, in order for migratory cells to reach their maximum velocity, adhesion levels of integrins 
to the ECM should be at intermediate levels. This is important as high levels of contact will make it 
hard for a cell to break the contacts, leading to immobilisation of the cell, while low levels of contact 
decrease the traction necessary for movement (Hood and Cheresh 2002). It is worth mentioning that 
there are other proteins involved in cell migration such as cortactin, an actin binding protein that has 




1.5.3 Role of the actin cytoskeleton in macrophage phagocytosis 
Phagocytosis can be defined as the uptake of cells and particles that are more than 0.05 µm in 
diameter (Aderem and Underhill 1999). Phagocytosis is dependent on cellular organisation of the actin 
cytoskeleton. Indeed, mouse macrophages are unable to uptake IgG-coated erythrocytes after 
treatment with the actin-perturbing drug cytochalasin B (Kaplan 1977). It has been reported that cells 
with a high rate of phagocytosis such as macrophages are characterised by the presence of specific 
phagocytic receptors such as Fc Fragment Of IgG receptors (FcRs) (Aderem and Underhill 1999). 
Demonstrating the importance of FcRs to phagocytosis, endothelial cells and fibroblasts transfected 
with cDNA encoding FcRs displayed significantly increased phagocytic capacity (Indik, Park et al. 1995).  
The most prevalent FcRs associated with the induction of innate immune responses in human 
macrophages are FcγRI (also known as CD64), FcγRIIA (also known as CD32), and FcγRIII (also known 
as CD16) (Ravetch 1997). FcγRIIA is composed of immunoreceptor tyrosine-based activation motif 
(ITAM) located in the cytoplasm, a transmembrane region, and Fc binding site located extracellularly. 
Binding of a ligand to the Fc receptor causes activation of the ITAM motif via phosphorylation. FcγRI 
and FcγRIII (CD16) share a similar structure with FcγRIIA (CD32) but lack the presence of ITAM within 
their cytoplasm (Ravetch 1997). Accordingly, FcγRI and FcγRIII bind to specific transmembrane 
proteins that display ITAM motif (Sanchez Mejorada and Rosales 1998). The initial phosphorylation of 
ITAM is mediated by the Src family of tyrosine kinases (Greenberg 1995); this triggers sequential 
activation of Syk kinase family members , leading to rearrangement and reorganisation of the actin 
cytoskeleton within the cell and eventually the formation of phagosomes (Ghazizadeh, Bolen et al. 
1995).  
Alternative downstream effectors of actin cytoskeleton reorganisation and phagosome formation 
have been proposed during Fc-mediated responses. First, PI3-kinase may contribute to Syk-dependent 
signalling necessary for FcγR-mediated phagocytosis, as mouse macrophages lacking Syk or exposed 
to a PI3-kinase inhibitor are still able to polymerise actin during FcγR-mediated phagocytosis of latex 
beads, but unable to internalise them (Crowley, Costello et al. 1997). The Rho family of small GTPases 
are also important regulators of the actin cytoskeleton (Caron and Hall 1998). Relatedly, the Rho family 
of small GTPases can regulate phagocytosis, as Rho inhibition in a mouse macrophage cell line 
suppressed FcγR aggregation, an initial step during phagocytosis (Hackam, Rotstein et al. 1997). 
Similarly, the downregulation of Cdc42 and Rac1 (with dominant-negative constructs) in a mouse 
macrophages cell line prevented the accumulation of actin filaments at the phagocytic cup, leading to 
the inhibition of phagocytosis (Cox, Chang et al. 1997). Finally, myosins (a family of motor proteins) 
participate in phagocytic cup development, as myosin II accumulates around the phagocytic cup in 




lipoprotein (Stendahl, Hartwig et al. 1980). Other myosin family members including myosin IX and 
myosin V may also participate in macrophage phagocytic cup formation due to their co-localisation 
with actin filaments during FcγR-mediated phagocytosis (Swanson, Johnson et al. 1999).  
 
Complement-receptors (CR) are also expressed by macrophages which can mediate phagocytosis. 
including CR1, CR3, and CR4 (Brown 1991). The mechanism of phagocytosis differs between CRs and 
FcRs. Although, both are dependent on reorganisation of the actin cytoskeleton. While FcγRs engulf 
material which has been coated with IgG antibodies, CRs bind material covered by complement. The 
relation of both receptor families to RhoA is considered another important difference between them, 
as CR-triggered phagocytosis requires the involvement of RhoA, whereas during FcγR-mediated 
phagocytosis the role of RhoA is controversial (Rougerie, Miskolci et al. 2013). FcR-mediated 
phagocytosis involves extensive remodelling of the actin cytoskeleton, requiring extensions from the 
plasma membrane to reach the surface of the material/particle until covering it completely, and the 
formation of an invagination pushes the particle toward the cell body in order to engulf it (Qualmann 
and Mellor 2003). Conversely, CRs opsonise material targeted for phagocytosis with minimal changes 
to their cell membrane, with the material sinking within the cells into the phagosomes, the contact 
areas are considered loose but rich with different cytoskeletal proteins such as, vinculin, paxillin, α-
actinin, and F-actin (Allen and Aderem 1996). Moreover, CRs require additional stimulation in order 
to opsonise material such as, GM-CSF and TNFα (Aderem and Underhill 1999). It has also been 
revealed that internalisation of particles via CRs does not induce oxidative burst or pro-inflammatory 
responses compared to phagocytosis via FcRs (Aderem and Underhill 1999). 
 
Macrophages can also utilise MRC1 for the phagocytosis of pathogens that express fucose or mannose 
on their surface (Stahl and Ezekowitz 1998). During MRC1-mediated phagosome formation, actin 
cytoskeleton modifications are required similar to CRs and FcRs, which includes different cytoskeletal 
proteins such as, talin and F-actin. However, unlike CRs and FcRs, paxillin and vinculin are not involved 
in MRC1-mediated phagosome formation (Allen and Aderem 1996). MRC1 ligation with pathogens 







1.5.4 Role of actin cytoskeleton in foam cell formation 
Macrophages are the major inflammatory cell type involved in the progression of atherosclerosis; 
macrophages readily internalise oxLDL. Excess free cholesterol (unesterified cholesterol) within 
macrophages is converted via acyl coenzyme A: cholesterol acyl transferase (ACAT) into cholesterol 
ester within the endoplasmic reticulum, which is subsequently stored as lipid droplets within the 
cytoplasm of macrophages (Martin and Parton 2006, Weibel, Joshi et al. 2012). It has been reported 
that cholesterol esters accumulate within the endoplasmic reticulum bilayer until the lipid droplets 
develop and bud off. Recent evidence has highlighted the potential participation of the cytoskeleton 
to macrophage foam cell formation. Microtubules are polymers of tubulin which form part of the 
cytoskeleton and facilitate the movement of lipid droplets within cells (Robenek, Hofnagel et al. 2006). 
Cytoskeletal proteins such as actin and tubulin have been identified bound to lipid droplets, potentially 
aiding their movement and storage alongside provision of stability and support to the droplets 
(Cermelli, Guo et al. 2006). Further support for an association between actin cytoskeleton 
reorganisation and foam cell formation is provided by the evidence that numerous cytoskeletal 
proteins are upregulated when macrophages accumulate modified lipoproteins (Becker, Gharib et al. 
2010). Furthermore, disruption of the actin cytoskeleton can inhibit the conversion of free cholesterol 
into cholesterol esters in macrophages (Tabas, Zha et al. 1994). In addition, the interaction between 
lipid droplets and cytosolic neutral cholesterol ester hydrolase is facilitated by cytoskeletal proteins, 
which is important for the formation of foam cells (Weibel, Joshi et al. 2012). Accordingly, cytoskeletal 
proteins appear to contribute to determining the size and composition of lipid droplets. Studies 
showed that disruption of the actin cytoskeleton of macrophages using actin perturbing drugs results 
in the formation of smaller lipid droplets with reduced cholesterol ester content, but enriched in 
triglycerides (Weibel, Joshi et al. 2012). More recent evidence demonstrated that macrophage foam 
cell formation in mouse atherosclerotic plaques is associated with depolymerisation and subsequent 
repolymerisation of F-actin via the activation of the Rho family of small GTPases Cdc42 and Rho, but 
not Rac1 (Singh, Haka et al. 2019). 
 
Accordingly, in this study we aim to modulate the actin cytoskeleton in two divergent macrophage 
subsets, M-Mac and GM-Mac, and assess effects on their phagocytosis, and foam cell formation, the 
key mechanisms involved in the progression of atherosclerotic plaques. As such, the findings should 
provide therapeutic insight into how strategies to modulate the macrophage actin cytoskeleton 






The actin cytoskeleton is differentially regulated in macrophage subsets and subsequently dictates 
their function and contribution to atherosclerosis. 
 
1.7 Aim 
To address the above hypothesis, the aims of this study are to: 
 Assess the effect of actin-perturbing drugs on macrophage polarisation. 
 Assess the effect of actin-perturbing drugs on foam cell formation in macrophage subsets. 
 Determine the effects of SUMOylation on differing modes of macrophage polarisation and 


















2.1 Cell culture of THP-1 cells and primary human macrophages 
 
2.1.1 Dulbecco’s Phosphate Buffered Saline (DPBS) 
Dulbecco’s Phosphate Buffered Saline free from magnesium and calcium (Themo Fisher Scientific; 
catalogue number: 14190), was used and stored at room temperature. 
2.1.2 Hank’s Balanced Salt Solution (HBSS) 
Hank’s Balanced Salt Solution with Phenol Red without calcium and magnesium (Lonza; catalogue 
number: BE10-543F), was used and stored at room temperature. 
2.1.3 Serum-free Roswell Park Memorial Institute 1640 (RPMI-1640) Medium 
RPMI 1640 without L-glutamine was purchased from Thermo Fisher Scientific (catalogue number: 
21870076) and supplemented as in Table 2.1. All supplements were filtered by using a syringe filter to 
prevent infection, mixed and finally stored at 4°C. 
Table 1: Media composition for RPMI Reagent 
Reagent Final Concentration Supplier 
Gentamycin 400 µl/500 ml PAA (P11-040) 
Penicillin and Streptomycin 100 lU/ml & 100 µl/ml PAA (P11-010) 
L-glutamine  2 mM PAA (M11-004) 
 
2.1.4 10% FBS/RPMI 1640 culture media 
Serum-free RPMI 1640 without L-glutamine (Thermo Fisher Scientific; catalogue number: 21870076) 
was supplemented with foetal bovine serum (FBS) gold to obtain 10% FBS/RPMI. All the components 
of 10% FBS/RPMI are listed in Table 2.2. FBS was added using a syringe filter to prevent infection, 
mixed well and finally stored at 4°C.  
Table 2: Media composition for 10% FBS/RPMI Reagent 
Reagent Final Concentration Supplier 
Foetal Bovine Serum 10% PAA (A11-151) 
Gentamycin 400 µl/500 ml PAA (P11-040) 
Penicillin and Streptomycin 100 lU/ml & 100 µl/ml PAA (P11-010) 





2.2 Culture of THP-1 cells 
THP-1 cells, which are a human monocytic cell line derived from an acute monocytic leukaemia patient, 
were obtained from ATCC (catalogue number: TIB-202). Cells were thawed using hot tap water, then 
10 ml of 10% FBS/RPMI media was added. Cells were centrifuged at 1500 rpm for 5 minutes. After 
discarding the supernatant, the cell pellet was resuspended in 10 ml 10% FBS/RPMI media. Cells were 
then transferred to a flask containing 30 ml of 10% FBS/RPMI media and incubated at 37 oC in 5% CO2. 
2.2.1 Subculturing of THP-1 cells 
To maintain cultures, the cell suspension was centrifuged at 1500 rpm for 5 minutes. After discarding 
the supernatant, the cell pellet was resuspended in 10% FBS/RPMI media. Cells were then added to a 
fresh flask at 1x105 per ml in 10% FBS/RPMI media. In order to maintain cells between 5x104 cells per 
ml and 8x105 cells per ml, medium was renewed, and cells density checked by counting every 3 days. 
2.2.2 Counting of THP-1 cells 
To maintain cultures, the THP-1 cells were counted using a Neubauer Chamber (Haemocytometer). To 
calculate the concentration of the cells, the following formula was applied: 
 
                           Concentration = Number of cells x 104 
                                                         Number of large corner squares (i.e up to 4) 
 
2.2.3 THP-1 cell seeding and differentiation into macrophages 
Counted cells were seeded at 1x105 cells/ml in fresh 10% FBS/RPMI media. To differentiate THP-1 cells 
into macrophages, cells were treated with 8.1 µM of Phorbol 12-myristate 13-acetate (PMA) (Sigma; 
catalogue number: P1585) for 72 hours prior to use. THP-1 cells differentiated into macrophages were 
treated with 20 ng/ml of either M-CSF (Miltenyi Biotec; catalogue number: 130-093-963), or GM-CSF 
(Miltenyi Biotec; catalogue number: 130-093-862) for 7 days by changing the media every 3 days to 






2.2.4 THP-1 cells storage 
Confluent cell suspension was centrifuged at 1500 rpm for 5 minutes. After discarding the supernatant, 
the cell pellet was resuspended in 1 ml of Cell Banker II cell freezing media (Amsbio; catalogue number: 
11891) and then transferred to cryovials. Cryovials were placed at -80 ºC freezer for 24 hours then 
stored under liquid nitrogen. 
 
2.3 Human monocyte isolation from fresh blood with SepMate-50 tubes 
Human peripheral blood mononuclear cells (PBMCs) were isolated from the whole blood of healthy 
donors, (which were collected under South West 4 Research Ethics Committee reference 
09/H0107/22) and diluted in PBS without calcium and magnesium (Themo Fisher Scientific) 1× (ratio 
1:1). Diluted samples were subjected to density gradient separation on 15 ml of Ficoll-Paque (Sigma; 
catalogue number: GE17-1440-02) within SepMate-50 tubes (Stem cell technologies; catalogue 
number: 85450). Keeping the tube vertical, diluted blood was added down the side of the tube, then 
the tube centrifuged for 10 minutes at 2,500 rpm at room temperature. After centrifugation, the top 
layer which contains the peripheral blood mononuclear cells (PBMCs) was tranferred (by pouring) into 
a Falcon tube. PBMCs were then washed three times using sterile HBSS (5-7 ml of buffer if 2-3 ml of 
blood was used) under centrifugation of 10 minutes at 1600 rpm for each wash. To isolate monocytes 
by adhesion, the cell pellet was resuspended in 10% FBS/RPMI media and 1 x 106 of cells (PBMCs)/well 
were added to 6-well tissue culture plate for two hours at 37 ºC. After two hourss, the non-adherent 
cells were removed by washing 3 times with sterile DPBS. To mature freshly isolated monocytes into 
macrophages, fresh 10% FBS/RPMI media supplemented with 20ng/ml of M-CSF (Miltenyi Biotec; 
catalogue number: 130-096-491) or GM-CSF (Miltenyi Biotec; catalogue number: 130-095-372) were 
added and cells were cultured for 7 days by changing 10% FBS/RPMI media supplemented with 20 






2.4 Molecular biology  
 
2.4.1 Cell lysis 
Cells were washed twice with DPBS and lysed in 350 µl of Buffer RLT obtained from RNeasy Plus Mini 
Kit (Qiagen; catalogue number: 74136). Before use, 10% β-mercaptoethanol was added to the buffer 
RLT to inactivate endogenous RNases. To facilitate lysis of cells, wells were scraped with a rubber 
plunger from a 1 ml syringe. Lysates were transferred to DNAse/RNAse-free eppendorf tubes and 
stored at -20 ºC freezer. 
2.4.2 RNA extraction and purification 
RNA isolation and purification were performed using the Qiagen RNeasy Plus Mini Kit (Qiagen; 
catalogue number: 74136). Cell lysates were transported to gDNA eliminator spin columns to shear 
genomic DNA and reduce viscosity of lysates, then centrifuged at 10,000 rpm for 30 seconds. To adjust 
binding conditions, 350 µl of 70% ethanol was added to each sample. Samples were then applied to 
RNeasy spin columns for the adsorption of RNA to the membrane and centrifuged at 10,000 rpm for 
15 seconds. Contaminants were removed with simple wash spins (700 µl of buffer RW1, and twice 
with 500 µl of buffer RPE). Finally, to elute the RNA, 30 µl of RNAse-free water was added and 
centrifuged at 10,000 rpm for 1 minute. Columns were discarded, and the RNA was stored at -20°C if 
not used immediately. 
2.4.3 RNA quantification 
The concentration of total RNA was assessed using a NanoDrop spectrophotometer (LabTech; model 
number: ND-1000). RNA samples (1.5 µl) were added to the NanoDrop to quantify the RNA 
concentration (ng/ml) by measuring the absorbance at 230 nm, 260 nm, and 280 nm. Samples with a 
260/280 ratio = 2.0 indicates pure nucleic acid content, whereas samples with 260/230 ratio ≤ 1.8 
(indicates the presence of contaminants such as proteins, ethanol or phenol) or a 260/230 ratio >2.2 
were excluded from further analysis. 
2.4.4 Reverse transcription polymerase chain reaction (RT-PCR) 
Reverse transcription of RNA to generate cDNA was performed using the QuantiTect Reverse 
transcription kit (Qiagen; catalogue number: 205311). Firstly, 2 µl of genomic DNA wipeout buffer was 
applied to each RNA sample to remove RNA secondary structure, then the sample was denatured at 




immediately cooled on ice. Subsequently, 6 µl of master mix was added to each sample, (composed 
of Quantiscript Reverse Transcriptase, Quantiscript RT Buffer, and RT Primer Mix) and incubated at 42 
ºC for 30 minutes, then at 95 ºC for 3 minutes. Finally, samples were cooled to 4 ºC and cDNA was 
stored at -20 oC. 
2.4.5 Quantitative PCR (qPCR) 
A LightCycler 480 SYBR Green I Master kit (Roche; catalogue number: 04707516001) was used to 
perform quantitative PCR (qPCR). Firstly, a SYBR Green Mastermix was added to each well of a 96 well 
plate (Greiner Bio-one; catalogue number: 669 285) and composed of 5 µl SYBR green, 3 µl PCR grade 
water and 1 µl primers. Secondly, 1 µl of cDNA was added to the Mastermix within each well. Samples 
of cDNA were previously normalised to the same concentration, were tested as duplicates, and a blank 
RT reaction sample was used as a negative control for each primer. Plastic plate sealers (Greiner Bio-
one; catalogue number: 676040) were used to seal the plates. The plates were then centrifuged at 
2,500 rpm for 30 seconds using an MPS-1000 mini-plate spinner (Labnet). The plates were then loaded 
onto a LightCycler 480 real-time PCR System (Roche) to detect cDNA sequences under the following 
conditions: 
Table 3: Program used qPCR on the LightCycler 480 system 
STEP TEMPERATURES (ºC) TIME 
Pre-Incubation 95 5 minutes 





















Cooling 40 -1.5 ºC/sec 
 
Individual genes within a sample generate a specific expression intensity which is presented as Cycles 
to Threshold (CT), this value indicates the cycle number whereby the amplified cDNA reaches a linear 
threshold of detection. The CT value is used to calculate the fold change in mRNA expression using the 
following equation: 
                                        𝑓𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 = 2 −∆C𝑇 




Considering all cDNA samples were run in duplicate, two CT values were generated per sample. 
These values were averaged to give a mean CT value for each sample. 
 
2.4.6 Primer design 
Primers for the analysis of qPCR were designed using the Primer Blast software available on the Sigma-
Aldrich website and purchased from Sigma. Additional pre-designed and validated QuantiTect primer 
assays were purchased from Qiagen if the Sigma primers proved problematic. The table below displays 
the characteristics of the primers used for qPCR analysis: 
 
Table 4: List of primers used for qPCR 
GENE FORWARD/REVERSE PRIMER SEQUENCE 
ABCA1 REVERSE CCTATGTGCTGCCATATGAAGCTG 
 FORWARD CTGGCAAGGTACCATCTGAGGTCT 
ABCG1 REVERSE CTGCACTGTGACATCGACGAGA 
 FORWARD CTCTGCCCGGATTTTGTACCTG 
CD36 REVERSE GTGAAGTTGTCAGCCTCTGTTCCA 
 FORWARD GTGCAAAATCCACAGGAAGTGATC 
CSF1 REVERSE TTGGGGTACAGGCAGTTGCAATCA 
 FORWARD CAAGGCCTGCGTCCGAACTTTCTA 
CSF1R REVERSE AGCTCAAGTTCAAGTAGGCACTCT 
 FORWARD TCCCTCAACAATCTGACTTTCATA 
CSF2 REVERSE AATATTCCCATTCTTCTGCCATGC 
 FORWARD ACTTTCTGCTTGTCATCCCCTTTG 
CSF2RA REVERSE ATGACATTTGGGGCCAGGCG 
 FORWARD CCGCCGTGCCTGGGTAAATT 
FSCN1 REVERSE CCTTGTTATAGTCGCAGAAC 
 FORWARD CAACATCAAAGACTCCACAG 
IL-10 REVERSE TCTATAGAGTCGCCACCCTGATGTC 
 FORWARD TCTTCCCTGTGAAAACAAGAGCAAG 
LOX-1 (OLR1) REVERSE GACAGCGCCTCGGACTCTAAATAA 
 FORWARD TGTTACCTATTTTCCTCGGGCTCA 
MMP12 FORWARD TTACCCCCTTGAAATTCAGCAAGA 
 REVERSE CGTGAACAGCAGTGAGGAACAAGT 
MRC1 REVERSE ATCCGTCCAAAGGAACGTGTGT 
 FORWARD AAATTGGCAAGAGGCACGAAAA 
MSR1 REVERSE GCCAGGGTTTGAGACAGAAAGTGT 




NCOR1 REVERSE ACGGCCCTCTTCAGTCTCCTCT 
 FORWARD GTTGGTGAGGAGCTGCTTGGTT 
PPARA REVERSE GGACTCAACAGTTTGTGGCAAG 
 FORWARD CCGAGCTCCAAGCTACTCTT 
RDX REVERSE TCGAGTCTGTTCTTCTAGTTC 
 FORWARD CATCAGAAGCAGTTGGAAAG 
SPARC REVERSE AAAGGGTTAAACCACAGGTCATTA 
 FORWARD GACACAAAAACACATGAGCATACA 
TGFBI  REVERSE GTTGGTGGCTAGGATGTCTTTATT 
 FORWARD CCCTAGTGAGACTTTGAACCGTAT 
TGFBR1 REVERSE CCATTGATATTGCTCCAAACCACA 
 FORWARD ATCGTCGAGCAATTTCCCAGAATA 
TGFBR2 REVERSE CGAAAGCATGAAGGACAACGTG 
 FORWARD ACTGAAGCGTTCTGCCACACAC 
TGFBR3 REVERSE AGTGTGTGCCTCCTGACGAAGC 
 FORWARD TGCTCCGATCACAAAGGCTGCA 
TIMP3 REVERSE CTCGTTCTTGGAAGTCACAAAGCA 
 FORWARD CTTCCGAGAGTCTCTGTGGCCTTA 
VCL REVERSE GATTTATTAGCAGTACCAACCG 
 FORWARD AGAGGTATTTGATGAGAGGG 
 
 
2.5 Western blotting  
 
2.5.1 Protein extraction by sodium dodecyl sulphate (SDS) lysis 
Cells were washed twice with DPBS and subsequently lysed using 100 µl of SDS lysis buffer (5% SDS, 
50 mm Tris hydrochloric acid (HCL) (pH 6.8), 10% glycerol). To facilitate lysis of cells, wells were scraped 
with a rubber plunger from a 1 ml syringe. Lysates were transferred to 0.5 ml eppendorf tubes and 
stored within a -20 ºC freezer until further anlaysis. 
2.5.2 Protein assay 
To calculate the protein concentration of samples, the colorimetric Bicinchoninic Acid (BCA) Assay kit 
(Thermo Scientific; catalogue number: 23235) was used in accordance with the manufacturer’s 
instructions. Using a 96-well plate, 140 µl of High-Performance Liquid Chromatography water (HPLC) 
grade water was added to the appropriate wells. To construct a standard curve, 0, 0.1, 0.25, 0.5, 1.0, 
2.5, 5.0 and 10 mg/ml of bovine serum albumin were used. Then, 1 µl of the sample was added to the 
appropriate wells, with all samples and standards analysed in duplicate. Next, 150 µl of BCA reaction 
mix solution (prepared from 50% of reagent A, 48% of reagent B, and 2% of reagent C) was added to 




nm in a GloMax plate reader (Promega). Finally, a standard curve was plotted, and the protein 
concentration of the samples calculated. 
2.5.3 Gel electrophoresis 
To ensure equal volume and protein concentration of each sample, the approrpaite volume of HPLC 
water was added to cell lysates. Before heating samples to 95 ºC for 5 minutes, 1.5 µl of Bromothenol 
blue and 1.5 µl of β-mercaptoethanol were added to each sample, to break all the disulfide bonds and 
denature the protein of interest, then, a BLUeye Prestained Protein Ladder (Geneflow; catalogue 
number: S6-0024) was prepared as a molecular weight marker. Samples were loaded into 7.5% Mini-
PROTEAN® TGX™ Stain-Free Gels (Bio-Rad; catalogue number: 456-8024) and subjected to 
electrophoresis through a 10% running buffer containing 1X Tris/ Glycine/ SDS (TGS) (Bio-Rad; 
catalogue number: 161-0732) in a Mini-PROTEAN® Tetra Cell (Bio-Rad; catalogue number: 165-8004) 
at 200 V for 35 minutes. 
After 35 minutes of electrophoresis, the precast gel packs were opened and placed within a ChemiDoc 
MP System and exposed to ultraviolet (UV) light for 5 minutes. The principle of stain-free gels is based 
on the interaction between tri-halo compounds (present in the precast gel) and tryptophan residues 
(present in proteins). This interaction produces a fluorescent signal which is activated and detectable 
under UV light. The images produced were used to both control and calculate the total protein amount 
loaded. 
2.5.4 Protein transfer 
Following electrophoresis and imaging under UV light, the Trans-Blot Turbo Transfer Starter System 
(Bio-Rad; catalogue number: 170-4155) was used to transfer seperated proteins within the gels onto 
a 0.2 µM mini nitrocellulose membrane (Bio-Rad; catalogue number: 170-4158) or 0.2 µM midi 
nitrocellulose membrane (Bio-Rad; catalogue number: 170-4159). 
2.5.5 Immunodetection  
After protein transfer, in order to avoid non-specific binding of subsequently deployed antibodies to 
the surface of the membrane, the membrane was incubated with a blocking solution consisitng of 5% 
skimmed milk powder in Tris-Buffered Saline-Tween (TBS-T) (20 mM Tris, 137 mM NaCl, 0.1% (v/v) 
Tween; pH:7.6) for one hour. Then, membranes were incubated with the relevant primary antibody 
diluted in SignalBoost Immunoreaction Enhancer Kit A (Merck Milipore; catalogue number: 407207-




Subsequently, membranes were washed with 5% skimmed milk powder/TBS-T (twice briefly and once 
for 60 minutes), then incubated with the relevant horseradish peroxidase (HRP)-conjugated secondary 
antibody (as detailed in Table 6) diluted in SignalBoost Immunoreaction Enhancer Kit B (Merck 
Millipore; catalogue number: 407207-1kit) for 1 hour at room temperature. The membrane was then 
subjected to multiple washes with TBS-T (twice briefly, twice for 30 minutes, and once for 5 minutes). 
Finally, any positive immuno-labelling was detected using a ChemiDoc MP Imaging System (Bio-Rad) 
after incubating the membrane with Luminate Forte Western HRP substrate (Merk Millipore; 
catalogue number: WBLUF0100). 
2.5.6 Densitometry 
To determine the density of detected bands (densitometry), Image Lab software (Bio-Rad) was used. 
In order to analyse and assess the differences between band densities, stain free gels were used to 
normalise the data obtained. 
Table 5: List of primary antibodies used for Western blotting 





TGFβI Goat 1/250 64 kDa Sc14741 Santa cruz 
OLR1 Mouse 1/500 31 kDa MABS186 Merck Millipore 
CD36 Rabbit 1/1000 90 kDa D8L9T Cell Signaling 
Technology 
NCOR2 Rabbit 1/500 220 kDa NB120-2781 Novus Biologicals 
MSR1 Goat 1/1000 80 kDa AF2708 R&D systems 
pSTAT5A Rabbit 1/1000 90 kDa PA5-37744 Invitrogen 
TGFβR1 Rabbit 1/500 56 kDa AB135814 abcam 
TGFβR2 Rabbit 1/1000 65 kDa AB186838 abcam 




Table 6: List of secondary antibodies used for Western blotting 





Anti-Goat Rabbit 1/1000 P0449 Dako 
Anti-Rabbit Goat 1/1000 P0448 Dako 





2.6 Immunocytochemistry on cell cultures 
 
2.6.1 Immunocytochemistry for F-actin using phalloidin 
Cells were seeded at 1x105 cells/well on 13mm circular glass coverslips in a 24 well plate. Cells were 
then fixed using 500 µl/well of 3% paraformaldehyde in DPBS for 10 minutes. Subsequently, wells 
were washed twice with DPBS. To permit permeabilisation of the cells and permit access to the F-actin 
filaments, cells were incubated with 0.2 % Triton/DPBS (500 µl/well) for 15 minutes, followed by three 
washes with DPBS (500 µl/well) for 3 minutes. Cells were then incubated with 400 µl of Image-iT™ FX 
fluorescence signal enhancer (Thermo Fisher Scientific; catalogue number: I36933) for 30 minutes to 
prevent non-specific binding of antibodies to cells. Cells were then incubated with (300 units/ml) 
AlexaFluor 594-phalloidin (Thermo Fisher Scientific; catalogue number: 21836) in DPBS (400 µl/well 
for 30 minutes in the dark). Cells were subsequently washed 3 times for 3 minutes with 500 µl/well of 
DPBS then coverslips were removed and mounted upon glass microscope slides with Prolong gold 
mounting medium containing DAPI (4’,6-diamindino-2-phenylindole) (Molecular Probes; catalogue 
number: P36931) for labelling of nuclei. Finally, a fluorescent microscope was used to visualise F-actin 
filaments (red) and nuclei (blue), and the percentage of nucleated cells positive for F-actin, or the F-
actin content within nucleated cells were assessed in six random x20 magnification fields per coverslip, 
with average number of cells in x20 magnification was approximately 200 cells/image, while average 
number of cells in x40 magnification was approximately 20 cells/image. 
2.6.2 Fluorescent immunocytochemistry (ICC) 
Cells were seeded at 1x105 cells/well on 13mm circular glass coverslips in a 24 well plate. All volumes 
used for the 24 well plates were between 250 and 500 µl per well. Cells were then fixed using 3% 
paraformaldehyde in DPBS for 10 minutes. Subsequently, wells were washed twice with DPBS and 
subjected to permeabilisation through incubation with 0.2 % Triton/DPBS for 15 minutes, followed by 
washing with DPBS for 2 minutes. Next, cells were incubated in Image-iT™ FX fluorescence signal 
enhancer (Thermo Fisher Scientific; catalogue number: I36933) for 30 minutes to prevent non-specific 
binding of antibodies to cells. Liquid was carefully removed, and cells were incubated with relevant 
primary antibody diluted in DPBS at 4 ºC overnight (see Table 7). The next day, cells were washed 3 
times for 2 minutes with DPBS and then incubated with relevant fluorescently-conjugated secondary 
antibody for 1 hour at room temperature in the dark (see Table 8). Cells were washed 3 times for 3 
minutes with DPBS, then coverslips were removed and mounted upon glass microscope slides with 




catalogue number: P36931) for labelling of the nuclei. Finally, a fluorescent microscope was used to 
image and count cells within ten random x 40 magnification fields. Data is presented as percentage of 
nucleated cells (blue) immune-labelled positive (green or red). Quantification was done blinding using 
manual counting. 
 
Table 7: List of primary antibodies used for ICC 





TGFβI Goat 1/250 Sc14741 Santa cruz 
MMP-12 Mouse 1/500 ab56305 Abcam 
PPARα Rabbit 1/500 NBP1-03288 Novus Biologicals 
NCOR1 Rabbit 1/800 E4S4N Cell Signaling Technology 
POU2F1 Rabbit 1/1000 GTX105202 GeneTex 
SPARC Mouse 1/500 MAB941 R&D systems 
pSMAD3 Rabbit 1/250 44-246G Invitrogen 
NCOR2 Rabbit 1/500 HPA001928 Sigma 
pSTAT5A Rabbit 1/200 C71E5 Cell Signaling Technology 
OLR1 Mouse 1/250 MABS186 Merck Millipore 
 
Table 8: List of secondary antibodies used for ICC 





Anti-Goat-DyLight 488 Horse 1/200 DI-3088 Vector laboratories 
Anti-Rabbit-DyLight 488 Horse 1/200 DI-1088 Vector laboratories 
Anti-Mouse-DyLight 488 Horse 1/200 DI-2488 Vector laboratories 
Anti-Rabbit-DyLight 594 Goat 1/200 A11012 Invitrogen 
 
 
2.6.3 Live/dead assay 
To assess the incidence of cell death, a Ready Probes cell viability imaging kit (blue/green) (Thermo 
Fisher Scientific; catalogue number: R37609) was used. Cells were seeded at 1x105 cells/well in a 24 
well plate. After the appropriate experimental conditions, two drops each of NucBlue Live and 
NucGreen Dead reagents/ml were added to each well and incubated for 20 minutes. An inverted 
fluorescence microscope was used to image and count the number of dead (green labelled) and live 




2.7 Oil red O histochemistry on cells 
Cells were seeded at 1x105 cells/well on 13mm circular glass coverslips in a 24 well plate and co-
incubated with 10 µg/ml Dil-conjugated human oxidized low-density lipoprotein (Dil-oxLDL) (Thermo 
Scientific Fisher; catalogue number: L34358) for 24 hours to assess lipid accumulation and subsequent 
foam cell formation. The next day, cells were fixed with 3% paraformaldehyde in DPBS and rinsed in 
DPBS. Afterwards, cells were rinsed in 60% isopropanol for approximately 20 seconds to permeabilise 
the cells, then stained wih Oil red O which is a fat soluble dye that is used for staining neutral 
triglycerides and lipids, for 15 minutes at room temperature. Oil red O was removed carefully, and 
cells were rinsed in 60% isopropanol for approximately 20 seconds. For brightfield microscopy 
assessment, cells were washed in distilled water and subsequently stained for 3 minutes with Mayer’s 
haematoxylin (Merck; catalogue number: 100579). Cells were then incubated in tap water for 5 
minutes to aid ‘blueing’ of the nuclei. Coverslips were removed and mounted upon glass microscope 
slides with VectaMount AQ Aqueous Mounting Medium (VectorLabs; catalogue number: H-5501-60). 
For Fluorescence microscopy assessment, cells were washed in distilled water, coverslips removed, 
and mounted with ProLong gold mounting medium containing DAPI (Molecular Probes; catalogue 
number: P36931) for labelling the nuclei. Finally, cells were analysed with a brightfield or fluorescent 
microscope respectively, to visualise lipid accumulation (red). Data is presented as percentage of 
nucleated cells (blue) with lipid accumulation (red) and termed as foam cell macrophages. 
 
2.8 Efferocytosis assay 
Recipient PBMC monocyte-derived monocytes macrophages were seeded at 1x105 cells/well in a 24 
well plate. To produce apoptotic labelled macrophages, THP-1 cells were differentiated into 
macrophages and seeded at 1x105 cells/well in a 24 well plate, and labelled with 5µM Vybrant® CFDA 
SE (carboxyfluorescein diacetate, succinimidyl ester) Cell Tracer Kit (Invitrogen; catalogue number: 
V12883) in DPBS for 15 min at room temperature. The cells were then placed in fresh 10% FBS/RPMI 
media for six hours. To induce apoptosis, cells were washed twice with DPBS and then 2.5 ng/ml of 
Super-Fas-Ligand (Enzo; catalogue number: ALX-522-020-C005) in serum free medium was added and 
cells incubated for 24 hours. For assessment of efferocytosis, the labelled apoptotic THP-1 
macrophages which were in suspension (which have therefore undergone apoptosis and detached) 
were collected, vortexed and resuspended in 10% FBS/RPMI medium. At the same time the recipient 
cells were washed twice with DPBS and then co-incubated with the 10% FBS/RPMI media containing 




and the green fluorescence channel using an inverted fluorescence microscope, within six random x20 
magnification fields per well. Data was presented as the percentage of macrophages containing 
fluorescently-labelled apoptotic cells. 
 
2.9 Cell Fractionation assay 
To permit the assessment of protein expression within cell membrane fractions alone, a Cell 
Fractionation kit (Cell Signaling Technologies; catalogue number: 9038) was used. Cells were seeded 
at 1x105 cells/well in a 24 well plate and exposed to the appropriate experimental conditions. All 
subsequent steps were perfomred on ice or at 4 °C, with the exception for the addition and sonication 
of the CyNIB buffer. Cells were washed with cold PBS once, and then trypsinised through incubation 
with 0.5% Trypsin-EDTA (Thermo Fisher Scientific; catalogue number: 15400054) at 37°C, 5% CO2 for 
5 minutes until cells were detached from the plate. Cold 10% FBS/RPMI media was then added to 
deactivate the trypsin. Next, cells were collected and centrifuged at 1,000 rpm for 5 minutes. The 
supernatant was then discarded, and the cell pellet was washed with cold PBS. To separate the 
cytoplasmic fraction, cells were centrifuged at 1,400 rpm at 4 °C for 5 minutes and the supernatant 
discarded. The remaining cell pellet was resuspended in cytoplasm isolation buffer, vortexed for 5 
seconds and incubated on ice for 5 minutes, then centrifuged for 5 minutes at 1,400 rpm. The 
supernatant was saved which represents the cytoplasmic fraction. To separate the membrane fraction, 
the cell pellet was resuspended in membrane isolation buffer, vortexed for 15 seconds, then incubated 
on ice for 5 minutes. Cells were then centrifuged at 10,000 rpm for 5 minutes and the supernatant 
was saved, which represents the membrane fraction. To separate the cytoskeletal and nuclear fraction, 
the cell pellet was resuspended in cytoskeleton/nucleus isolation buffer, sonicated for 5 seconds at 
20% power for 3 times and saved. This represents the cytoskeletal and nuclear fraction. All lysates 
were stored within a -20 °C freezer. 
 
2.10 Immunohistochemistry of human coronary atherosclerotic plaques 
 
2.10.1 Human coronary samples 
Coronary artery segments were collected from cadaveric heart donors from the Bristol Valve Bank and 




(08/H0107/48). The patients with coronary arteries histologically defined as non-diseased, harbouring 
stable, or unstable plaques (n=10/group) were of similar age and gender ratio, as described previously 
(Di Gregoli, Somerville et al. 2020). Coronary artery plaques were histologically classified as stable or 
unstable through evaluation of intraplaque cellular content, lipid/necrotic core size, and collagen 
amount, as shown to be effective delineators in human coronary plaque phenotyping (Davies, 
Richardson et al. 1993, Falk, Nakano et al. 2013), and as described previously (Di Gregoli, Jenkins et al. 
2014, Di Gregoli, Mohamad Anuar Nur et al. 2017). 
 
2.10.2 Immunohistochemistry (IHC) 
Serial paraffin sections were deparaffinised through incubation with Clearene (Surgipath) for three 
periods of 5 minutes. Afterwards, sections were rehydrated with incubation in 100% ethanol twice for 
5 minutes, once in 90% (v/v) ethanol for 5 minutes, once in 70% (v/v) ethanol for 5 minutes, and finally 
5 minutes in HPLC water. To ensure efficient antigen retrieval, sections were microwaved for 2 x 6 
minutes in 10 mM citrate buffer (pH 6.0). Slides were left for 30 minutes at room temperature to cool, 
and then transferred for 5 minutes under running tap water. Slides were then washed 3 x 5 minutes 
with PBS, and then the tissue sections delineated using a hydrophobic wax pen (ImmEdge Pen; Vector 
Labs; catalogue number: H-4000). In order to inhibit endogenous peroxidase activity, slides were 
incubated with BLOXALL Blocking Solution (Vector laboratories; catalogue number: SP-6000) for 10 
minutes. Slides were then incubated with 10% (v/v) horse serum/PBS for 30 minutes at room 
temperature. This was followed by 3 washes in PBS and incubation with 50 µl of appropriate primary 
antibody (see Table 9 for details) diluted in PBS, overnight at 4 °C. A negative control was included 
using the same species IgG diluted to the same IgG concentration as the primary antibody that was 
used. Next day, sections were washed 3 times in PBS then incubated with 50 µl of relevant biotinylated 
secondary antibody (see Table 10 for details) diluted in PBS, for 30 minutes at room temperature. 
Again, sections were washed 3 times with PBS then incubated with 50 µl of Extravidin-horseradish 
peroxidase (Sigma; catalogue number: E2886) diluted 1:200 in PBS, for 30 minutes at room 
temperature, followed by 3 washes with PBS. To detect antibody labelling, 250 µl of SIGMAFAST 3,3’-
Diaminobenzidine (DAB) Peroxidase Substrate (Sigma; catalogue number: D4293) was added to 
sections for 10 minutes at room temperature and then sections were washed in tap water. To visualise 
cell nuclei, sections were subsequently stained for 3 minutes with Mayer’s haematoxylin (Merck; 
catalogue number: 100579). Slides were then washed in tap water for 5 minutes to remove 
haematoxylin and aid ‘blueing’ of the nuclei. Sections were then dehydrated through 5-minute 
incubations in a graduated ethanol series (once in 70% ethanol, once in 90% ethanol, and twice in 100% 




mounted with coverslips in DPX mountant (Merck; catalogue number: 109249). Cells with both blue 
and brown staining were detected as positive nucleated cells, where cells with only blue nuclei were 
considered as negative cells. Ten fields at x40 magnification were acquired per section using a 
computerised image analysis program (Image Pro Plus; DataCell, Maidenhead, United Kingdom). The 
percentage of positive cells was quantified using ImageJ.  
 
Table 9: List of primary antibodies used for IHC 
Antibody Species Dilution used Catalogue number Company 
SENP1 Rabbit 1/100 HPA011765 Sigma 
pSTAT5A Rabbit 1/100 PA5-37744 Invitrogen 
SUMO1 Rabbit 1/50 4930S Cell Signaling Technology 
SUMO2/3 Rabbit 1/100 NBP1-95473 Novus biologicals 
 
 
Table 10: List of secondary antibodies used for IHC 
Antibody Species Dilution used Catalogue number Company 
Anti-Rabbit IgG-Biotin Goat 1/200 B7389 Sigma 
 
 
2.11 Statistical analysis 
Values are expressed as mean ± standard error of the mean (SEM). Group values were compared using 
Graphpad Instat. Data from THP-1 cell and monocyte/macrophage experiments comparing two 
groups was analysed using a two-tailed, paired t-test. An analysis of variance (ANOVA) multiple 
comparison test with Student-Newman-Keuls Multiple Comparisons tests was used for experiments 
with greater than two comparison groups. In all cases, statistical significance was concluded when the 
two-tailed probability was less than 0.05. N-values in macrophages differentiated from THP-1 cells 
represent number of replicates, while n-values in Human peripheral blood mononuclear cells (PBMCs) 
represent the number of healthy donors and n-values in plaque samples represent number of patients 
with coronary arteries histologically defined as non-diseased, harbouring stable, or unstable plaques 













3 EFFECT OF ACTIN-PERTURBING DRUGS ON THE 







3.1.1  THP-1 as a model for human macrophages 
THP-1, which is a cell line, originated from a child patient suffering from acute monocytic leukaemia, 
and were established first by Tsuchiya et al in 1980 (Tsuchiya, Yamabe et al. 1980). This cell line is 
universally used as a model to study the behaviour and function of macrophages (Chanput, Mes et al. 
2014). THP-1 cells display as round single nucleated cells in suspension and express specific monocytic 
markers (Qin 2012). It has been reported that differentiation of THP-1 cells into macrophage-like cells 
can be achieved either by incubation with phorbol-12-myristate-13-acetate (PMA), or 1 α,25-
dihydroxy vitamin D3 (vD3) for 72 hours (Chanput, Mes et al. 2014). It has been shown that the 
majority of THP-1 cells treated with PMA stick to tissue culture surfaces and change their morphology 
to a flatter shape (Qin 2012). 
Macrophages differentiated from THP-1 cells with PMA for 72 hours show more similarities to PBMC 
monocyte-derived macrophages compared to macrophages originated from THP-1 cells exposed to 
vD3 for 72 hours (Qin 2012, Chanput, Mes et al. 2014). THP-1 derived macrophages incubated with 
PMA for 72 hours differentiate into more mature cells, with low proliferation rates, and high 
phagocytic capacity (Qin 2012). THP-1 derived macrophages show marked expression of macrophage-
associated cell surface markers including CD11b and CD14, similar to PBMC monocyte-derived 
macrophages. 
The use of THP-1 cells has lots of advantages. First, the proliferation rates of THP-1 monocytes 
compared to primary human macrophages is significantly higher, with THP-1 numbers able to 
quadruple in less than four days. Second, THP-1 cells are easy to handle and are safe to use in tissue 
culture since there is no evidence of any viruses or toxins within the cells (Chanput, Mes et al. 2014). 
Third, due to their immortalised property, THP-1 cells can be cultured for up to 25 passages without 
change in their activity or sensitivity. It has been demonstrated that THP-1 cells can be preserved in 
liquid nitrogen for many years and remain viable after thawing (Mangan and Wahl 1991). Finally, 
compared to the inherent heterogeneity observed in PBMC monocyte-derived macrophages between 
different donors, THP-1 cells decrease this variability making reproducibility of results easier. This 
property is important when studying chemicals/molecules with high variability in their biological 
functions such as ox-LDL (Rogers, Thornton et al. 2003). However, this can also be considered as a 
weakness, when considering therapeutics will need to be applicable to heterogeneous populations. 
Other limitations have been reported for THP-1 cells including the demonstration that the reduced 
expression of LDL receptors in THP-1 cells requires higher doses of ox-LDL compared to their primary 




immortalised human-monocyte macrophage cell lines, for example, U937, ML-2, and MMO MAC6 
cells. Results showed that the monocytic properties for these cells were weaker when compared to 
THP-1 cells (Chanput, Mes et al. 2014). 
 
 
3.1.2 Role of fasudil and pravastatin as actin perturbing drugs 
Rho-associated protein kinases (ROCK), serine/ threonine kinases with a molecular weight of 160 kDa, 
consist of a middle coiled-coil domain, an amino-terminal kinase domain, a Rho-binding domain, and 
a carboxy-terminal cysteine-rich region. The carboxy-terminal region has a power of hydrogen (PH) 
domain which is important for the auto inhibition of the amino-terminal region of ROCK (Julian and 
Olson 2014). ROCKs were the first identified down-stream kinases of the small family GTPases, such 
as RhoA which is a well-characterised regulator of the cell cytoskeleton. RhoA is usually located in the 
cytosol of the cell in an inactive form. When a stimulator affects the cell (such as growth factor 
activation of Guanine nucleotide exchange factors (GEFs)), the inactive RhoA in a Rho-GDP form is 
changed to Rho-GTP form by Rho-GEF. This activation leads to the translocation of activated RhoA to 
the cell membrane. On the cell membrane, activated RhoA can bind and activate a number of kinases 
including ROCKs (Liu, Li et al. 2013). 
Studies showed that humans have two ROCK isoforms: ROCK1 and ROCK2. They are located on 
different chromosomes, with ROCK1 located on chromosome 18 while ROCK2 is located on 
chromosome 2 (Dong, Yan et al. 2010). ROCK1 and ROCK2 share 65% homology of their amino acid 
sequence and 90% of their kinase domain (Dong, Yan et al. 2010). It has been reported that the two 
isoforms are differentially expressed throughout the body, for example ROCK2 is expressed within the 
brain and heart, while ROCK1 is predominantly expressed within the liver, kidney, and lung (Dong, Yan 
et al. 2010). 
ROCK1 and 2 have been proposed to play contributory roles in atherogenesis, as deployment of a 
ROCK1/2 inhibitor (Y-27632) in mice decreased early atherosclerotic lesion formation which was 
associated with blunted Rho-kinase activity (Mallat, Gojova et al. 2003). It is postulated that the 
RhoA/ROCK pathway effects on atherosclerosis are related to the dysfunction of endothelial cells, 
immune response and inflammation (Dong, Yan et al. 2010), leading to augmented expression of pro-
inflammatory cytokines and associated recruitment of monocytes and subsequent macrophage 
accumulation.  
Further insights have suggested ROCK activation plays roles throughout the different stages of 
atherosclerotic plaque formation. First, ROCK activation is involved in the downregulation of eNOS 




facilitating vascular smooth muscle cell (VSMC) growth (Yamakawa, T et al 2000), effects which 
promote atherogenesis (Wang, H.W. et al 2008). Second, ROCK activation has been associated with 
monocyte recruitment and related macrophage accumulation in developing atherosclerotic lesions, 
where their uptake of ox-LDL induces their transformation into foam cells, the hallmark of 
atherosclerosis (Dong, Yan et al. 2010). Relatedly, it has recently been shown that ROCKs increase the 
phagocytic capacity of macrophages via regulation of their actin cytoskeleton (Julian and Olson 2014). 
Rac activation increases the formation of spikes and lamellipodia, while Cdc42 regulates the formation 
of cell membrane protrusions such as filopodia. Principally, ROCKs promote the stability of actin 
filaments via phosphorylation of LIM kinase-1 (LIMK1) and subsequent down-stream activation of 
effector proteins, for example myosin and resultant generation of actin-myosin contraction. ROCKs 
can also phosphorylate myosin light chain (MLC) which thereafter increases actin stress fibre and focal 
adhesion formation (Julian and Olson 2014). It has been reported that polarisation of macrophages 
towards different macrophage subsets involves Rho/ROCK signalling. Studies showed that inhibiting 
the ROCK2 signalling pathway shifted anti-inflammatory M2 macrophages towards a pro-
inflammatory M1 phenotype, as evidenced by increased expression of pro-inflammatory macrophage 
markers (Zandi, Nakao et al. 2015), demonstrating ROCK signalling regulates macrophage plasticity. 
Accordingly, modulation of the ROCK signalling pathway may represent an attractive therapeutic 
avenue for inflammatory cardiovascular diseases such as atherosclerosis. 
 
Fasudil (1-(5-isoquinolinesulfonyl)-homo-piperazine) is a ROCK inhibitor that is clinically approved for 
the treatment of patients with cerebral vasospasm after subarachnoid haemorrhage surgery (in 
Japan), and recently approved for use in clinical trials for Raynaud’s disease, atherosclerosis and 
amyotrophic lateral sclerosis (ALS) (Shi and Wei 2013). Fasudil competes with ATP binding to the 
kinase domain of ROCK, the prevention of ATP attachment leads to inhibition of the RhoA/ Rho kinase 
(ROCK) signalling pathway. Studies showed that inhibition of the RhoA/ROCK signalling pathway by 
fasudil enhances the expression of eNOS, which decreases endothelial dysfunction, the contraction of 
VSMCs, and monocyte/macrophage recruitment and their polarisation to different phenotypes. 
However, in contrast to the aforementioned study by Zandi and colleagues (Zandi, Nakao et al. 2015), 
ROCK inhibition with fasudil was able to significantly decrease the expression of pro-inflammatory M1 
macrophage markers such as CD40, and iNOS, while significantly increasing the levels of anti-
inflammatory M2 markers including CD206, suggesting fasudil shifts macrophage polarisation towards 
an anti-inflammatory phenotype (Liu, Li et al. 2013). A comparison of the two studies (Liu, Li et al. 
2013, Zandi, Nakao et al. 2015) reveals some differences which may explain the divergent effects on 




bone-marrow). More importantly, fasudil inhibits both ROCK1 and 2, while the study from Zandi and 
colleagues (Zandi, Nakao et al. 2015) deployed a ROCK2-specific inhibitor, suggesting that targeting of 
both ROCK isoforms is necessary to shift macrophages towards an anti-inflammatory phenotype. 
The recruitment and infiltration of monocytes through the endothelial layer during atherogenesis is 
regulated by different adhesion molecules and chemokines such as ICAM-1 and MCP-1, which have 
an essential role for the localised accumulation of monocyte/macrophages. Fasudil treatment has 
been shown to decrease the infiltration of monocyte/macrophages through suppression of MCP-1 and 
the inflammatory cytokine TNF-α, while enhancing the production of anti-inflammatory cytokines 
such as IL-10, in part supporting the anti-inflammatory actions of ROCK1/2 inhibition. Furthermore, 
with actin cytoskeleton remodelling a major downstream consequence of ROCK signalling, these 
findings support a fundamental role for ROCK signalling and associated reorganisation of the actin 
cytoskeleton on macrophage behaviour including their migration, proliferation, adhesion, and 
polarisation (Liu, Li et al. 2013, Rao, Ye et al. 2017). Accordingly, a reduced chemotactic response 
alongside shifting of macrophage polarisation towards an anti-inflammatory phenotype afforded with 
fasudil treatment, would be expected to affect the phagocytic capacity of macrophages and their 
subsequent transformation into foam cells, which are considered as critical steps for the formation of 
atherosclerosis. Indeed, two independent studies have shown that administration of ROCK1/2 
inhibitors (either Y-27632 or fasudil) are able to blunt the formation and progression of atherosclerotic 
plaques in mice (Mallat, Gojova et al. 2003, Wu, Xu et al. 2009) 
Statins (3-hydroxy-3-methylglutaryl-coenyme A reductase inhibitors) are a family of drugs used to 
effectively reduce circulating LDL-cholesterol levels in clinical practices (Byrne, Cullinan et al. 2019). 
Moreover, statins are administered to patients as primary or secondary prevention of cardiovascular 
disorders. Primary prevention involves treating patients who do not have clinical cardiovascular 
indications but are predicted to be of future high risk, while secondary prevention comprises treating 
patients suffering from CVD to limit the occurrence of an adverse cardiovascular event (Perk, De 
Backer et al. 2012). Statins are termed pleiotropic compounds as alongside their ability to lower LDL-
cholesterol levels, they can exert additional athero-protective effects through modulation of 
inflammatory and vascular cells (Sawada and Liao 2013). Statins prevent the synthesis of isoprenoid 
intermediates that are essential for the biosynthesis of the cholesterol pathway, such as 
farnesylpyrophosphate (FPP) and geranyl-geranylpyrophosphate (GGPP), which are downstream 
effectors of L-mevalonic acid (Sawada and Liao 2013). Additionally, FPP and GGPP regulate post-
translational modification (isoprenylation) of GTP-ase family members, such as Rho, Ras, and Rac (Van 
Aelst and D'Souza-Schorey 1997). Isoprenylation has a vital role in the functional activity of multiple 




signaling pathways such as Rho-GTPases (Van Aelst and D'Souza-Schorey 1997). Accordingly, inhibiting 
isoprenylation of GTP-ase family members with statins, blunts the activity of Rho, Ras, and Rac 
(Sawada and Liao 2013). As such, in addition to perturbing cholesterol synthesis, a key mechanism of 
statin action in regulating CVD is considered to be through the inhibition of Rho or its kinase ROCK 
(Takemoto, Sun et al. 2002). Mechanistically, statins can improve the function of endothelial cells 
through increasing the levels of eNOS (Essig, Nguyen et al. 1998), by enhancing mRNA stability of eNOS 
via inhibition of the Rho/ROCK pathway (Laufs, La Fata et al. 1998). Moreover, administration of statins 
to patients suffering from stable atherosclerosis lead to an improvement of endothelial dysfunction 
through the inhibition of ROCK activity (Dong, Yan et al. 2010). Furthermore, studies reported that the 
anti-inflammatory effects of statins involve the inhibition of inflammatory chemokines and cytokines 
such as MCP-1, IL-6, and IL-8 (Oesterle, Laufs et al. 2017). Additionally, by inhibiting the activity of 
Rac1, statins reduce the production of ROS and downregulate the inflammatory pathways (Dichtl, 
Dulak et al. 2003). Studies in a rabbit model showed that statins inhibited the release of MMP-1, MMP-
3, and MMP-9 by macrophages and VSMCs (Luan, Chase Alex et al. 2003). MMPs have an essential 
role in the degradation of ECM proteins, especially elastin, and subsequent remodelling of the arterial 
wall (Harris, Smith et al. 2010, Myasoedova, Chistiakov et al. 2018). Supporting a direct anti-
inflammatory effect of statins upon atherosclerosis, either pravastatin or simvastatin administration 
to hypercholesteroleamic mice significantly retarded atherogenesis and improved the stability of 
established atherosclerotic lesions, without affecting plasma LDL-cholesterol levels (Bea, Blessing et 
al. 2002, Johnson, Carson et al. 2005). 
 
3.1.3 Aim of this Chapter 
In this chapter, I attempt to ascertain whether THP-1 derived macrophages represent a realistic model 
for mimicking the properties of two recently-characterised macrophage subsets proposed to play 
opposing roles in atherosclerosis. In addition, the effect of actin perturbing drugs (fasudil and 
pravastatin) on the behaviour and function of macrophages including their polarisation, are assessed 










3.2.1 Macrophages differentiated from THP-1 cells mirror the morphological 
divergency of human PBMC-derived macrophages in response to GM-CSF or M-
CSF 
To assess whether macrophages obtained from THP-1 cells acquire a similar morphology as human 
PBMC derived macrophages after polarisation with GM-CSF or M-CSF, THP-1 cells were incubated with 
PMA for 72 hours to induce their adherence then differentiated through incubation with 20 ng/ml of 
granulocyte-macrophage colony-stimulating factor (GM-CSF), or macrophage colony-stimulating 
factor (M-CSF) for 6 days to obtain two distinct macrophage subsets (GM-Mac and M-Mac 
respectively). This protocol was used throughout this chapter to generate the GM-Mac and M-Mac 
subsets from THP-1 cells. 
 
As has been reported for human PBMC-derived macrophages (Waldo, Li et al. 2008), morphological 
differences were observed between the GM-CSF and M-CSF polarised THP-1 macrophage subsets. 
Macrophages incubated with GM-CSF exhibited a rounded shape in contrast to macrophages 
incubated with M-CSF which displayed a mixture of rounded and elongated morphology (Figure 3.1). 









Figure 3.1 Effect of M-CSF and GM-CSF maturation on the morphology of THP-1 
macrophages. 
Representative phase contrast microscopy images of (A) six-day M-CSF (20 ng/ml) directed THP-1 
macrophages (M-Mac), and (B) six-day GM-CSF (20 ng/ml) directed macrophages (GM-Mac). Scale 






3.2.2 GM-CSF polarised macrophages differentiated from THP-1 cells have reduced 
F-actin accumulation compared to M-CSF polarised macrophages 
With alterations in macrophage morphology and function associated with changes in F-actin content 
(Grosheva, Haka et al. 2009), GM-CSF (GM-Mac) and M-CSF (M-Mac) polarised THP-1 macrophages 
were stained with AlexaFluor 594-conjugated phalloidin to enable the visualisation and quantification 
of cellular F-actin content. The average accumulation of F-actin was significantly reduced within GM-















Figure 3.2 GM-CSF polarised THP-1 macrophages (GM-Mac) display reduced F-actin accumulation 
compared to M-Macs. 
A: Quantification of F-actin content within M-Mac and GM-Mac subsets, measured within six random 
x 20 magnification fields. ** indicates p<0.01; two tailed, paired t-test, n=4. 
B: Representative images of F-actin within M-Mac and GM-Mac subsets, stained with AlexaFluor 594-
conjugated phalloidin (red) alongside a DAPI nuclear counterstain (blue).  
Scale bar represents 10 µm and applies to both panels. N-values in macrophages differentiated from 






























3.2.3 Addition of M-CSF to GM-Macs does not rescue their decreased F-actin content  
To assess the plasticity of GM-Macs differentiated from THP-1 cells by assessing the effect of M-CSF 
addition on pro-inflammatory GM-Mac F-actin content, six-day GM-CSF polarised THP-1 macrophages 
were incubated with M-CSF (20 ng/ml) for 24 hours. Analysis of AlexaFluor 594-conjugated phalloidin-
labelled images showed that 24-hour addition of M-CSF to GM-Macs did not influence F-actin content 
within the GM-Mac subset (Figure 3.3). Our finding suggests that GM-Macs (differentiated from THP-

















Figure 3.3 M-CSF addition does not affect F-actin content in GM-Macs.  
A: Quantification of F-actin content within M-Mac, GM-Mac, and GM-Mac treated with M-CSF, 
measured within six random x 20 magnification field. ** indicates p<0.01 and N.S denotes not 
significant vs GM-Mac; ANOVA, Student-Newman-Keuls Multiple Comparisons Test, n=4.  
B: Representative images of F-actin within M-Mac, GM-Mac, and GM-Mac treated with M-CSF, stained 
with AlexaFluor 594-conjugated phalloidin (red) alongside a DAPI nuclear counterstain (blue). Scale 
bar represents 10 µm and applies to all panels. N-values in macrophages differentiated from THP-1 
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3.2.4 Addition of GM-CSF to M-Mac subsets significantly reduced F-actin content and 
changed cell morphology to GM-Mac phenotype, which was associated with 
increased expression of MMP-12 and colony stimulating factor 2 receptor 
subunit alpha (CSF2RA) 
To assess the effect of GM-CSF addition on anti-inflammatory M-Mac F-actin content, six-day M-CSF 
polarised THP-1 macrophages were incubated with GM-CSF (20 ng/ml) for 24 hours. Quantification of 
AlexaFluor 594-conjugated phalloidin labelling revealed that GM-CSF addition to M-Macs significantly 
reduced F-actin content (25%; p<0.01; n=4; Figure 3.4) which was associated with a shift in cell 
















Figure 3.4 GM-CSF addition reduced M-Mac F-actin content.  
A: Quantification of F-actin content within M-Mac, GM-Mac, and M-Macs treated with GM-CSF, 
measured within six random x 20 magnification field. ** indicates p<0.01, * indiates p<0.05 vs M-Mac 
and $ indiates p<0.05 vs GM-Mac; ANOVA, Student-Newman-Keuls Multiple Comparisons Test, n=4. 
B: Representative images of F-actin within M-Mac, GM-Mac, and M-Macs treated with GM-CSF, 
stained with AlexaFluor 594-conjugated phalloidin (red) alongside a DAPI nuclear counterstain (blue). 
Scale bar represents 10 µm and applies to all panels. N-values in macrophages differentiated from 










To examine whether the morphological changes exerted on the anti-inflammatory M-Mac subset by 
GM-CSF stimulation was associated with a shift towards a GM-Mac phenotype, mRNA expression for 
M-Mac markers and regulators (TGFBI, CSF1, and CSF1R) and GM-Mac indicators (MMP12, CSF2, and 
CSF2RA) were assessed. Q-PCR analysis showed GM-CSF addition to M-Macs induced a significant 
increase in MMP12 and CSF2RA mRNA expression (5-fold; p<0.05, and 1.4-fold; p<0.01 respectively; 





















Figure 3.5 GM-CSF addition increased M-Mac MMP12 and CSF2RA mRNA expression. 
Quantification of MMP12, CSF1R, TGFBI, CSF2, CSF1, and CSF2RA mRNA expression in M-Mac and M-
Mac macrophages treated with 20 ng/ml of GM-CSF for 24 hours, assessed by RT-qPCR. Data 
presented as fold change against unstimulated M-CSF matured (M-Mac) macrophages (mean ± SEM; 
*indicates p<0.05; two tailed, paired t-test, n=4). N-values in macrophages differentiated from THP-1 











































































3.2.5 M-Mac and GM-Mac subsets derived from THP-1 cells regulate mRNA 
expression of select MMPs, CSFRs, and scavenger receptor markers in the same 
manner as primary human macrophages 
To ascertain whether macrophage subsets differentiated from THP-1 cells display the same patterns 
of gene expression as primary human macrophages, six-day M-Mac and GM-Mac derived from THP-1 
cells were assessed for mRNA expression of markers deemed characteristic of the GM-Mac subset 
(MMP12 and SPARC) or M-Macs (TIMP3 and TGFBI). 
Results showed that GM-Mac derived from THP-1 cells exhibited significantly increased mRNA 
expression of MMP12, SPARC and TIMP3 compared to M-Macs (4-fold; P< 0.001, 3-fold; P< 0.01, and 
3.5-fold; P< 0.01 respectively; n=10; Figure 3.6), whereas expression of TGFBI mRNA levels were 
signficantly decreased (30%; P< 0.05; n=10; Figure 3.6). These findings are in line with observations 
from human primary PBMC-derived macrophages (JLJ unpublished study and (Waldo, Li et al. 2008)), 






















Figure 3.6 M-Mac and GM-Mac subsets derived from THP-1 cells display similar mRNA expression 
patterns of specific cell markers as primary human macrophages. 
Quantification of TGFBI, TIMP3, MMP12, and SPARC mRNA expression in M-Mac and GM-Mac subsets 
derived from THP-1 cells, assessed by RT-qPCR. Data presented as fold change against M-CSF matured 
(M-Mac) macrophages (mean ± SEM; *indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001; 
two tailed, paired t-test, n=10). N-values in macrophages differentiated from THP-1 cells represent 


























































Next, the mRNA expression of genes associated with phagocytosis and macrophage polarisation were 
assessed between M-Mac and GM-Mac subsets differentiated from THP-1 cells, including numerous 
pivotal scavenger receptors MSR1, OLR1 (LOX-1), CD36, and MRC1 alongside different CSF receptors. 
Q-PCR results revealed significantly increased mRNA expression of the scavenger receptors MRC1, 
CD36, and MSR1 in the anti-inflammatory M-Mac subset compared to pro-inflammatory GM-Macs 
(2.5-fold; p<0.05, 4.7-fold; p<0.01, and 25-fold; p<0.001 respectively; n=4; Table 3.1). Moreover, 
analysis showed levels of the anti-inflammatory cytokine IL10 and the receptor for M-CSF, CSF1R, were 
also significantly increased in the M-Mac subset (3.2-fold; p<0.05, and 2.2-fold; p<0.05 respectively; 
n=4; Table 3.1). In contrast, the scavenger receptor OLR1 (LOX-1) and the GM-CSF receptor CSF2RA 
were significantly increased in the GM-Mac subset when compared to M-Macs (1.5-fold; p<0.05, and 
5-fold; p<0.001 respectively; n=4; Table 3.1). 
These findings further support the notion that M-Macs represent an anti-inflammatory macrophage 
subset, through increased expression of IL10 and MSR1 (CD206), which are well-characterised markers 
of the anti-inflammatory M2 macrophage phenotype (Johnson and Newby 2009). Additionally, M-Mac 
and GM-Mac display distinct sets of scavenger receptors suggesting different mechanisms for the 
uptake of modified lipoproteins, with the M-Mac subset favouring CD36 and MSR1, while OLR1 is 
increased in GM-Macs. Furthermore, there appears to be positive feedback mechanisms for 
polarisation in both subsets, with M-Macs increasing expression of CSF1R (the receptor for M-CSF) 
and GM-Macs exhibiting elevated CSF2RA expression (the specific receptor for GM-CSF). Finally, the 
results from THP-1-derived M-Mac and GM-Mac subsets are similar to those observed in M-CSF and 







Gene Macrophage subsets differentiated from THP-1 cells 
 
M/GM fold change ± SEM 
OLR1 (LOX-1) 0.19 ± 0.06 
CD36 4.76 ± 0.02 
MSR1 25 ± 0.005 
MRC1 2.5 ± 0.08 
IL10 3.2 ± 0.03 
CSF1R 2.21 ± 0.05 





Table 3.1: Table summarising mRNA expression changes between THP-1-derived M-Mac and GM-
Mac subsets 
Quantification of key lipoprotein-related scavenger receptors (OLR1, CD36, MSR1, and MRC1) and 
anti-inflammatory cytokine IL10, the receptor for M-CSF, CSF1R, and the receptor for GM-CSF, CSF2RA, 
assessed by RT-qPCR. Data presented as fold change compared to M-CSF matured (M-Mac) 
macrophages (mean ± SEM; green filled-box indicates significantly decreased compared to M-CSF 
matured (M-Mac) macrophages (p<0.05); red filled-box indicates significantly increased compared to 
M-CSF matured (M-Mac) macrophages (p<0.05); two tailed, paired t-test, n=4). N-values in 











3.2.6 M-Mac and GM-Mac subsets derived from THP-1 cells regulate protein 
expression of MMP-12, SPARC, and TGFβI similar to primary human 
macrophages 
To validate the findings observed at the mRNA level, ICC was performed to assess the protein 
expression of MMP-12, SPARC, and TGFβ-induced in M-Mac and GM-Mac subsets. In line with the q-
PCR data, significantly increased protein expression of MMP-12 and SPARC (3-fold; p<0.001, and 2-
fold; p<0.05 respectively; n=6; Figure 3.7 and 3.8 respectively) was observed in the GM-Mac subset 
















Figure 3.7 MMP-12 protein expression is increased in THP-1-derived GM-Macs.  
A: Quantification of cellular MMP-12 protein expression in M-Mac and GM-Mac subsets derived from 
THP-1 cells, assessed by immunocytochemistry. Data presented as percentage of positive cells 
calculated within 10 random x 40 magnification fields.  *** indicates p<0.001; two tailed, paired t-test, 
n=6. N-values in macrophages differentiated from THP-1 cells represent number of replicates. 
B: Representative images of immunocytochemistry for MMP-12 within M-Mac and GM-Mac subsets. 
Positive cells are shown as green and all nuclei are stained blue with DAPI. Scale bar represents 10 µm 
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Figure 3.8 SPARC protein expression is increased in THP-1-derived GM-Macs. 
A: Quantification of cellular SPARC protein expression in M-Mac and GM-Mac subsets derived from 
THP-1 cells, assessed by immunocytochemistry. Data presented as percentage of positive cells 
calculated within 10 random x 40 magnification fields. *indicates p<0.05; two tailed, paired t-test, n=6. 
N-values in macrophages differentiated from THP-1 cells represent number of replicates. 
B: Representative images of immunocytochemistry for SPARC within M-Mac and GM-Mac subsets. 
Positive cells are shown as green and all nuclei are stained blue with DAPI. Scale bar represents 10 µm 






















































Figure 3.9 TGFβ-induced protein expression is decreased in THP-1-derived GM-Macs.  
A: Quantification of cellular TGFβ-induced protein expression in M-Mac and GM-Mac subsets derived 
from THP-1 cells, assessed by immunocytochemistry. Data presented as percentage of positive cells 
calculated within 10 random x 40 magnification field. *indicates p<0.05; two tailed, paired t-test, n=6. 
N-values in macrophages differentiated from THP-1 cells represent number of replicates. 
B: Representative images of immunocytochemistry for TGFβI within M-Mac and GM-Mac subsets. 
Positive cells are shown as green and all nuclei are stained blue with DAPI. Scale bar represents 10 µm 





































3.2.7 Actin perturbing drugs (fasudil and pravastatin) cause a reduction in F-actin 
content within M-Mac and GM-Mac subsets 
Due to the differential accumulation of F-actin within M-Mac and GM-Mac subsets, the effect of the 
actin-perturbing drugs fasudil and pravastatin on cytoskeleton rearrangement were explored. 
However, in the first instance a range of different doses of fasudil and pravastatin were administrated 
to macrophages in order to identify the appropriate concentration of fasudil and pravastatin that 
modulates F-actin content within macrophage subsets without affecting cell viability. 
Results with fasudil treatment showed that 100 µM of fasudil caused a significant increase in the 
percentage of cell death for M-Mac and GM-Mac subsets (39.1% and 31.3% respectively; Figure 3.10) 
and therefore deemed toxic at this dose. In contrast, the 1 µM and 10 µM doses of fasudil did not 
significantly induce cell death in either macrophage subset (Figure 3.10). However, further analysis 
revealed that 10 µM of fasudil exerted a greater effect on F-actin content compared to the 1 µM dose, 
therefore the 10 µM dose of fasudil was deployed in subsequent experiments. Similarly for pravastatin, 
the highest dose (10 µM) significantly induced cell death in both M-Mac and GM-Mac subsets (11.2% 
and 14.0%; Figure 3.11), and was therefore considered toxic, while both 1 µM and 5 µM doses of 
pravastatin were not overtly harmful to either macrophage subset (Figure 3.11). As the 5 µM dose of 








Figure 3.10 Effect of Fasudil on M-Mac and GM-Mac cell viability 
Quantification of cell death in M-Mac and GM-Mac subsets derived from THP-1 cells and treated for 
24 hours with increasing doses of Fasudil, assessed by immunocytochemistry. Data presented as 
percentage of dead cells calculated within six random x 20 magnification fields. ** indicates p<0.01; 
ANOVA, Student-Newman-Keuls Multiple Comparisons Test, n=4 N-values in macrophages 
differentiated from THP-1 cells represent number of replicates.  
 
 
Figure 3.11 Effect of pravastatin on M-Mac and GM-Mac cell viability. 
Quantification of cell death in M-Mac and GM-Mac subsets derived from THP-1 cells and treated for 
24 hours with increasing doses of pravastatin (statin), assessed by immunocytochemistry. Data 
presented as percentage of dead cells calculated within six random x 20 magnification fields. ** 
indicates p<0.01; ANOVA, Student-Newman-Keuls Multiple Comparisons Test, n=4. N-values in 
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Next, the selected doses of the two actin perturbing drugs were assessed and validated for their ability 
to alter F-actin content in the two different macrophage subsets. Image analysis demonstrated that 
the M-Mac subset treated with either 10 µM of fasudil or 5 µM of pravastatin showed a significant 
reduction in the accumulation of F-actin (74%; p<0.001, and 63%; p<0.001 respectively; n=5; Figure 
3.12). Similarly, GM-Macs treated with either 10 µM of fasudil or 5 µM of pravastatin showed a 
















Figure 3.12 Fasudil or pravastatin addition reduced M-Mac F-actin content.  
A: Quantification of F-actin content within M-Macs treated with fasudil (10 µM) or pravastatin (5 µM) 
for 24 hours, measured within six random x 20 magnification fields. Data presented as fold change in 
average cell area positive for F-actin; *** indicates p<0.001; two tailed, paired t-test, n=5. N-values in 
macrophages differentiated from THP-1 cells represent number of replicates. 
B: Representative images of F-actin within M-Macs treated with fasudil (10 µM) or pravastatin (5 µM) 
for 24 hours, stained with AlexaFluor 594-conjugated phalloidin (red) alongside a DAPI nuclear 












































Figure 3.13 Fasudil or pravastatin addition reduced GM-Mac F-actin content.  
A: Quantification of F-actin content within GM-Macs treated with fasudil (10 µM) or pravastatin (5 µM) 
for 24 hours, measured within six random x 20 magnification fields. Data presented as fold change in 
average cell area positive for F-actin; *** indicates p<0.001; two tailed, paired t-test, n=5. N-values in 
macrophages differentiated from THP-1 cells represent number of replicates. 
B: Representative images of F-actin within GM-Macs treated with fasudil (10 µM) or pravastatin (5 µM) 
for 24 hours, stained with AlexaFluor 594-conjugated phalloidin (red) alongside a DAPI nuclear 




























3.2.8 Actin perturbing drugs (fasudil and pravastatin) regulate the mRNA expression 
of TGFBI, MMP12, and TIMP3 in M-Mac and GM-Mac subsets 
The previous results showed that fasudil (10 µM) or pravastatin (5 µM) were able to regulate the 
accumulation of F-actin within both M-Mac and GM-Mac subsets derived from THP-1 cells. As such, 
qPCR was preformed to assess whether alterations in F-actin content was associated with changes in 
mRNA expression of the macrophage subset markers TGFBI, MMP12, and TIMP3. Results showed that 
pravastatin (5 µM) significantly increased mRNA expression of TGFBI, MMP12, and TIMP3 in the anti-
inflammatory M-Mac subset (1.9-fold, 4.7-fold, and 1.5-fold respectively; p<0.05; n=5; Figure 3.14), 
while fasudil (10 µM) only increased TGFBI levels (2.7-fold; p<0.05; n=5; Figure 3.14), with MMP12 
and TIMP3 expression unaffected (Figure 3.14). In regard to the pro-inflammatory GM-Mac subset, 
pravastatin similarly increased TGFBI and TIMP3 mRNA expression (1.9-fold and 2-fold respectively; 
p<0.05; n=5; Figure 3.14), with no effect upon MMP12 levels (Figure 3.14). Fasudil administration also 
had no effect on GM-Mac MMP12 levels or TGFBI expression, although TIMP3 mRNA expression was 
significantly elevated (2.8-fold; p<0.05; n=5; Figure 3.14). These findings suggest that F-actin 
perturbation with pravastatin, and to a lesser degree fasudil, shifts macrophages towards an anti-





































Figure 3.14 Fasudil or pravastatin addition regulates TGFBI, MMP12, and TIMP3 mRNA expression 
in M-Mac and GM-Mac subsets. 
Quantification of TGFBI, MMP12, and TIMP3 mRNA expression in M-Mac and GM-Mac subsets derived 
from THP-1 cells, treated for 24 hours with fasudil (10 µM) or pravastatin (5 µM) and assessed by RT-
qPCR. Data presented as fold change against untreated M-Macs or untreated GM-Macs (mean ± SEM, 
*indicates p<0.05; two tailed, paired t-test, n=5). N-values in macrophages differentiated from THP-1 
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3.2.9 Pravastatin regulates mRNA expression of genes associated with F-actin 
dependent cytoskeleton rearrangement in M-Mac and GM-Mac subsets 
Fascin, an actin-bundling protein, has an essential role in regulating and maintaining the stability of 
actin filament bundles which is important for the adhesion and migration of cells (Jayo A 2010). 
Another actin-binding protein, Radixin, has an essential role in forming a link between plasma 
membrane proteins and the actin cytoskeleton (Ivetic 2004). While vinculin, a cytoskeletal protein, is 
involved in linkage of the actin cytoskeleton to focal adhesions, particularly at cell-matrix and cell-cell 
junctions (Mierke 2009). 
As either fasudil or pravastatin altered the F-actin content within both M-Mac and GM-Mac subsets, 
changes in the mRNA expression of genes associated with F-actin regulated cytoskeleton 
rearrangement were assessed. QPCR analysis revealed fasudil addition did not significantly change the 
mRNA expression of Fascin 1 (FSCN1), Vinculin (VCL), or Radixin (RDX) in either macrophage subset 
(Figure 3.15). However, pravastatin significantly increased the mRNA expression of FSCN1, VCL, and 
RDX (40%; p< 0.05, 17%; p< 0.01, and 54%, p< 0.05; respectively; n=5; Figure 3.15) within the M-Mac 
subset, alongside elevated levels of FSCN1, and VCL in GM-Macs (20%; p< 0.01, and 30%, p< 0.05; 





























Figure 3.15 Pravastatin addition regulates FSCN1, VCL, and RDX mRNA expression in M-Mac and 
GM-Mac subsets. 
Quantification of FSCN1, VCL, and RDX mRNA expression in M-Mac and GM-Mac subsets derived from 
THP-1 cells, treated for 24 hours with fasudil (10 µM) or pravastatin (5 µM) and assessed by RT-qPCR. 
Data presented as fold change against untreated M-Macs or untreated GM-Macs (mean ± SEM, 
*indicates p<0.05, ** indicates p<0.01; two tailed, paired t-test, n=5). N-values in macrophages 










M-Mac M-Mac + 10
µM fasudil
















M-Mac M-Mac + 10
µM fasudil















M-Mac M-Mac + 10
µM fasudil



































M-Mac M-Mac + 10 µM
fasudil



































3.2.10 Pravastatin regulates TGFβI and MMP-12 protein expression in M-Mac and GM-
Mac subsets 
To validate the effects of pravastatin on TGFBI and MMP12 mRNA expression in the M-Mac and GM-
Mac subsets translated to the protein level, fluorescent immunocytochemistry (ICC) was performed. 
Results showed pravastatin administration significantly increased protein expression of the anti-
inflammatory marker TGFβI in both the M-Mac and GM-Mac subsets (1.5-fold; p<0.05, and 2-fold; 
p<0.05; n=4; Figure 3.16 and 3.17 respectively). In line with pravastatin exerting anti-inflammatory 
effects, the protein expression of MMP-12 was significantly reduced in GM-Macs treated with 














Figure 3.16 Pravastatin increased TGFβI protein expression in M-Macs.  
A: Quantification of cellular TGFβI protein expression in M-Mac subset derived from THP-1 cells after 
24 hour pravastatin adminstration, assessed by immunocytochemistry. Data presented as percentage 
of TGFβI positive cells calculated within 10 random x 40 magnification fields. *indicates p<0.05; two 
tailed, paired t-test, n=4. N-values in macrophages differentiated from THP-1 cells represent number 
of replicates. 
B: Representative images of immunocytochemistry for TGFβI within M-Macs treated with 
pravastatin for 24 hours. Positive cells are shown as green and all nuclei are stained blue with DAPI. 
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Figure 3.17 Pravastatin increased TGFβI protein expression in GM-Macs.  
A: Quantification of cellular TGFβI protein expression in GM-Mac subset derived from THP-1 cells after 
24 hour pravastatin adminstration, assessed by immunocytochemistry. Data presented as percentage 
of TGFβI positive cells calculated within 10 random x 40 magnification fields. *indicates p<0.05; two 
tailed, paired t-test, n=4. N-values in macrophages differentiated from THP-1 cells represent number 
of replicates. 
B: Representative images of immunocytochemistry for TGFβI within GM-Macs treated with 
pravastatin for 24 hours. Positive cells are shown as green and all nuclei are stained blue with DAPI. 
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Figure 3.18 Pravastatin reduced MMP-12 protein expression in GM-Macs.  
A: Quantification of cellular MMP-12 protein expression in GM-Mac subset derived from THP-1 cells 
after 24 hour pravastatin adminstration, assessed by immunocytochemistry. Data presented as 
percentage of MMP-12 positive cells calculated within 10 random x 40 magnification fields. *indicates 
p<0.05; two tailed, paired t-test, n=4. N-values in macrophages differentiated from THP-1 cells 
represent number of replicates. 
B: Representative images of immunocytochemistry for MMP-12 within GM-Macs treated with 
pravastatin for 24 hours. Positive cells are shown as green and all nuclei are stained blue with DAPI. 
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3.2.11  Fasudil regulates TGFβI and MMP-12 protein expression in M-Mac and GM-
Mac subsets 
To validate the findings observed in macrophage subsets treated with fasudil regarding the reduction 
in F-actin content in both M-Mac and GM-Mac subsets, alongside increased mRNA expression of TGFBI 
in M-Macs, western blotting and fluorescent immunocytochemistry (ICC) were performed. Results 
showed that despite no effect at the mRNA level, fasudil administration induced a significant reduction 
in the protein expression of MMP-12 in the GM-Mac subset (3-fold; p<0.01; n=4; Figure 3.19), 
suggesting a shift towards an anti-inflammatory phenotype through as yet unidentified post-
transcriptional mechanism with no significant change in the protein expression of MMP-12 in the M-
Mac subsets. A similar discrepancy was observed for TGFβI expression, with fasudil-treated M-Macs 
showing a significant reduction in TGFβI protein expression (2-fold; p<0.01; n=5; Figure 3.20), whereas 
mRNA levels were increased (Figure 3.14), while no effect on the protein expression of TGFβI in the 
GM-Mac subsets was detected. A reduction in TGFβI would suggest ROCK inhibition and associated F-
actin perturbation with fasudil, drives the M-Mac subset towards a more GM-Mac phenotype through 























Figure 3.19 Fasudil reduced MMP-12 protein expression in GM-Macs.  
A: Quantification of cellular MMP-12 protein expression in GM-Mac subset derived from THP-1 cells 
after 24 hour fasudil adminstration, assessed by immunocytochemistry. Data presented as percentage 
of MMP-12 positive cells calculated within 10 random x 40 magnification fields. *indicates p<0.05; two 
tailed, paired t-test, n=4. N-values in macrophages differentiated from THP-1 cells represent number 
of replicates. 
B: Representative images of immunocytochemistry for MMP-12 within GM-Macs treated with fasudil 
for 24 hours. Positive cells are shown as green and all nuclei are stained blue with DAPI. Scale bar 

























































Figure 3.20 Fasudil reduced TGFβI protein expression in M-Macs.  
A: Quantification of cellular TGFβI protein expression in M-Mac subset derived from THP-1 cells after 
24 hour fasudil adminstration, assessed by immunocytochemistry. Data presented as percentage of 
TGFβI positive cells calculated within 10 random x 40 magnification fields. *indicates p<0.05; two 
tailed, paired t-test, n=4. N-values in macrophages differentiated from THP-1 cells represent number 
of replicates. 
B: Representative images of immunocytochemistry for TGFβI within M-Macs treated with fasudil for 
24 hours. Positive cells are shown as green and all nuclei are stained blue with DAPI. Scale bar 
represents 10 µm and applies to both panels. 
C: Representative Western blot for TGFβI. Stain free gel is shown as a loading control. Approximate 








































 Addition of recombinant TGFβ fails to rescue the inhibitory effect of fasudil on 
pSMAD3 
 
Considering the effects of F-actin modulation through fasudil administration is associated with 
changes in expression of TGFβ-induced (TGFβI), which as its name suggests is induced by TGFβ 
signalling, it is plausible that differences in F-actin content between macrophage subsets regulates 
TGFβ signalling or vice versa. Accordingly, phosphorylated SMAD3 (pSMAD3) expression was assessed 
in M-Mac and GM-Mac subsets, as a marker of active TGFβ signalling (Feng, Zhang et al. 2017). 
Quantification revealed a significant reduction in the nuclear expression of pSMAD3 within the GM-
Mac subset compared to M-Macs (2.4-fold, p<0.0001; n=9; Figure 3.21), in keeping with concomitant 
decreased F-actin content and TGFBI expression in GM-Macs. Relatedly, to next determine if F-actin 
perturbation (through ROCK inhibition) suppressed TGFβ signalling, the effect of fasudil on pSMAD3 
expression was evaluated in the M-Mac subset where F-actin is abundant. Indeed, M-Mac nuclear 
pSMAD3 expression was significantly reduced by fasudil treatment (67%, p<0.0001; n=5; Figure 3.22). 
Interestingly, co-incubation with recombinant TGFβ was unable to rescue the inhibitory effect of 
fasudil on pSMAD3 expression in M-Macs (Figure 3.22). In contrast, within the GM-Mac subset where 
F-actin content and TGFβI expression is low pSMAD3 positivity was unaffected by fasudil treatment or 



















Figure 3.21 GM-Macs exhibit reduced nuclear protein expression of pSMAD3 expression compared 
to the M-Mac subset. 
A: Quantification of nuclear pSMAD3 expression in M-Mac and GM-Mac subsets derived from THP-1 
cells, assessed by immunocytochemistry. Data presented as percentage of nuclear pSMAD3 positive 
cells calculated within ten random x 40 magnification fields. *** indicates p<0.001; two tailed, paired 
t-test, n=9. N-values in macrophages differentiated from THP-1 cells represent number of replicates. 
B: Representative images of immunocytochemistry for pSMAD3 within M-Mac and GM-subsets. 
Positivity of pSMAD3 is observed as red and all nuclei are stained blue with DAPI, nuclear pSMAD3 
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Figure 3.22 Fasudil reduces pSMAD3 expression in M-Macs, and is unaffected by exogenous TGFβ. 
A: Quantification of nuclear pSMAD3 expression in M-Mac subset with and without addition of fasudil 
(10 µM) and/or recombinant TGFβ (0.2 ng/ml) for 24 hours, assessed by immunocytochemistry. Data 
presented as percentage of nuclear pSMAD3 positive cells calculated within ten random x 40 
magnification fields. *** indicates p<0.001, ANOVA, Student-Newman-Keuls Multiple Comparisons 
Test, n=5. N-values in macrophages differentiated from THP-1 cells represent number of replicates. 
B: Representative images of immunocytochemistry for pSMAD3 within M-Macs with and without 
addition of fasudil (10 µM) and/or recombinant TGFβ (0.2 ng/ml) for 24 hours. Positive cells are shown 
as red and all nuclei are stained blue with DAPI, nuclear pSMAD3 therefore appears cyan in colour. 
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Figure 3.23 Addition of fasudil and/or recombinant TGFβ had no effect on expression of pSMAD3 in 
GM-Macs.  
A: Quantification of nuclear pSMAD3 expression in GM-Mac subset with and without addition of 
fasudil (10 µM) and/or recombinant TGFβ (0.2 ng/ml) for 24 hours, assessed by immunocytochemistry. 
Data presented as percentage of nuclear pSMAD3 positive cells calculated within ten random x 40 
magnification fields. No statitsical differences were detected by ANOVA, Student-Newman-Keuls 
Multiple Comparisons Test, n=5. N-values in macrophages differentiated from THP-1 cells represent 
number of replicates. 
B: Representative images of immunocytochemistry for pSMAD3 within GM-Macs with and without 
addition of fasudil (10 µM) and/or recombinant TGFβ (0.2 ng/ml) for 24 hours. Positive cells are shown 
as red and all nuclei are stained blue with DAPI, nuclear pSMAD3 therefore appears cyan in colour. 
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  Addition of fasudil and/or recombinant TGFβ does not affect TGFβ receptor mRNA 
expression 
 
Considering fasudil perturbation of SMAD3 phosphorylation and associated downregulation 
of TGFβI protein expression in M-Macs could not be rescued through addition of recombinant 
TGFβ (Figure 3.22), aberrant expression of the TGFβ receptors was examined as a candidate 
mechanism. Quantification of qPCR revealed that mRNA expression of TGFBR1, TGFBR2, and 
TGFBR3 were unaffected by fasudil administration in both M-Mac and GM-Mac subsets 
(Figure 3.24). Furthermore, addition of recombinant TGFβ alone or in combination with fasudil 
also similarly did not induce any change in TGFβ receptor mRNA expression within either the 





























































Figure 3.24 Addition of fasudil and/or recombinant TGFβ does not alter TGFβ receptor mRNA 
expression in M-Mac and GM-Mac subsets. 
Quantification of TGFBR1, TGFBR2, and TGFBR3 mRNA expression in M-Mac and GM-Mac subsets 
derived from THP-1 cells, treated for 24 hours with fasudil (10 µM) and/or recombinant TGFβ (0.2 
ng/ml) and assessed by RT-qPCR. Data presented as fold change against untreated M-Macs or 
untreated GM-Macs (mean ± SEM, ANOVA, Student-Newman-Keuls Multiple Comparisons Test, n=5). 








































































































































 Addition of fasudil and/or recombinant TGFβ does not affect TGFβ receptor protein 
expression  
 
To confirm that the TGFβ receptors were unaffected by fasudil treatment and/or addition of 
recombinant TGFβ at the protein level, western blotting was performed. Analysis confirmed TGFβR1, 
TGFβR2, and TGFβR3 protein expression were unchanged by fasudil administration in both M-Mac 
and GM-Mac subsets (Figure 3.25), or after addition of recombinant TGFβ alone or in combination 














































Figure 3.25 Addition of fasudil and/or recombinant TGFβ does not alter TGFβ receptor protein 
expression in M-Mac and GM-Mac subsets. 
Quantification and representative western blots of TGFβR1, TGFβR2, and TGFβR3 protein expression 
in M-Mac and GM-Mac subsets derived from THP-1 cells, treated for 24 hours with fasudil (10 µM) 
and/or recombinant TGFβ (0.2 ng/ml). Stain free gel is shown as a loading control. Data presented as 
fold change against untreated M-Macs or untreated GM-Macs (mean ± SEM, ANOVA, Student-
























































































































































56 kDa TGFβR1 
TGFβR2 65 kDa 
Stain free gel 
TGFβR3 110 kDa 








 Addition of a neutralizing TGFβ antibody blunts signalling as demonstrated by 
reduced pSMAD3 in M-Mac subsets but not when treated with fasudil 
 
The above findings confirmed fasudil administration does not affect TGFβ receptor expression and 
is therefore not responsible for the fasudil-mediated effects on TGFβ signalling. However, fasudil 
may aberrantly affect TGFβR function and subsequent down-stream signalling in M-Macs. 
Accordingly, a TGFβ1, 2, and 3 neutralising antibody was deployed to assess basal TGFβ signalling 
(through SMAD3 phosphorylation) in M-Macs alongside subsequent effects of fasudil co-incubation. 
Image analysis and quantification showed that addition of a TGFβ neutralising antibody (1 ng/ml) 
reduced the number of M-Macs with nuclear SMAD3 phosphorylation (56%; p<0.001; n=4; Figure 
3.26), indicating TGFβ signalling is activated in the M-Mac subset under basal conditions. Moreover, 
the reduction in SMAD3 phosphorylation achieved with TGFβ inhibition was comparable to that 
observed with fasudil (Figure 3.26), implying a shared mechanism. Indeed, co-incubation with fasudil 
and the TGFβ neutralising antibody failed to exert a synergistic effect on pSMAD3 inhibition in M-
Macs (Figure 3.26), further supporting the involvement of a common regulatory process affecting 
down-stream TGFβ signalling. As expected, considering the GM-Mac subset already exhibit blunted 
TGFβ signalling as evidenced by reduced pSMAD3 (Figure 3.21), addition of a TGFβ neutralising 
antibody exerted no additional effect on the number of GM-Macs expressing nuclear pSMAD3 
















Figure 3.26 TGFβ inhibition reduces pSMAD3 expression in M-Macs to comparable levels as fasudil. 
Quantification of nuclear pSMAD3 expression in M-Mac subset with and without addition of fasudil 
(10 µM) and/or a TGFβ neutralising antibody (1 ng/ml) for 24 hours, assessed by 
immunocytochemistry. Data presented as percentage of nuclear pSMAD3 positive cells calculated 
within ten random x 40 magnification fields. *** indicates p<0.001, ANOVA, Student-Newman-Keuls 
Multiple Comparisons Test, n=4. N-values in macrophages differentiated from THP-1 cells represent 
number of replicates. 
B: Representative images of immunocytochemistry for pSMAD3 within M-Macs with and without 
addition of fasudil (10 µM) and/or a TGFβ neutralising antibody (1 ng/ml) for 24 hours. Positive cells 
are shown as red and all nuclei are stained blue with DAPI, nuclear pSMAD3 therefore appears cyan 
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Figure 3.27 TGFβ inhibition does not affect pSMAD3 expression in GM-Macs, with and without 
fasudil. 
Quantification of nuclear pSMAD3 expression in GM-Mac subset with and without addition of fasudil 
(10 µM) and/or a TGFβ neutralising antibody (1 ng/ml) for 24 hours, assessed by 
immunocytochemistry. Data presented as percentage of nuclear pSMAD3 positive cells calculated 
within ten random x 40 magnification fields. *** indicates p<0.001, ANOVA, Student-Newman-Keuls 
Multiple Comparisons Test, n=4. N-values in macrophages differentiated from THP-1 cells represent 
number of replicates. 
B: Representative images of immunocytochemistry for pSMAD3 within GM-Macs with and without 
addition of fasudil (10 µM) and/or a TGFβ neutralising antibody (1 ng/ml) for 24 hours. Positive cells 
are shown as red and all nuclei are stained blue with DAPI, nuclear pSMAD3 therefore appears cyan 
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  TGFβ inhibition does not alter TGFB receptor mRNA expression in M-Mac or GM-
Mac subsets 
 
To assess whether endogenous TGFβ regulates macrophage subset TGFB receptor expression, 
q-PCR was performed on both macrophage subsets treated with 10 µM of fasudil and/or 1 
ng/ml of a TGFβ neutralising antibody for 24 hours. Quantification demonstrated that TGFβ 
inhibition does not alter the mRNA expression of TGFBR1, TGFBR2, or TGFBR3 in either the M-


















Figure 3.28 Addition of a TGFβ neutralising antibody did not affect TGFB receptor mRNA expression in either 
M-Mac or GM-Mac subsets. 
Quantification of TGFBR1, TGFBR2, and TGFBR3 mRNA expression in M-Mac and GM-Mac subsets 
derived from THP-1 cells, treated for 24 hours with fasudil (10 µM) and/or a TGFβ neutralising 
antibody (1 ng/ml) and assessed by RT-qPCR. Data presented as fold change against untreated M-
Macs or untreated GM-Macs (mean ± SEM, ANOVA, Student-Newman-Keuls Multiple Comparisons 
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THP-1 cells have been universally used as a model to study macrophage function and behaviour 
(Chanput, Mes et al. 2014), due to their accessibility, easily maintained in tissue culture, and safe due 
to no evidence of any viruses or toxins within the cells. The first aim within this chapter was to assess 
the ability of macrophages differentiated from THP-1 cells to polarise towards distinct macrophage 
subsets in a comparable manner to human PBMC-derived macrophages. Accordingly, due to the ease 
of access and use, THP-1 derived macrophages could supplement human primary macrophages during 
assessments of macrophage subsets. As such, in order to characterise and validate the THP-1 
macrophages, alterations in specific morphological, functional, and molecular characteristics 
observed between primary human macrophage subsets were assessed. 
The actin cytoskeleton has an essential role in modulating morphological, functional, and molecular 
activities in macrophages, including migration, phagocytosis and foam cell formation (Lee and 
Dominguez 2010). Accordingly, the second aim within this chapter was to assess the effect of two 
actin perturbing drugs (fasudil and pravastatin) on the behaviour of different macrophage subsets 
differentiated from THP-1 cells, alongside examining their effect on different cell markers at both 
mRNA and protein levels, and their effect on genes regulating actin cytoskeleton arrangement. It is 
proposed that altered actin cytoskeleton arrangement in macrophage subsets may differentially alter 
their behaviour and subsequently effect the progression of atherosclerosis. 
 
3.3.1 The morphology of macrophages differentiated from THP-1 cells in response to 
different colony stimulating factors 
Macrophages within atherosclerotic plaques exist as a heterogeneous population (Stout and Suttles 
2004). Different CSFs, growth factors, and cytokines have been reported to regulate the differentiation 
of macrophages towards pro- and anti-inflammatory phenotypes (Waldo, Li et al. 2008, Wolfs, 
Donners et al. 2011). Morphological differences have been demonstrated between different 
macrophage subsets. Human monocyte-derived macrophages differentiated in the presence of GM-
CSF for 7 days display a rounded morphology, while M-CSF directed maturation generates 
macrophages with an elongated shape (Waldo, Li et al. 2008). Reassuringly, macrophages 
differentiated from THP-1 cells also exhibited a round-shape when matured with GM-CSF, and an 
elongated morphology with M-CSF differentiation, suggestive of differences in their actin cytoskeleton.  
Actin exists in two forms, a monomeric globular form (G-actin) and a polymeric filamentous form (F-
actin). F-actin imparts a central role in the formation of the dynamic cytoskeleton of the cell, and 




macrophages, the F-actin cytoskeleton also contributes to multiple cellular functions including 
lamellipodia extrusion, cell locomotion, cytokinesis, and phagocytosis (Miller, Worrall et al. 2003, 
Rougerie, Miskolci et al. 2013). Considering the observed differences in cell morphology alongside the 
associated actions of the actin cytoskeleton, F-actin accumulation within macrophage subsets was 
examined. F-actin accumulation within anti-inflammatory M-CSF polarised macrophages was 
markedly greater compared to pro-inflammatory GM-CSF directed macrophages, indicating that actin 
filament rearrangements are different between divergent macrophage subsets. This finding and 
avenue of investigation is supported by the observation that disruption of F-actin filaments using the 
actin perturbing drug chondramide A in tumour-associated macrophages, altered cell shape and 
reduced the viability of anti-inflammatory macrophages while promoting pro-inflammatory 
macrophages properties (Pergola, Schubert et al. 2017). Taken together, the above findings confirm 
that the actin cytoskeleton behaves differently in distinct macrophage subsets, potentially affecting 
their behaviour and function.  
Macrophage maturation is not considered terminal under the exposure of a single CSF. Studies have 
shown competition between different CSFs in macrophage differentiation and polarisation, for 
example, GM-CSF stimulation of M-CSF polarised macrophages can promote switching towards a pro-
inflammatory phenotype (Di Gregoli and Johnson 2012). This proposition has been extended through 
the findings within this chapter which demonstrate MMP-12 as a robust marker for pro-inflammatory 
GM-CSF polarised macrophages derived from THP-1 cells (as is observed in human primary 
macrophages (Waldo, Li et al. 2008) which is upregulated in GM-CSF stimulated M-Macs. These effects 
mirror those of reduced F-actin accumulation within GM-CSF stimulated M-Macs. A possible 
mechanism for GM-CSF reversing the effects of M-CSF polarisation can be garnered from a previous 
study which showed that during inflammation GM-CSF levels are increased while macrophage 
expression of the M-CSF receptor (CSF1R) is compromised, favouring a GM-CSF response, due in part 
to the macrophages reduced ability to react to M-CSF (Becker, Liu et al. 2012). Similarly, a M-CSF 
resistant model has been proposed where under physiological conditions abundant M-CSF dictates 
that macrophages are polarised towards an anti-inflammatory phenotype, but can be converted to 
pro-inflammatory macrophages during inflammation due to increased levels of GM-CSF (Hamilton 
2008). Subsequently, during the resolution phase of inflammation when the levels of GM-CSF are 
lowered, macrophages can revert to an anti-inflammatory phenotype when M-CSF concentrations are 
dominant (Hamilton 2008). Collectively, the results within this chapter alongside the published 
findings suggest that while M-CSF permits canonical macrophage polarisation, their exposure to GM-
CSF promotes transition to a pro-inflammatory phenotype that is resistant to successive M-CSF 




concentrations of M-CSF and/or longer incubation periods to revert back to an anti-inflammatory 
phenotype. 
 
3.3.2 Validation of macrophage subsets differentiated from THP-1 cells 
A primary feature associated with the polarisation of macrophages towards distinct phenotypes is 
their expression of specific markers at mRNA and protein levels. Evidence provided within this chapter 
revealed M-Macs differentiated from THP-1 cells display increased mRNA and protein expression of 
TGFBI, compared to pro-inflammatory GM-Macs. TGFBI is involved in tissue repair  and modulation of 
immune responses (Singh and Ramji 2006), and studies on primary human macrophages showed that 
anti-inflammatory macrophages increase their production of TGFBI after their uptake of apoptotic 
cells (Nacu, Luzina et al. 2008). Additionally, macrophages differentiated from THP-1 cells showed 
increased protein expression of TGFBI after engulfment of apoptotic Jurkat T cells (Nacu, Luzina et al. 
2008). A further study demonstrated that human PBMC-derived anti-inflammatory macrophages 
express high levels of TGFBI compared to pro-inflammatory macrophages (Gratchev, Guillot et al. 
2001). Taken together, these findings demonstrate the applicability of deploying TGFBI as a marker 
for anti-inflammatory macrophages (such as M-Mac), both PBMC-derived and those generated from 
THP-1 cells. 
Conversely, pro-inflammatory GM-Macs differentiated from THP-1 cells under the direction of GM-
CSF displayed an upregulation of MMP-12 mRNA and protein expression when compared to M-CSF 
polarised anti-inflammatory M-Macs. MMP-12 is involved in the degradation of ECM proteins, 
especially elastin, and subsequent remodelling of the arterial wall (Harris, Smith et al. 2010, 
Myasoedova, Chistiakov et al. 2018). Furthermore, MMP-12 has been shown to play a major 
contributory role to the development and progression of atherosclerosis in mouse models and 
humans (Johnson, George et al. 2005, Johnson Jason, Devel et al. 2011, Scholtes, Johnson et al. 2012) 
In line with the findings reported here, two previous studies reported increased expression of MMP-
12 in GM-CSF polarised human PBMC-derived macrophages compared to their M-CSF directed 
counterparts (Waldo, Li et al. 2008, Aristorena, Gallardo-Vara et al. 2019, Di Gregoli, Somerville et al. 
2020). In addition, MMP-12 levels can be significantly upregulated in M-CSF polarised macrophages 
with pro-inflammatory mediators such as LPS, IFN, TNFα, and IL-1β (Huang, Sala-Newby et al. 2012) 
Collectively, the above support the use of MMP-12 as a marker of pro-inflammatory macrophages of 
both PBMC and THP-1 cell origin. 
Comparable to MMP-12, the mRNA and protein expression of SPARC (also known as osteonectin) was 




within M-CSF polarised anti-inflammatory M-Macs. Elevated SPARC expression has been associated 
with calcification, neovascularisation, inflammation, and increased MMP expression within aortic 
stenosis, which have similar characteristics within advanced atherosclerotic plaques (Charest, Pépin 
et al. 2006), Relatedly, it has been previously reported that SPARC promotes pro-inflammatory (M1) 
macrophage polarisation of human PBMC-derived macrophages (Toba, de Castro Brás et al. 2015) , 
and enhances their release of MMP-1 and MMP-9 (Shankavaram, DeWitt et al. 1997). Finally, 
transcriptomic analysis of GM-CSF polarised, and M-CSF directed human PBMC-derived macrophages 
demonstrated SPARC expression was markedly increased in GM-CSF macrophages (Waldo, Li et al. 
2008). Therefore, SPARC can be considered a marker of pro-inflammatory GM-Macs, derived from 
PBMCs and THP-1 cells 
Finally, and in agreement with a previous study (Waldo, Li et al. 2008), TIMP3 mRNA expression is 
increased in pro-inflammatory GM-Macs compared to anti-inflammatory M-Macs, of both PBMC and 
THP-1 origin. However, while a further study also demonstrated GM-CSF polarisation increased TIMP-
3 mRNA levels, protein expression was significantly decreased through a novel post-transcriptional 
mechanism regulated by microRNA-181b (Di Gregoli, Mohamad Anuar Nur et al. 2017) . Comparing 
M1 and M2 human macrophages, elevated TIMP-3 expression was associated with the anti-
inflammatory M2 macrophage subset (Huang, Sala-Newby et al. 2012) . Furthermore, macrophage 
TIMP-3 protein expression within atherosclerotic plaques is restricted to anti-inflammatory 
macrophages (Johnson, Jenkins et al. 2014) , while loss of TIMP-3 expression promotes atherosclerosis 
in mice and TIMP-3 restoration in macrophages prevents plaque progression (Di Gregoli, Mohamad 
Anuar Nur et al. 2017). As such, while decreased TIMP-3 mRNA expression may delineate macrophage 
subsets from both PBMC and THP-1 origin, at the protein level increased TIMP-3 expression is 
observed in anti-inflammatory macrophages. 
Gene array studies showed specific transcriptome differences between M-CSF and GM-CSF polarised 
macrophages with variations in the expression of genes associated with inflammation and cholesterol 
homeostasis (Waldo, Li et al. 2008). Previous studies reported that expression of anti-inflammatory 
molecules such as IL-10 are upregulated in anti-inflammatory macrophages compared to their pro-
inflammatory counterparts (Di Gregoli and Johnson 2012). Reassuringly, this response is mirrored in 
M-Macs differentiated from THP-1 cells.  
Foam cell formation due to the uptake of ox-LDL is an essential process for the progression of 
atherosclerotic plaques. Modified lipids are taken-up through scavenger receptors expressed by 
macrophages (Ley, Miller et al. 2011). Although both M-Mac and GM-Mac subsets uptake lipid and 




the haemostasis of lipids and expression of scavenger receptors (Waldo, Li et al. 2008). M-Macs 
differentiated from THP-1 cells showed increased expression of CD36, MRC1 and MSR1 while GM-
Macs displayed heightened levels of LOX-1 (OLR1) at the mRNA level. Likewise, human M-CSF 
polarised PBMC-derived macrophages had increased expression of CD36, MSR1 and MRC1 and 
decreased expression of LOX-1 compared to GM-CSF directed macrophages (Di Gregoli and Johnson 
2012). Supporting the use of differential scavenger receptor expression for delineating macrophage 
subsets, a further study demonstrated that MRC1 can be used as an M2 or anti-inflammatory 
macrophage marker in both mice and humans (Rőszer 2015). In conclusion, macrophages 
differentiated from THP-1 cells display similar expression patterns of genes that regulates their activity 
and behaviour to that observed in human PBMC-derived macrophages and can be utilised to identify 
changes in their phenotype. 
 
3.3.3 F-actin content in macrophage subsets in response to fasudil or pravastatin 
The assembly of F-actin filaments is in part directed by the Rho family of small GTP-ases and their 
related kinases ROCK1 and ROCK2. Accordingly, fasudil (ROCK inhibitor) and pravastatin (inhibits 
isoprenylation of Rho family of small GTP-ases) have been proposed to directly regulate the actin 
cytoskeleton of cells. Previous studies reported that fasudil caused disruption and decreased 
polymerisation of F-actin filaments and bundles in fibroblasts (Li, Wu et al. 2018). Another study 
demonstrated that fasudil inhibited F-actin filament formation while increasing G-actin content in 
astrocytes (Lau, O'Shea et al. 2011).These findings are in agreement with the observations in this 
chapter which demonstrated fasudil administration to macrophage subsets differentiated from THP-
1 cells decreased their F-actin accumulation. This comparable response further supports the use of 
THP-1 derived macrophages for the assessment of changes in the F-actin cytoskeleton between 
macrophage subsets. Likewise, macrophage subsets differentiated from THP-1 cells showed 
decreased F-actin filament content when treated with pravastatin. In agreement, it has been 
demonstrated that the F-actin cytoskeleton of macrophages became disorganised after treatment 
with a statin  (Kamal, Chakrabarty et al. 2018). Another study showed that the administration of 
fluvastatin caused disruption of F-actin filaments and loss of stress fibre formation in VSMCs (Kato, 
Hashikabe et al. 2004).  
As mentioned above, fasudil and pravastatin significantly induced morphological changes in different 
macrophage subsets associated with F-actin rearrangement within the macrophage subsets examined. 
Changes in the morphology of macrophages might have consequence for cellular behaviour, including 




TGFBI at mRNA and protein levels. This suggests that pravastatin shifts the polarisation of 
macrophages towards an anti-inflammatory phenotype. In support of this proposition, a previous 
study reported that simvastatin and atorvastatin therapy for 6 weeks reduced the number of M1 (pro-
inflammatory) macrophages within human atherosclerotic aortic aneurysms while increasing the 
quantity of M2 (anti-inflammatory) macrophages, apportioned to shifting intra-aneurysm M1 
macrophages towards an M2 phenotype (van der Meij, Koning et al. 2013). The heightened expression 
of TGFBI with statin treatment is in line with reports linking TGFβ levels and statins, with increased 
synthesis of TGFβ observed in monocytes/macrophages upon inhibition of HMG-CoA reductase levels 
through statin addition (Porreca, Di Febbo et al. 2002). Furthermore, studies showed that statins 
promote the activation of the TGFβ-induced Smad pathway, alongside enhanced expression of TGFβ 
receptor type II, and heightened synthesis of TGFβ in VSMCs (Rodríguez-Vita, Sánchez-Galán et al. 
2008).  
As previously stated, MMP-12 is a robust marker of the GM-Mac subset in human PBMC-derived 
macrophages (Waldo, Li et al. 2008, Aristorena, Gallardo-Vara et al. 2019, Di Gregoli, Somerville et al. 
2020) and as demonstrated within this chapter, similarly for GM-CSF directed THP-1 macrophages. 
Supporting the proposed anti-inflammatory properties of statins, the results within this chapter show 
that pravastatin decreased MMP-12 protein levels of THP-1 derived GM-Macs. It has been reported 
previously that statins inhibit macrophage and VSMC production of MMPs (Luan, Chase Alex et al. 
2003) (Hohensinner, Baumgartner et al. 2018). Specifically, simvastatin reduced fibroblast MMP-12 
mRNA expression (Kamio, Liu et al. 2010). Interestingly, while the increased MMP-12 expression in 
GM-CSF polarised macrophages occurs at the mRNA and protein level, the inhibitory action of 
pravastatin administration was only observed at the protein level, suggesting statins may regulate pro-
inflammatory MMP-12 protein levels through a post-transcriptional mechanism, such as microRNA 
regulation. Indeed, a previous study demonstrated that GM-Mac MMP-14 protein expression is 
repressed by a microRNA, miR-24 (Di Gregoli, Jenkins et al. 2014) .  
As such, the concomitant increased expression of the anti-inflammatory marker TGFBI and decreased 
levels of the pro-inflammatory marker MMP-12 in macrophages after treatment with pravastatin, 
suggests that pravastatin shifts macrophages towards an anti-inflammatory phenotype. Considering 
the changes pravastatin also exerted on macrophage F-actin accumulation, a potential mechanism 
linked to the shifting in the polarisation of macrophages may be due to changes in gene expression of 
actin filament modulators. Indeed, findings within this chapter demonstrated the mRNA expression 
of cytoskeletal proteins which facilitate F-actin binding to the cell membrane (fascin, radixin, and 
vinculin) were generally increased in both M-Mac and GM-Mac macrophage subsets after treatment 




significantly enhanced the expression of genes related to the organisation of the actin cytoskeleton 
(Gbelcová, Rimpelová et al. 2017). Related, it was demonstrated that statins prevent activation and 
relocation of RhoA to the cell membrane, therefore preventing ROCK activation at the cell membrane 
and perturbing actin stress fibre formation (Brandes Ralf 2005, Dong, Yan et al. 2010)  We can 
therefore speculate that the deactivation of ROCK through blunted translocation of RhoA to the cell 
membrane, might be due to the regulation of actin binding genes that are regulated by the 
administration of statins. This would suggest that statins regulate the actin cytoskeleton of 
macrophages and subsequently regulate their behaviour and polarisation towards, in part underlying 
their anti-inflammatory response during chronic inflammation, such as is seen during atherosclerotic 
plaque progression. However, given that TGFβ is a growth factor that can modulate intracellular 
signalling mechanisms and MMP expression, while MMP-12 can cleave multiple substrates which may 
influence cell function and TGFβ signalling (Di Gregoli, Somerville et al. 2020), these markers of M-
Mac and GM-Mac subsets respectively, may exert direct effects on the actin cytoskeleton which are 
modulated by statins.  
With regard to THP-1 derived GM-Mac expression of MMP-12, fasudil exerted a similar effect to that 
observed with pravastatin administration chiefly suppressed expression of MMP-12 at the protein 
level with no significant change in mRNA expression. Again, such findings suggest the involvement of 
a novel post-transcriptional mechanism, which requires further investigation to evaluate if a 
microRNA or another epigenetic regulatory pathway directs fasudil modulation of MMP-12 protein 
expression in GM-Macs. Although previous studies have reported that fasudil decreases the 
expression of MMPs (MMP-2 and MMP-9) in retinal microglial cells, markedly perturbing their 
migratory capacity (Xu, Xu et al. 2016), effects on MMP-12 levels have not been previously 
investigated. Nonetheless, the findings within this chapter suggests that fasudil (similar to pravastatin) 
shifts the polarisation of pro-inflammatory GM-Macs towards an anti-inflammatory macrophage 
phenotype, evidenced by decreased expression of MMP-12 (at the protein level). Supporting an anti-
inflammatory action of fasudil, a previous study reported that administration of fasudil to pro-
inflammatory M1 macrophages (polarised with IFN) shiftes their phenotype towards a M2-like 
macrophage, attributed through decreased expression of the M1 marker iNOS alongside upregulated 
expression of the M2 marker CD206 (Liu, Li et al. 2013).  
It should be noted that although TGFBI mRNA expression was increased in THP-1 derived M-Macs, 
protein expression was decreased, suggesting that fasudil shifts the polarisation of anti-inflammatory 
macrophages towards a pro-inflammatory phenotype, an observation that warrants further 
investigation. In agreement with this observation, it has been reported that administration of fasudil 




macrophages towards a pro-inflammatory phenotype by decreasing the expression of anti-
inflammatory macrophage markers (such as CD206) alongside the decreased secretion of anti-
inflammatory molecules such as IL-10 (Zandi, Nakao et al. 2015). 
3.3.4 TGFβ signalling in response to fasudil in anti-inflammatory macrophages 
As mentioned earlier, TGFβ has an essential role in modulation of immune reactions and tissue repair 
(Singh and Ramji 2006). Moreover, TGFβ is a growth factor that can direct multiple functions involved 
in cell differentiation, proliferation, and survival (Gong, Shi et al. 2012). Previous studies reported that 
TGFβ signalling has an essential role in regulating the expression of genes characteristic of M2 (anti-
inflammatory) macrophages. While loss of TGFβ type II receptor expression blunted the polarisation 
of macrophages towards an anti-inflammatory phenotype (Gong, Shi et al. 2012). Within this chapter, 
it is demonstrated that fasudil administration reduced TGFBI protein expression in anti-inflammatory 
M-Macs, implying a shift in polarisation towards a pro-inflammatory phenotype. ROCK (the target of 
fasudil) is considered as a main downstream signalling molecule within the TGFβ pathway, with a 
previous mouse diabetic retinopathy study demonstrating that blocking TGFβ signalling suppressed 
cellular responses associated with ROCK activity, such as elevated expression of α-smooth muscle 
actin (α-SMA) and phosphorylation of myosin light chain (MLC) (Kita, Hata et al. 2008). TGFβ biological 
activity depends on activation of the Smad pathway (Samarakoon, Overstreet et al. 2013), with 
activation of TGFβ signalling significantly augmenting phosphorylation of SMAD3 (Feng, Zhang et al. 
2017). Accordingly, SMAD3 phosphorylation (pSMAD3) was deployed as a marker for the activation of 
TGFβ signalling in this chapter, with GM-Macs displaying reduced pSMAD3 compared to anti-
inflammatory M-Macs, suggesting that TGFβ signalling is blunted in pro-inflammatory macrophages, 
in line with the differences in TGFBI expression. In agreement, it has been reported that the release 
of TGFβI as a result of the activation of TGFβ signalling, is higher in IL-4 polarised anti-inflammatory 
M2 macrophages compared to IFN-directed pro-inflammatory M1 macrophages (Gratchev et al. 
2001).  
Interestingly, although fasudil adminstration to M-Macs blunted TGFβ signalling (as evidenced by 
reduced pSMAD3 and TGFBI expression), this could not be rescued through the addition of 
recombinant TGFβ, suggesting the inhibitory action of fasudil is upon the pathway and not TGFβ itself. 
Exploring the pathway further in this chapter, fasudil did not alter the mRNA or protein expression of 
any TGFβ receptors in M-Macs, or their responsiveness to TGFβ, as shown through assessment of 
pSMAD3 after deployment of a TGFβ neutralising antibody. Therefore, it can be proposed that the 
inhibitory effect of fasudil on the TGFβ signalling pathway within M-Macs is between TGFβ receptor 
activation and phosphorylation of SMAD3, or upon another pathway/mechanism that modulates 




administration of a ROCK inhibitor (Y-27632) to occular fibroblasts blocked TGFβ-mediated pSMAD3 
levels, which was attributed to a decreased SMAD mRNA expression (Feng, Zhang et al. 2017). 
Accordingly, this suggests that in anti-inflammatory M-Macs TGFβ-mediated signalling through 
SMAD3 phosphorylation is facilitated by Rho/ROCK regulation of SMAD3 levels. This hypothesis 
warrants further investigation as it may explain the relationship between F-actin cytoskeleton 
alteration during differential macrophage polarisation and associated anti- and pro-inflammaotry 
actions, such as TGFβ-mediated signalling. 
In conclusion, both M-Macs and GM-Macs treated with pravastatin showed increased expression of 
the anti-inflammatory marker TGFBI and decreased levels of the pro-inflammatory marker MMP-12. 
Fasudil exerted similar effect to that observed with pravastatin co-incubation. GM-Macs treated with 
fasudil showed increased expression of TGFBI and suppressed expression of MMP-12 suggesting that 
pravastatin and fasudil shift macrophages toward an anti-inflammatory phenotype. Since foam cell 
formation due to the uptake of ox-LDL via scavenger receptors expressed by macrophages is an 
essential process for the progression of atherosclerotic plaques, it is important to assess the effect of 















4 EFFECT OF ACTIN-PERTURBING DRUGS ON FOAM CELL 







Monocytes and macrophages and have an essential role in the development of atherosclerotic 
plaques, especially through their uptake of oxLDL via scavenger receptors and their subsequent 
transformation into foam cells within developing intimal lesions (Glass and Witztum 2001). The 
formation of foam cells also plays a central role in the progression of atherosclerosis. As an innate 
immune mechanism concerning self-protection, macrophages uptake and eliminate modified lipids 
via reverse cholesterol transport which involves cholesterol efflux pathways and the regulation of 
specific transporters such as ABCA1 and ABCG1 (Schmitz, Langmann et al. 2001). However, when the 
engulfment of modified lipids exceeds efflux capacity in macrophages, cytoplasmic stored droplets of 
altered lipids accumulate and results in foam cell formation (Zhou, Mei et al. 2012). It has been 
reported that ROCK has a pivotal role in the development of cardiovascular diseases such as 
atherosclerosis. Studies have shown that deficiency of ROCK1 in macrophages inhibited their 
transformation into foam cells and delayed the development of atherosclerotic plaques, thought to 
be due to decreased uptake of modified lipoproteins (Wang, Liu et al. 2008), although it must be noted 
increased cholesterol efflux was not assessed as a potential contributing factor. Similarly, another 
study showed that oxLDL accumulation within macrophages increased ROCK2 activity, and deficiency 
of ROCK2 in bone marrow cells (predominantly monocyte/macrophages) significantly decreased 
atherosclerotic plaque formation within the aorta and aortic sinus (Zhou, Mei et al. 2012). 
Furthermore, ROCK2-deficiency resulted in decreased macrophage foam cell formation due to 
heightened cholesterol through a PPAR/LXR/ABCA1 pathway, effects which could be replicated in 
wild-type macrophages through fasudil administration (Zhou, Mei et al. 2012). Accordingly, we can 
conclude that ROCK signalling within macrophages participates in atherogenesis and therefore ROCK 
inhibition in macrophages might be a therapeutic target for suppressing the development of 
atherosclerosis.  
Treatment of symptomatic CVD patients with statins has been shown to associate with the regression 
of coronary atherosclerotic plaques, and subsequent diminished rates of mortality and morbidity 
related to CVD (Hofnagel, Luechtenborg et al. 2007). In addition to their cholesterol-lowering 
properties, the pleiotropic effect of statin therapy has many clinical implications to atherosclerosis 
including the ability of statins to ameliorate oxidative stress (Tsiara, Elisaf et al. 2003), and therefore 
retard the generation of oxLDL. Relatedly, studies have shown that statins reduce both lipid 
accumulation and foam cell formation within atherosclerotic plaques (Crisby, Nordin-Fredriksson et 




isoprenylation. Activation of the anti-oxidative enzyme catalase inhibits the translocation of Rac1 from 
the cytosol to the cell membrane, resulting in downregulation of NADPH oxidase activity and 
subsequent reduced ROS production (Wassmann, Laufs et al. 2002). It has also been reported that 
statins regulate the expression of scavenger receptors, through the reduced isoprenylation of small 
family GTP-ases such as Ras and Rho. Studies have described that inactivation of Ras and Rho results 
in the downregulation of the expression of multiple macrophage scavenger receptors including LOX-
1 and SR-A (Umetani, Kanayama et al. 1996). Therefore, statin modulation of macrophage scavenger 
receptors through perturbation of Rho/ROCK signalling would be expected to reduce foam cell 
formation, and therefore inhibit lipid core formation/expansion, and subsequently stabilise advanced 
atherosclerotic plaques.  
 
4.1.1 Aim of this chapter 
In this chapter, I attempt to evaluate the effect of actin perturbing drugs (fasudil and pravastatin) on 
the ability of divergent macrophage subsets to accumulate modified lipids and transform into foam 
cells, alongside assessing the effect of fasudil and pravastatin on the ability of different macrophage 








4.2.1 Monocytes exhibit lipid accumulation and early foam cell formation, which is 
blunted by co-incubation with fasudil 
Within the previous chapter it was confirmed that THP-1-derived macrophages display similar 
polarisation towards M-Mac and GM-Mac phenotypes as human blood monocyte-derived 
macrophages, supporting the use of THP-1-derived macrophages for in vitro studies. A further 
benefit of THP-1 cells is their ability to be grown and studied in vitro while remaining 
monocytic, a function not possible with human blood-derived monocytes. This beneficial 
capacity of THP-1 cells was exploited to assess whether monocytes can form foam cells, THP-
1 cells without PMA-induced differentiation to ensure they remain monocytic, were incubated 
with either M-CSF or GM-CSF for either 24 hours or 72 hours alongside 10 µg/ml of Dil-oxLDL. 
Afterwards, cells were subjected to Oil red O staining to visualize oxLDL accumulation (foam 
cell formation). Images revealed that 24-hour M-CSF or GM-CSF stimulated monocytes were 
able to accumulate lipid and form foam cells to a comparable level (Figure 4.1). However, 
monocytes that were incubated for 72 hours with GM-CSF displayed significantly increased 
foam cell formation compared to monocytes incubated for 72 hours with M-CSF (62%; p<0.05; 
n=5; Figure 4.2). Comparing monocyte-derived foam cell formation between the 24-hour and 
72-hour time-points revealed M-CSF stimulated monocytes displayed a significant reduction 
in oxLDL accumulation at the later time-point compared to their 24-hour counterparts (73%; 
p<0.05; n=5; Figure 4.1 and 4.2). However, no statistical difference was observed between 24-
hour and 72-hour GM-CSF-incubated monocytes (Figure 4.1 and 4.2), suggesting M-CSF 





























Figure 4.1 Monocytes incubated for 24 hours with M-CSF or GM-CSF were able to accumulate oxLDL 
and form foam cells. 
A: Quantification of monocyte-derived foam cell formation after 24-hour incubation with M-CSF or 
GM-CSF, plus Dil-oxLDL (10 µg/ml). Monocytes were stained with Oil Red O to visualise accumulation 
of oxLDL. Cells were counted within 10 random x 40 magnification field. *indicates p<0.05, two tailed, 
paired t-test n=5. N-values in macrophages differentiated from THP-1 cells represent number of 
replicates. 
B: Representative images of monocyte-derived foam cells showing lipid accumulation. Monocytes 
were stained with Oil Red O to visualise accumulation of oxLDL (red) and cells counterstained with 













































Figure 4.2 Monocytes incubated for 72 hours with M-CSF or GM-CSF differentially accumulate oxLDL 
and form foam cells. 
A: Quantification of monocyte-derived foam cells after 72-hour incubation with M-CSF or GM-CSF, 
plus Dil-oxLDL (10 µg/ml). Monocytes were stained with Oil Red O to visualise accumulation of oxLDL. 
Cells were counted within 10 random x 40 magnification field. *indicates p<0.05, two tailed, paired t-
test n=5. N-values in macrophages differentiated from THP-1 cells represent number of replicates. 
B: Representative images of monocyte-derived foam cells showing lipid accumulation. Monocytes 
were stained with Oil Red O to visualise accumulation of oxLDL (red) and cells counterstained with 





































To assess the effect of fasudil on monocyte lipid accumulation, monocytes were incubated for 72 
hours with M-CSF or GM-CSF, plus 10 µg/ml of Dil-oxLDL with and without 10 µM of fasudil. Afterwards, 
cells were subjected to Oil Red O staining to visualize oxLDL accumulation (foam cell formation). Image 
analysis demonstrated that fasudil significantly reduced the ability of monocytes incubated with GM-
SCF to form foam cells (36%; p<0.05; n=5; Figure 4.3), whereas fasudil did not change the ability of M-


















Figure 4.3 Fasudil reduced the ability of GM-CSF stimulated monocytes to accumulate oxLDL and 
form foam cells but not with M-CSF stimulated monocytes. 
A: Quantification of monocyte-derived foam cells after 72-hour incubation with M-CSF or GM-CSF, Dil-
oxLDL (10 µg/ml), plus or minus fasudil (10 µM). Monocytes were stained with Oil Red O to visualise 
accumulation of oxLDL. Cells were counted within 10 random x 40 magnification fields. *indicates 
p<0.05, two tailed, paired t-test n=5. N-values in macrophages differentiated from THP-1 cells 
represent number of replicates. 
B: Representative images of monocyte-derived foam cells showing lipid accumulation. Monocytes 
were stained with Oil Red O to visualise accumulation of oxLDL (red) and cells counterstained with 

























































4.2.2 Intermediate and mature GM-CSF polarised macrophages accumulate more 
lipid compared to M-CSF macrophages, which is blunted by the administration 
of fasudil or pravastatin 
To assess the difference in the ability of macrophage subsets to form foam cells, macrophages 
obtained from THP-1 cells were divided into two groups according to the period of time that 
the cells were incubated with colony stimulating factors. The first group were termed 
intermediate macrophages which were treated with M-CSF or GM-CSF for 3 days. The second 
group were classified as mature macrophages and were treated with M-CSF or GM-CSF for 6 
days. Subsequently, intermediate and mature macrophages were exposed to 10 µg/ml of Dil-
oxLDL for 24 hours. Afterwards, cells were subjected to Oil Red O staining to visualize oxLDL 
accumulation (foam cell formation). Image analysis showed that macrophages in both groups 
were able to accumulate lipid and form foam cells (Figure 4.4). However, both intermediate 
and mature GM-Macs displayed significantly increased foam cell formation compared to their 
























Figure 4.4 GM-Macs derived from THP-1 cells in both intermediate and mature groups displayed 
increased foam cell formation compared to M-Macs derived from THP-1 cells. 
A: Quantification of foam cell formation in intermediate and mature M-Mac and GM-Mac after 24-
hour incubation with Dil-oxLDL (10 µg/ml). Macrophages were stained with Oil Red O to visualise 
accumulation of oxLDL. Cells were counted within 10 random x 40 magnification fields. *indicates 
p<0.05, ** indicates p<0.01 compared to M-Mac, two tailed, paired t-test n=5. N-values in 
macrophages differentiated from THP-1 cells represent number of replicates. 
B: Representative images of foam cells showing lipid accumulation within intermediate and mature 
M-Mac and GM-Mac. Macrophages were stained with Oil Red O to visualise accumulation of oxLDL 
(red) and cells counterstained with DAPI (blue) to depict nuclei. Scale bar represents 10 µm and applies 
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To assess the effect of fasudil or pravastatin on the ability of intermediate and mature M-Macs to form 
foam cells, M-Macs in both groups were incubated with 10 µg/ml of Dil-oxLDL alongside either 10 µM 
of fasudil or 5 µM of pravastatin for 24 hours. Image analysis of Oil Red O-stained cells demonstrated 
that neither fasudil or pravastatin affected foam cell formation in intermediate (Figure 4.5) or mature 

















Figure 4.5 Fasudil or pravastatin did not change the ability of intermediate M-Macs derived from 
THP-1 cells to accumulate oxLDL and form foam cells. 
A: Quantification of foam cell formation in intermediate M-Mac after 24-hour incubation with Dil-
oxLDL (10 µg/ml), plus or minus fasudil (10 µM) or pravastatin (5 µM). Macrophages were stained with 
Oil Red O to visualise accumulation of oxLDL. Cells were counted within 10 random x 40 magnification 
fields. ANOVA, Student-Newman-Keuls Multiple Comparisons Test n=5. N-values in macrophages 
differentiated from THP-1 cells represent number of replicates. 
B: Representative images of foam cells showing lipid accumulation within intermediate macrophages. 
Macrophages were stained with Oil Red O to visualise accumulation of oxLDL (red) and cells 















































Figure 4.6 Fasudil or pravastatin did not change the ability of mature M-Macs derived from THP-1 
cells to accumulate oxLDL and form foam cells. 
A: Quantification of foam cell formation in mature M-Mac after 24-hour incubation with Dil-oxLDL (10 
µg/ml), plus or minus fasudil (10 µM) or pravastatin (5 µM). Macrophages were stained with Oil Red 
O to visualise accumulation of oxLDL. Cells were counted within 10 random x 40 magnification fields. 
ANOVA, Student-Newman-Keuls Multiple Comparisons Test n=5. N-values in macrophages 
differentiated from THP-1 cells represent number of replicates. 
B: Representative images of foam cells showing lipid accumulation within mature macrophages. 
Macrophages were stained with Oil Red O to visualise accumulation of oxLDL (red) and cells 

































To assess the effect of fasudil or pravastatin on the ability of intermediate and mature GM-Macs to 
form foam cells, GM-Macs in both groups were incubated with 10 µg/ml of Dil-oxLDL alongside either 
10 µM of fasudil or 5 µM of pravastatin for 24 hours. Quantification of Oil Red-stained cells 
demonstrated that in intermediate GM-Macs, fasudil and pravastatin induced a significant reduction 
in foam cell formation (28%; p<0.05, and 73%; p<0.001 respectively; n=5; Figure 4.7), although the 
inhibitory effect was markedly greater with pravastatin treatment. Similar effects were observed in 



































Figure 4.7 Fasudil or pravastatin reduced the ability of intermediate GM-Macs derived from THP-1 
cells to accumulate oxLDL and form foam cells. 
A: Quantification of foam cell formation in intermediate GM-Mac after 24-hour incubation with Dil-
oxLDL (10 µg/ml), plus or minus fasudil (10 µM) or pravastatin (5 µM). Macrophages were stained with 
Oil Red O to visualise accumulation of oxLDL. Cells were counted within 10 random x 40 magnification 
fields. *indicates p<0.05, ** indicates p<0.01, ANOVA, Student-Newman-Keuls Multiple Comparisons 
Test n=5. N-values in macrophages differentiated from THP-1 cells represent number of replicates. 
B: Representative images of foam cells showing lipid accumulation within the intermediate 
macrophages. Macrophages were stained with Oil Red O to visualise accumulation of oxLDL (red) and 
























































Figure 4.8 Fasudil or pravastatin reduced the ability of mature GM-Macs derived from THP-1 cells to 
accumulate oxLDL and form foam cells. 
A: Quantification of foam cell formation in mature GM-Mac after 24-hour incubation with Dil-oxLDL 
(10 µg/ml), plus or minus fasudil (10 µM) or pravastatin (5 µM). Macrophages were stained with Oil 
Red O to visualise accumulation of oxLDL. Cells were counted within 10 random x 40 magnification 
fields. *indicates p<0.05, ANOVA, Student-Newman-Keuls Multiple Comparisons Test n=5. N-values in 
macrophages differentiated from THP-1 cells represent number of replicates. 
B: Representative images of foam cells showing lipid accumulation within mature macrophages. 
Macrophages were stained with Oil Red O to visualise accumulation of oxLDL (red) and cells 
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4.2.3 GM-Macs derived from human blood monocytes accumulate more lipid 
compared to M-Macs and this is reduced by the administration of fasudil or 
pravastatin 
To validate the results observed in THP-1 cells, human blood-derived monocytes were 
polarised towards an M-Mac or GM-Mac phenotype for seven days then exposed to 10 µg/ml 
of Dil-oxLDL for 24 hours. As observed in THP-1-derived macrophages, primary GM-Macs 
displayed significantly increased foam cell formation (labelled oxLDL accumulation) compared 
to their M-Mac counterparts (3-fold; p<0.05; n=5; Figure 4.9). Also mirroring the effects 
observed in THP-1 cells, fasudil (10 µM) or pravastatin (5 µM) administration significantly 
reduced foam cell formation in primary human GM-Macs (85%; p<0.01, and 92%; p<0.01 














Figure 4.9 GM-Macs derived from human blood-derived monocytes displayed increased foam cell 
formation compared to M-Macs. 
Quantification and representative phase contrast images showing the percentage of foam cells 
formed in human primary macrophages. Macrophages were incubated with Dil-oxLDL (10 µg/ml) for 
24 hours then stained with Oil Red O to visualise oxLDL accumulation. Cells were counted within 10 
random x 20 magnification fields. *indicates p<0.05, two tailed, paired t-test, n=5. Scale bar represents 
200 µm and applies to both panels. N-values in macrophages derived from PBMCs represent the 
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Figure 4.10 Fasudil or pravastatin reduced the ability of GM-Macs derived from human blood-
derived monocytes to accumulate oxLDL and form foam cells. 
Quantification and representative phase contrast images showing the percentage of foam cells 
formed in human primary macrophages. Macrophages were incubated with Dil-oxLDL (10 µg/ml) with 
and without either fasudil (10 µM) or pravastatin (5 µM) for 24 hours, after which cells were stained 
with Oil Red O to visualise oxLDL accumulation. Cells were counted within 10 random x 20 
magnification fields. ** indicates p<0.01, ANOVA, Student-Newman-Keuls Multiple Comparisons Test 
n=5. Scale bar represents 200 µm and applies to all panels. N-values in macrophages derived from 
































4.2.4 Fasudil or pravastatin regulate the mRNA expression of select scavenger 
receptors and lipid transporters that modulate lipid homeostasis in primary 
human macrophages 
Given the marked effect of fasudil and pravastatin on GM-Mac foam cell formation, the 
expression of key scavenger receptors and lipid transporters that regulate macrophage 
cholesterol homeostasis were examined to gain insight into potential mechanisms 
underlying the affect of cytoskeleton-modifying drugs on GM-Mac oxLDL accumulation. In 
brief, human blood-derived monocytes were polarised towards a GM-Mac phenotype for 
differing time periods to generate early (1 day GM-CSF), intermediate (3-day GM-CSF), and 
mature GM-Macs (7-day GM-CSF), which were then treated with 10 µg/ml of Dil-oxLDL with 
and without either 10 µM of fasudil or 5 µM of pravastatin for 24 hours. Subsequent RT-
qPCR analysis was performed on RNA extracted from cells for gene expression of key 
lipoprotein-related scavenger receptors (MSR1, OLR1, CD36, and MRC1) and cholesterol 
efflux genes (ABCG1, PPARA, and NCOR1). All genes were comparable across the early, 
intermediate, and mature in untreated GM-Mac groups, with the exception of OLR1 which 
was decreased in intermediate and mature GM-Macs, and PPARA which was significantly 
increased in mature GM-Macs (Table 4.1). Focussing on early GM-Macs, oxLDL exposure 
increased MRC1 mRNA expression which could be blunted with pravastatin co-incubation, 
but not with fasudil (Table 4.2). ABCG1 levels were also elevated by oxLDL exposure, which 
was not altered by either fasudil or pravastatin co-incubation (Table 4.2). Within 
intermediate GM-Macs, MSR1 and OLR1 mRNA expression was decreased by oxLDL 
exposure and were unaffected by fasudil or pravastatin treatment (Table 4.3). Within 
intermediate GM-Macs, CD36 levels were similarly decreased with oxLDL addition, which 
was reversed with fasudil co-incubation, but not with pravastatin (Table 4.3). Interestingly, 
pravastatin administration alongside oxLDL exposure significantly decreased expression of 
MRC1 and ABCG1 in intermediated GM-Macs (Table 4.3). Finally, in mature GM-Macs mRNA 
expression of OLR1 was significantly decreased while PPARA was increased by oxLDL 
exposure compared to untreated GM-Macs, with both effects unaltered by fasudil or 
pravastatin treatment (Table 4.4). MSR1, ABCG1, and NCOR1 levels were also increased in 
mature GM-Macs exposed to oxLDL, which could be prevented with pravastatin co-


















Table 4.1: Table summarising mRNA expression changes between human monocyte-derived early, 
intermediate, and mature GM-Macs. 
Quantification of key lipoprotein-related scavenger receptors (MSR1, OLR1, CD36, and MRC1) and 
cholesterol efflux genes (ABCG1, PPARA, and NCOR1) in early, intermediate, and mature GM-Mac 
assessed by RT-qPCR. Data presented as fold change compared to unstimulated early GM-Mac (mean 
± SEM; green filled-box indicates significantly decreased compared to unstimulated early 
macrophages (p<0.05); red filled-box indicates significantly increased compared to unstimulated early 
macrophages (p<0.05); two tailed, paired t-test, n=5). N-values in macrophages derived from PBMCs 
represent the number of healthy donors. 
  
GM-Mac Early Intermediate Mature 
Treatment unstimulated unstimulated unstimulated 
CD36 1 1.05 ± 0.2 2.7 ± 1.96 
MSR1 1 0.81 ± 0.58 2.3 ± 1.5 
MRC1 1 1.10 ± 0.83 1.79 ± 1.3 
OLR1 1 0.08 ± 0.07 0.08 ± 0.06 
ABCG1 1 1.49 ± 1.39 2.59 ± 1.4 
PPARA 1 1.27 ± 0.18 2.99 ± 0.58 






Table 4.2: Table summarising mRNA expression changes between human monocyte-derived early 
GM-Macs exposed to oxLDL, with and without fasudil or pravastatin treatment. 
Quantification of key lipoprotein-related scavenger receptors (MSR1, OLR1, CD36, and MRC1) and 
cholesterol efflux genes (ABCG1, PPARA, and NCOR1) in early GM-Mac treated for 24 hours with 10 
µg/ml of Dil-oxLDL, and with or without fasudil (10 µM) or pravastatin (5 µM) and assessed by RT-
qPCR. Data presented as fold change compared to unstimulated early GM-Mac (mean ± SEM; red 
filled-box indicates significantly increased compared to unstimulated (p<0.05); two tailed, paired t-
test, n=5). N-values in macrophages derived from PBMCs represent the number of healthy donors. 
  
Mac Early GM-Mac 





CD36 1 1.39 ± 0.29 0.78 ± 0.19 1.05 ± 0.2 
MSR1 1 2.69 ± 1.26 1.39 ± 0.32 2.23 ± 0.76 
MRC1 1 2.07 ± 0.33 1.78 ± 0.58 0.82 ± 0.50 
OLR1 1 1.93 ± 0.65 2.06 ± 1.86 2.5 ± 1.64 
ABCG1 1 3.61 ± 0.85 2.21 ± 0.88 3.14 ± 1.31 
PPARA 1 1.05 ± 0.06 1.05 ± 0.05 1.05 ± 0.05 




Mac Intermediate GM-Mac 





CD36 1 0.39 ± 0.34 1.09 ± 0.97 0.15 ± 0.14 
MSR1 1 0.36 ± 0.22 0.57 ± 0.37 0.5 ± 0.26 
MRC1 1 0.41 ± 0.27 0.83 ± 0.64 0.07 ± 0.06 
OLR1 1 0.04 ± 0.01 0.07 ± 0.05 0.03 ± 0.02 
ABCG1 1 0.66 ± 0.49 1.73 ± 1.3 0.29 ± 0.22 
PPARA 1 1.27 ± 0.16 1.24 ± 0.13 1.24 ± 0.16 
NCOR1 1 2.23 ± 1.25 4.49 ± 2.03 1.19 ± 0.48 
 
Table 4.3: Table summarising mRNA expression changes between human monocyte-derived 
intermediate GM-Macs exposed to oxLDL, with and without fasudil or pravastatin treatment. 
Quantification of key lipoprotein-related scavenger receptors (MSR1, OLR1, CD36, and MRC1) and 
cholesterol efflux genes (ABCG1, PPARA, and NCOR1) in intermediate GM-Mac treated for 24 hours 
with 10 µg/ml of Dil-oxLDL, and with or without fasudil (10 µM) or pravastatin (5 µM) and assessed by 
RT-qPCR. Data presented as fold change compared to unstimulated intermediate GM-Mac (mean ± 
SEM; green filled-box indicates significantly decreased compared to unstimulated (p<0.05); two tailed, 






Mac Mature GM-Mac 





CD36 1 3.59 ± 2.98 1.79 ± 1.11 2.51 ± 1.9 
MSR1 1 5.43 ± 1.95 5.73 ± 2.35 2.24 ± 0.71 
MRC1 1 3.27 ± 2.55 1.24 ± 0.71 1.78 ± 1.31 
OLR1 1 0.06 ± 0.04 0.01 ± 0.01 0.03 ± 0.02 
ABCG1 1 6.44 ± 2.9 11.12 ± 5.65 10.71 ± 5.78 
PPARA 1 2.79 ± 0.42 3.05 ± 0.42 2.7 ± 0.27 
NCOR1 1 6.05 ± 2.58 5.08 ± 1.53 7.33 ± 2.9 
 
Table 4.4: Table summarising mRNA expression changes between human monocyte-derived mature 
GM-Macs exposed to oxLDL, with and without fasudil or pravastatin treatment. 
Quantification of key lipoprotein-related scavenger receptors (MSR1, OLR1, CD36, and MRC1) and 
cholesterol efflux genes (ABCG1, PPARA, and NCOR1) in mature GM-Mac treated for 24 hours with 10 
µg/ml of Dil-oxLDL, and with or without fasudil (10 µM) or pravastatin (5 µM) and assessed by RT-
qPCR. Data presented as fold change compared to unstimulated mature GM-Mac (mean ± SEM; red 
filled-box indicates significantly increased compared to unstimulated (p<0.05); green filled-box 
indicates significantly decreased compared to unstimulated (p<0.05); two tailed, paired t-test, n=5). 





4.2.5 Fasudil or pravastatin regulate the protein expression of select scavenger 
receptors and lipid transporters in primary human macrophages polarised with 
GM-CSF 
To further examine the results observed at the mRNA level for select scavenger recptors and 
cholesterol efflux regulators in GM-Macs, protein expression for the scavenger receptor OLR1, 
and CD36 alongside the cholesterol efflux regulatory molecules NCOR1, NCOR2, and PPARα 
were assesses in mature GM-Macs. Quantification of western blotting revealed that GM-Mac 
exposure to oxLDL for 24 hours significantly increased the protein expression of OLR1 (2.3-
fold; p<0.05; n=5; Figure 4.11), while co-incubation with fasudil or pravastatin significantly 
suppressed the oxLDL-induced increased OLR1 levels (61% and 54%, p<0.05 respectively; n=5; 
Figure 4.11). Although CD36 protein expression was not significantly increased in GM-Macs 
exposed to oxLDL, similar to OLR1, western blotting revealed that treatment with fasudil or 
pravastatin significantly reduced CD36 levels compared to oxLDL stimulated GM-Macs (70% 
and 64%; p<0.05 respectively; n=5; Figure 4.12). Due to difficulties sourcing reliable antibodies 
for the detection of NCOR1, NCOR2, and PPARα by western blotting, immunocytochemistry 
was deployed to assess cell positivity for these markers. OxLDL stimulation did not alter the 
percentage of GM-Macs positive for NCOR-1, NCOR-2, or PPARα when compared to 
unstimulated GM-Macs (Figures 4.13 – 4.14). However, relative to oxLDL treated GM-Macs, 
fasudil co-incubation significantly increased the percentage of NCOR1, NCOR2, and PPARα 
positive GM-Macs (1.4-fold: p<0.05, 2.0-fold: p<0.01, and 1.2–fold, respectively; p<0.05; n=5; 
Figure 4.13 - 4.15). Similarly, pravastatin co-administration significantly increased the 
percentage of GM-Macs positive for NCOR1, NCOR2, and PPARα compared to oxLDL 
stimulated GM-Macs(1.8-fold: p<0.001, 1.8-fold: p<0.01, and 1.3-fold; p<0.01 respectively; 

























Figure 4.11 Fasudil or pravastatin co-incubation reduced OLR1 protein expression in GM-Macs 
derived from human blood-derived monocytes treated with oxLDL. 
Quantification and representative western blot for OLR1 expression in GM-Macs treated with oxLDL 
(10 µg/ml) and with or without fasudil (10 µM) or pravastatin (5 µM). Stain free gel is shown as a 
loading control. Data presented as fold change (mean ± SEM, * indicates P< 0.05 vs GM-Mac, 
$ indicates P<0.05 vs GM-Mac + oxLDL. ANOVA, Student-Newman-Keuls Multiple Comparisons, n=5). 
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Figure4.12 Fasudil or pravastatin co-incubation reduced CD36 protein expression in GM-Macs 
derived from human blood-derived monocytes treated with oxLDL. 
Quantification and representative western blot for CD36 expression in GM-Macs treated with oxLDL 
(10 µg/ml) and with or without fasudil (10 µM) or pravastatin (5 µM). Stain free gel is shown as a 
loading control. Data presented as fold changed (mean ± SEM, * indicates P< 0.05. ANOVA, $ indicates 
P<0.05 vs GM-Mac + oxLDL. ANOVA, Student-Newman-Keuls Multiple Comparisons, n=5). N-values in 
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Figure 4.13 Fasudil and pravastatin co-incubation increased the percentage of NCOR1 positive GM-
Macs derived from human blood-derived monocytes. 
A: Quantification of cellular NCOR1 protein expression in GM-Macs exposed to oxLDL (10 µg/ml), and 
with or without fasudil (10 µM) or pravastatin (5 µM). Data presented as percentage of NCOR1 positive 
cells calculated within 10 random x 40 magnification fields. *indicates p<0.05, *** indicates p<0.001, 
$ indicates P<0.05 vs GM-Mac + oxLDL, $$ indicates P<0.01 vs GM-Mac + oxLDL. ANOVA, Student-
Newman-Keuls Multiple Comparisons Test, n=5 
B: Representative images of immunocytochemistry for NCOR1 within GM-Macs exposed to oxLDL (10 
µg/ml), and with or without fasudil (10 µM) or pravastatin (5 µM). Positive cells are shown as green 
and all nuclei are stained blue with DAPI. Scale bar represents 10 µm and applies to all panels. N-values 




























































Figure 4.14 Fasudil and pravastatin co-incubation increased the percentage of NCOR2 positive GM-
Macs derived from human blood-derived monocytes. 
A: Quantification of cellular NCOR2 protein expression in GM-Macs exposed to oxLDL (10 µg/ml), and 
with or without fasudil (10 µM) or pravastatin (5 µM). Data presented as percentage of NCOR2 positive 
cells calculated within 10 random x 40 magnification fields. ** indicates p<0.01, $$ indicates P<0.01 
vs GM-Mac + oxLDL. ANOVA, Student-Newman-Keuls Multiple Comparisons Test, n=5. N-values in 
macrophages derived from PBMCs represent the number of healthy donors. 
B: Representative images of immunocytochemistry for NCOR2 within GM-Macs exposed to oxLDL (10 
µg/ml), and with or without fasudil (10 µM) or pravastatin (5 µM). Positive cells are shown as green 
and all nuclei are stained blue with DAPI. Scale bar represents 10 µm and applies to all panels. 
C: Representative Western blot for NCOR2. Stain free gel is shown as a loading control. Approximate 
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Figure 4.15 Fasudil and pravastatin co-incubation increased the percentage of PPARα positive GM-
Macs derived from human blood-derived monocytes. 
A: Quantification of cellular PPARα protein expression in GM-Macs exposed to oxLDL (10 µg/ml), and 
with or without fasudil (10 µM) or pravastatin (5 µM). Data presented as percentage of PPARα positive 
cells calculated within 10 random x 40 magnification fields. *indicates p<0.05, ** indicates p<0.01, 
$ indicates P<0.05 vs GM-Mac + oxLDL, $$ indicates P<0.01 vs GM-Mac + oxLDL. ANOVA, Student-
Newman-Keuls Multiple Comparisons Test, n=5. N-values in macrophages derived from PBMCs 
represent the number of healthy donors. 
B: Representative images of immunocytochemistry for PPARα within GM-Macs subsets exposed to 
oxLDL (10 µg/ml), and with or without fasudil (10 µM) or pravastatin (5 µM). Positive cells are shown 
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4.2.6 Efferocytosis capacity is diminished in GM-CSF polarised macrophages but can 
be restored by fasudil and pravastatin addition  
Alongside the uptake of modified lipoproteins including oxLDL, macrophages can also engulf 
cells undergoing apoptosis through a process termed efferocytosis. To assess the efferocytosis 
capacity of M-CSF and GM-CSF polarised macrophage subsets, THP-1 cells were driven 
towards the two opposing macrophage subsets and then subjected to an efferocytosis assay 
which involves the addition of pre-labelled (green fluorescent protein) apoptotic macrophages. 
Their subsequent engulfment is quantified by merging fluorescence and polarised light 
microscopy images. Image analysis and associated quantification demonstrated that GM-
Macs exhibited significantly reduced efferocytosis compared to M-Macs (3-fold; p< 0.01; n=5; 
Figure 4.16). However, when GM-Macs were co-incubated with 5 µM of pravastatin their 
efferocytosis capacity was restored (3-fold; p<0.01; n=5; Figure 4.17), Moreover, co-
incubation with 10 µM of fasudil was able to increase the efferocytosis capacity of GM-CSF 




























Figure 4.16 GM-Macs derived from human blood-derived monocytes display decreased 
efferocytosis capacity compared to M-Macs. 
Quantification and representative images showing the percentage of M-Mac and GM-Mac undergoing 
efferocytosis as determined by the positivity for the uptake of exogenously added apototic 
macrophages (green). Cells were counted within 10 random x 40 magnification fields. ** indicates 
p<0.01, two tailed, paired t-test n=5. Scale bar represents 10 µm and applies to both panels. N-values 
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Figure 4.17 Fasudil and pravastatin increased the efferocytosis capacity of GM-Macs derived from 
human blood-derived monocytes. 
Quantification and representative images showing the percentage of GM-Macs positive for the uptake 
of apototic macrophages (green) with and without co-incubation with 10 µM of fasudil or 5 µM of 
pravastatin. Cells were counted within 10 random x 40 magnification fields. ** indicates p<0.01 
compared to GM-Mac, ANOVA, Student-Newman-Keuls Multiple Comparisons Test n=5. Scale bar 
represents 10 µm and applies to all panels. N-values in macrophages derived from PBMCs represent 







































Recent studies have shown that macrophage foam cell formation has a crucial role in both 
atherogenesis and the progression of atherosclerosis (Yu, Fu et al. 2013). Mechanistically, scavenger 
receptors including CD36 and MSR1 function as principal receptors to recognise and facilitate the 
uptake of modified lipoprotein, chiefly oxLDL. Once ingested, macrophages can efficiently process 
oxLDL-derived cholesterol to facilitate its export as HDL, with genes involved in reverse cholesterol 
transport and efflux, such as ABCA1 and ABCG1, capable of preventing macrophage foam cell 
formation (Li and Glass 2002). Consequently, in order to limit the accumulation of macrophage-
derived foam cells and subsequently the development and progression of atherosclerosis, a balance 
is needed between the uptake of lipids and their efflux from macrophages (Yu, Fu et al. 2013). As such, 
the main goal of this chapter is to investigate the ability of two divergent macrophage subsets (M-CSF 
and GM-CSF polarised macrophages) to accumulate lipid and form foam cells, alongside examining 
the effect of different actin perturbing drugs (fasudil and pravastatin) on macrophage foam cell 
formation. 
 
4.3.1 Lipid accumulation in monocytes and their response to fasudil treatment 
During the development and progression of atherosclerotic plaques, macrophage foam cell formation 
is an important characteristic, and their accrual is associated with adverse atherosclerosis-related 
clinical events. Macrophage foam cell formation is largely dictated by the dysregulated accumulation 
of cholesterol-rich modified lipoproteins (such as oxLDL) by phagocytosis, a process dependent on the 
deformation and invagination of the plasma membrane that is mediated by remodelling of the actin 
cytoskeleton (Aderem and Underhill 1999, Schrijvers, De Meyer et al. 2007). Monocytes are recruited 
to developing atherosclerotic plaques and mature into macrophages in order to facilitate their ability 
to phagocytose modified lipids, but recent evidence has suggested that monocytes, to a lesser extent, 
can themselves accumulate lipids (Mosig, Rennert et al. 2008, Mosig, Rennert et al. 2009). Our studies 
(using a monocytic cell line – THP-1) showed that monocytes can indeed accumulate lipids when co-
incubated with M-CSF or GM-CSF for both 24 and 72 hours. However, monocyte accumulation of 
oxLDL is markedly increased within GM-CSF-stimulated monocytes compared to M-CSF treated 
monocytes. These findings are in line with those from Mosig and colleagues who demonstrated 
differential oxLDL accumulation between divergent monocyte subsets retrieved from patients with 
familial hypercholesterolaemia, which appeared to be CD36-dependent (Mosig, Rennert et al. 2009). 
Moreover, monocyte accumulation of modified lipoproteins heightens their capacity to localise and 




chemokine receptors and adhesion molecules, such as CX3CR1 and β2-integrin (Mosig, Rennert et al. 
2009). Furthermore, proof-of-principle studies in hypercholesterolaemic Apoe-deficient mice also 
demonstrated monocyte accumulation of modified lipoproteins with associated altered function and 
phenotype of monocytes, and contributed to accelerated atherosclerotic plaque formation (Xu, Dai 
Perrard et al. 2015). Similarly, in hypercholesterolaemic Ldlr-deficient mice the accumulation of 
modified lipoproteins within circulating monocytes has been described, subsequently impairing their 
chemotaxis (Jackson, Weinrich et al. 2016). Mechanistically, monocyte engulfment of modified 
lipoproteins directly altered the dynamics of their actin cytoskeleton, through changes in the activity 
of RhoA (Jackson, Weinrich et al. 2016). Collectively, these findings suggest that modulating the actin 
cytoskeleton of monocytes, through perturbation of Rho signalling for instance, may prevent their 
uptake of modified lipoproteins and associated adverse contribution to atherosclerotic plaque 
development. 
4.3.2 Lipid accumulation in GM-Macs and modulation through fasudil or pravastatin 
treatment 
The findings presented reveal that in comparison to M-CSF, GM-CSF treatment of human monocytes 
or GM-CSF directed polarisation of either THP-1 cells or PBMC-derived macrophages, increased 
cytoplasmic lipid accumulation and subsequent foam cell formation. Published supporting findings 
have suggested that M-CSF and GM-CSF may have divergent effects on macrophage foam cell 
formation by differently expressing genes related to the homeostatsis of cholesterol (Waldo, Li et al. 
2008). Within the previous chapter, it was demonstrated that the actin cytoskeleton of macrophages 
is differentially affected by M-CSF or GM-CSF polarisation, which may be associated with the similar 
divergent regulation of foam cell formation between the two macrophage subsets. Indeed, in line with 
the proposition that the actin cytoskeleton may regulate lipid accumulation, foam cell formation was 
suppressed in GM-Macs (either THP-1 or PBMC-derived) through the addition of fasudil or pravastatin. 
This data suggest that statins are pleiotropic, and some of their beneficial effects on atherosclerosis 
are through anti-inflammatory mechanisms. Indeed, we can speculate from our findings that, through 
its pleiotropic effects, statin treatment suppresses macrophage foam cell formation through 
modulation of the actin cytoskeleton in pro-inflammatory, pro-atherosclerotic macrophages (GM-
Macs).It has been demonstrated that statin treatment is effective at reducing adverse coronary events 
(atherosclerosis-dependent MI) in patients with elevated CRP levels but low LDL-cholesterol levels 
(Ridker, Rifai et al. 2001). It has been reported in the Pravastatin Inflammation/CRP Evaluation 
(PRINCE); a multicentre, community-based trial, demonstrated that pravastatin (40 mg/day) reduced 
average CRP levels by 17% in coronary disease patients, mainly independent of lipid lowering (Albert, 




demonstrated that simvastatin (20 mg/day), pravastatin (40 mg/day), and atorvastatin (10 mg/day) 
significantly decreased high-sensitive CRP levels in patients suffering from hyperlipidaemia, which 
supports the anti-inflammatory effect of these drugs (Jialal, Stein et al. 2001). Another study showed 
that cerivastatin therapy for 8 weeks significantly reduced CRP levels by 13.3% among 785 patients 
suffering from primary hypercholesterolemia mainly in a lipid-independent manner (Ridker Paul, Rifai 
et al. 2001). 
As scavenger receptors are fundamental for the uptake of modified lipoproteins such as oxLDL, 
associated assessment of the key molecules demonstrated that several scavenger receptors, such as 
CD36 at mRNA level, is not changed by the co-incubation with fasudil or pravastatin, while the protein 
expression of CD36 is significantly reduced. Similarly, the mRNA expression of OLR1 is significantly 
reduced with the addition of oxLDL which is unaffected by the co-incubation with fasudil or pravastatin. 
On the other hand, the protein expression of OLR1 was significantly increased with the addition of 
oxLDL and it was significantly reduced with the co-incubation of fasudil or pravastatin. This suggests 
the involvement of a post-transcriptional mechanism that needs further investigation. Alongside the 
uptake of modified lipoproteins, efficient reverse cholesterol transport including cholesterol efflux 
from macrophages ensures that modified lipoproteins do not adversely accumulate within cells. 
Considering the increased foam cell formation observed within GM-CSF polarised macrophages, it is 
plausible that cholesterol efflux-associated genes/proteins are dysregulated in addition to increased 
scavenger receptor expression, and that modifying the actin cytoskeleton reverses such deleterious 
effects. Indeed, although mRNA expression of some cholesterol efflux genes such as NCOR1 were not 
altered in GM-CSF polarised macrophages, According to table 4.4, oxLDL addition to GM-Macs 
increased the mRNA expression of ABCG1, NCOR1, and PPARA, which was unaffected by fasudil, and 
suppressed by statin co-incubation for ABCG1 and NCRO1. Opposingly, the protein expression for 
NCOR1, NCOR2, and PPARα was not changed by oxLDL addition, but significantly increased by fasudil 
or pravastatin co-incubation suggesting enhanced cholesterol efflux. These findings highlight that a 
discrepancy exists between the mRNA and protein expression of cholesterol efflux mediators in 
mature GM-CSF polarised macrophages upon oxLDL accumulation. Similarly, in GM-Mac-derived foam 
cells, the actin cytoskeleton modifying drugs fasudil and pravastatin, differentially affect NCOR1 or 
PPARA mRNA and protein levels. Collectively, these novel results imply the involvement of a post-
transcriptional regulatory mechanism, such as the involvement of microRNAs, or protein modification 
pathways including ubiquitination or SUMOylation. In support of this proposition it has been reported 
that microRNA-generating enzyme Dicer has an essential role in macrophage activation in 
atherosclerotic plaque. Apoe-/- mice with Dicer deficient macrophages showed increased 




al. 2018). Another study showed miR-10b decrease the ability of peritoneal macrophages to efflux 
cholesterol by downregulating the expression of ABCA1, the expression of miR-10b is upregulated in 
advanced atherosclerotic plaques of Apoe-/- mice and the treatment with antagomiR-10b was able to 
promote reverse cholesterol transport in peritoneal macrophages by upregulating the expression of 
ABCA1 (Wang, Wang et al. 2018). It has been demonstrated that miR-19b enhances accumulation of 
cholesterol in THP-1 derived macrophages as well as mouse peritoneal macrophages and the 
formation of foam cells by blocking the efflux cholesterol of macrophages to apolipoprotein A-I (apoA-
I), the main protein component in HDL. MiR-19b directly binds to 3’UTR of ABCA1 transporter and 
regulates its expression resulting in the progression of aortic atherosclerotic plaques(Lv, Tang et al. 
2014). Corroborating studies have demonstrated a contributory role for PPARα in suppressing 
macrophage foam cell formation and subsequent atherosclerotic plaque development (Li, Binder et 
al. 2004, Srivastava 2011). Furthermore, statins have been shown to inhibit Rho/ROCK signalling and 
subsequently increase PPARα activity and suggest increased reverse cholesterol transport (Martin, 
Duez et al. 2001), providing additional credence to the findings within this chapter.  
As discussed previously, the aim of this study was to assess the effects of modulating the actin 
cytoskeleton on M-CSF polarised (M-Mac) and GM-CSF directed (GM-Mac) macrophage phenotypes, 
with particular focus on their ability to accumulate modified lipoproteins and subsequently modulate 
foam cell formation. Consequently, and in light of the above findings, using strategies to modulate the 
macrophage actin cytoskeleton or down-stream modulated pathways may be deployed 
therapeutically to influence the progression of cardiovascular diseases such as atherosclerosis. It has 
been demonstrated that ROCK2 deficiency in macrophages decreased macrophages lipid 
accumulation through enhanced cholesterol efflux PPAR/ABCA1-dependent, and in association, 
decreased atherosclerosis (Zhou, Mei et al. 2012). 
 
4.3.3 Efferocytosis capacity between different macrophage subsets and modulation 
through fasudil or pravastatin treatment 
Efferocytosis is a process in which immune cells, especially macrophages, can engulf apoptotic cell 
debris and remove dying cells, and is essential to prevent non-resolving inflammatory diseases such 
as atherosclerosis (Yurdagul, Doran et al. 2017). Accordingly, it has been demonstrated that defective 
efferocytosis is a crucial determinant of atherosclerosis lesion progression and the development of 
unstable advanced plaques (Yurdagul, Doran et al. 2017). Within this chapter I have demonstrated 
that GM-CSF polarised macrophages display impaired efferocytosis capacity compared to M-CSF 
polarised macrophages, which can be restored to M-Mac levels through the addition of pravastatin 




and Rho kinase inhibitor (Y-27632) significantly enhanced the efferocytosis capacity in macrophages 
via their ability to inactivate RhoA in both in vitro and in vivo studies (Morimoto, Janssen et al. 2006).  
Another study demonstrated that during lipopolysaccharide-induced neutrophil influx in the pleural 
cavity of mice, ROCK inhibition by fasudil, or Y-27632 was able to increase the efferocytosis capacity 
in macrophages (Galvão, Athayde et al. 2019). This data suggests a possible strategy to activate and 
















5 EFFECT OF SUMOYLATION ON MACROPHAGE SUBSET 







SUMOylation is a posttranslational modification that involves the covalent attachment of a small 
ubiquitin-like modifier (SUMO) proteins to lysine residues within specific protein substrates via an 
enzymatic cascade (Dehnavi, Sadeghi et al. 2019). SUMOylation is an essential modification that 
regulates the cellular, molecular, and systemic properties and functions of proteins (Dehnavi, Sadeghi 
et al. 2019) SUMO proteins have a molecular weight of 10 kDa and are considered members of the 
ubiquitin-like family. In humans, the SUMO family consists of four isoforms (Chang and Abe 2016); 
SUMO1 shares 50% sequence similarity to SUMO2, while SUMO2 shares 97% sequence identity to 
SUMO3. SUMO1, 2, and 3 are widely expressed, while SUMO4 can only be found within the spleen, 
lymph nodes, and kidneys. Additionally, the expression of mature SUMO4 has been demonstrated 
within cells under extreme stress conditions (Le, Sandhu et al. 2017). SUMO proteins are released in 
an inactive form that requires activation and maturation via sentrin-specific peptidases (SENPs). 
Binding of SUMOs to their substrates occur in three steps. First, mature SUMOs attach to SUMO-
Activating Enzyme Subunit 1 or 2 (SAE1/SAE2) that is known as E1 activating enzyme, the first step is 
ATP-dependent and needs ATP to be activated. Second, SUMO is passed to the E2 conjugating enzyme 
Ubc9. Finally, Ubc9 passes SUMO onto the E3 ligase Pc2 (polycomb protein 2), PIAS (protein inhibitor 
of activated STAT), and RanBP2 (Ran-binding protein 2) so that it can be attached to its target substrate. 
The attachment of a SUMO protein to its substrate is reversible, with deSUMOylation occuring via 
SENPs that leads to the release of mature SUMO from its target protein (as illustrated in figure 5.1) 


















Figure 5.1 Summary of SUMOylation pathway 
The precursor of small ubiquitin-like modifier (SUMO) is released in an inactive form and is matured 
and activated by sentrin specific proteases (SENPs). The first step which is an ATP-dependent step 
where mature SUMOs bind to (SAE1/SAE2) known as E1 activating enzyme. Second step, SUMO is 
passed to Ubc9 ,the E2 conjugating enzyme. Final step, Ubc9 passes SUMO onto the E3 ligase to be 
attached to target protein. SUMO protein attachment is reversible, with deSUMOylation occuring via 
SENPs. SENPs, sentrin specific proteases; SAE1/SAE2, SUMO-Activating Enzyme subunit 1/2; Ubc9, 










Sumoylation has been proposed to modulate multiple divergent and complimentary signalling 
pathways associated with atherosclerosis, including the pro-inflammatory NFĸB pathway. NFĸB is 
located in the cytoplasm of cells in an inactive form due to its attachment to members of the 
endogenous inhibitors of NFĸB, such as NFĸB Inhibitor Alpha (NFKBIA), also known as IkBα. Within 
atherosclerotic plaques, NFĸB is activated due to the presence of different pro-inflammatory factors 
including pro-inflammatory cytokines such as TNFα, or disturbed blood flow and associated low shear 
stress that leads to the upregulation of IkB kinase and subsequent phosphorylation of IkBα (Brown, 
Gerstberger et al. 1995). Phosphorylation of IkBα leads to its inactivation and the free NFĸB is able to 
translocate to the nucleus and mediate the upregulation of pro-inflammatory genes such as SELE (E-
selectin), VCAM1, ICAM1, and MCP1 (Xiao, Liu et al. 2013). It has been reported that SUMOylation 
regulates the activity of NFĸB. SUMOylation of IkBα via SUMO1 reduces its destruction and 
subsequently blocks NFĸB nuclear translocation and therefore downregulates the activation of NFĸB 
pathway. On the other hand, SUMOylation of IkBα via SUMO2/3 inactivates IkBα and subsequently 
upregulates NFĸB pathway (Desterro, Rodriguez et al. 1998) (Le, Sandhu et al. 2017). A similar pathway 
which has also been linked to atherosclerosis and proposed to undergo regulation through 
SUMOylation is the MAP kinase pathway. It has been reported that ROS and disturbed blood flow/low 
shear stress increases SUMOylation of Mitogen-Activated Protein Kinase 7 (MAPK7; also known as 
ERK5), a transcription factor that has an essential role in the growth and differentiation of endothelial 
cells. SUMOylation of MAPK7 inhibits the protein expression of eNOS in endothelial cells leading to 
endothelial cell dysfunction and inflammation, mechanisms associated with early atherosclerotic 
plaque formation (Le, Corsetti et al. 2012). These studies highlight the potential for the SUMOylation 
pathway to modulate cellular function and processes involved in atherosclerosis, although the role of 
SUMOylation in macrophage behaviour is understudied.  
A recent study reported that SUMOylation regulates processes related to the cellular cytoskeleton, 
including microtubule‐associated proteins, intermediate filaments, actin polymerisation, and actin‐
regulatory proteins (Alonso, Greenlee et al. 2015). It has been shown that SUMO2/3 are the 
preferential isoforms responsible for the modification of the actin cytoskeleton. Cellular fractionation 
experiments demonstrated that SUMOylation of actin (monomeric G-actin) was more abundant 
within the nuclear fraction, resulting in the inhibition actin filament formation (polymerisation into F-
actin) (Hofmann, Arduini et al. 2009). The Rho family of GTPases (such as Rac1 and RhoA) have also 
been shown to undergo regulation by SUMO proteins (Dehnavi, Sadeghi et al. 2019). It has been 
reported that SUMOylation of Rac1 by SUMO1 enhances cell migration and the formation of 
lamellipodia. SUMOylation is important for optimal binding of GTP to Rac1, and it has been 




inactive GDP-bound state. Relatedly, Rho GDP-dissociation inhibitors (RhoGDI) are also regulated by 
SUMOylation, and activation of RhoGDI via SUMOylation downregulates the activity of the Rho family 
of GTPases, which results in the inhibition of actin filament polymerisation (Yu, Zhang et al. 2012). 
Given the differences observed between M-Mac and GM-Mac morphology and associated F-actin 
accumulation, it is plausible that SUMOylation may differentially regulate the actin cytoskeleton in the 
two macrophage subsets. 
Topotecan is a topoisomerase I inhibitor agent used as a chemotherapeutic drug to treat cervical 
cancer, ovarian cancer, and small cell lung cancer (Pommier 2006). Topotecan is water-soluble and a 
semi-synthetic analogue of a natural camptothecin compound that was originally isolated from a 
Chinese tree, Camptotheca acuminate (Robati, Holtz et al. 2008). Topotecan blocks the activity of 
topoisomerase I and enhances the separation and repair of DNA strands during division; it prevents 
cancer cells from differentiation and growth, and therefore induces the death of cancerous cells. 
Moreover, topotecan has been shown to modulate the SUMOylation status of DNA topoisomerase I 
(Mo, Yu et al. 2002), and therefore topotecan has subsequently been proposed as a global inhibitor of 
SUMOylation (Bernstock, Ye et al. 2017). One of the cytotoxic properties of topotecan is due to its 
interference with the cytoskeletal elements of the cell such as actin filaments and microtubules (Wang, 
Tanaka et al. 2016). It has been reported that topotecan can instigate degradation and changes in 
cytoskeletal proteins (Cohen, Geva-Zatorsky et al. 2008). An in vitro study using Hela cells showed that 
topotecan reduced actin polymerisation (less F-actin) which was associated with a change in cell 
morphology and inhibiting their motility (Wang, Tanaka et al. 2016). As such, topotecan is a suitable 
compound to explore modulation of SUMOylation and subsequent effects on the actin cytoskeleton 
in divergent macrophage populations, which display disparate morphologies. 
Given the results from the previous two chapters demonstrate GM-CSF polarisation dictates the 
generation of a distinct macrophage phenotype compared to M-CSF polarisation, an understanding of 
the down-stream signalling pathways triggered by GM-CSF is of importance. The Janus Kinase/Signal 
Transducer and Activator of Transcription (JAK/STAT) signalling pathway is one of the most essential 
pathways responsible for the differentiation and maturation of monocyte/macrophages (Leonard and 
O'Shea 1998). The STAT family consists of seven members, STAT 1- 4, 5A, 5B, and STAT6. Binding of 
GM-CSF to its receptor activates the JAK tyrosine kinases, in turn, activated JAKs such as JAK2 results 
in activation of cytoplasmic STAT5A/B via phosphorylation, and the formation of homo- or 
heterodimers that are able to enter the nucleus and regulate the expression of distinct target genes 
(Lehtonen, Matikainen et al. 2002). Other than tyrosine phosphorylation, it has been shown that 
acetylation, ubiquitylation, and SUMOylation can modulate STAT signalling. SUMOylation of STAT5A/B 




phosphorylation of STAT5A/B occurs, suggesting that SUMOylation and phosphorylation of STAT5A/B 
act antagonistically to each other (Krämer and Moriggl 2012). A recently developed compound, 3-
hydroxy-1, 2, 3-benzotriazin-4(3H)-one (HODHBt), a benzotriazole derivative, which is a specific 
STAT5-SUMO protein-protein interaction inhibitor, that blocks SUMOylation of phosphorylated STAT5. 
As such, HODHBt retards the inhibitory effect of SUMO2/3 on STAT5 and therefore permits 
phosphorylation and activation of STAT5 and its translocation to the nucleus to drive gene expression 
(Bosque, Nilson et al. 2017).  
 
5.1.1  Aims of this chapter 
In the previous chapter, discrepancies were observed between mRNA and protein levels of some key 
molecules, suggesting the involvement of a post-transcriptional regulatory mechanism, such as 
SUMOylation. In this chapter, the aim is to evaluate the effect of SUMOylation on pro-inflammatory 
macrophage (GM-Mac) behaviour by using a global SUMOylation inhibitor (topotecan), alongside a 
specific inhibitor of STAT5 SUMOylation (HODHBt). In addition, the potential mechanisms by which 
SUMOylation regulates the properties of GM-Macs are assessed alongside preliminary investigation 
on the expression of SUMOylation-related proteins within human atherosclerotic plaques, to support 








5.2.1 Unstable plaques exhibit decreased SUMO1 and SUMO2/3 protein expression 
compared to non-diseased arteries and stable plaques 
In light of the recent evidence (provided in the introduction) demonstrating SUMOylation can regulate 
the actin cytoskeleton of cells alongside modulating functions related to inflammation such as 
phagocytosis and efferocytosis, the expression of key SUMOylation proteins was examined within 
human coronary artery atherosclerotic plaques. Specifically, to ascertain whether SUMOylation 
proteins (SUMO1 and SUMO2/3), inhibitors of SUMOylation (SENP3), and a potential SUMOylation 
target key to GM-CSF polarisation (pSTAT5A) were differentially expressed during atherosclerotic 
plaque progression and related to inflammation, immunohistochemistry was performed in three 
groups; sections of non-diseased coronary arteries, stable plaques, and unstable plaques. Image 
analysis and associated quantification of regions known to be rich in macrophage accumulation, 
demonstrated a significantly increased number of cells expressing pSTAT5A in stable and unstable 
plaques compared to non-diseased arteries (1.6-fold: p<0.01, 1.5-fold: p<0.05, respectively; n=10; 
Figure 5.2). The majority of positive cells were within the macrophage-rich shoulder regions of the 
atherosclerotic plaques. The percentage of intra-plaque cells expressing SUMO1 was also increased in 
stable plaques compared to non-diseased arteries SUMO1 (1.5-fold; p<0.001; n=10; Figure 5.3). 
However, a significant decrease in SUMO1 positive cell percentage was observed in unstable plaques 
when compared to stable lesions (49%; p<0.001; n=10; Figure 5.3) and non-diseased arteries (22%; 
p<0.05; n=10; Figure 5.3). SUMO2/3 positive cell percentage was also increased within stable plaques 
compared to non-diseased arteries (2.5-fold; p<0.001; n=10; Figure 5.4) and unstable plaques (1.9-
fold; p<0.001; n=10; Figure 5.4), while no statistically significant difference was detected between 
unstable plaques and non-diseased artery sections (Figure 5.4). Mirroring the changes seen for 
pSTAT5A, the percentage of intra-plaque cells positive for SENP3 was increased within stable (1.6-fold; 
p<0.01; n=10; Figure 5.5) and unstable plaques (1.3-fold; p<0.05; n=10; Figure 5.5), when compared 
to non-diseased artery sections. Taken together, these observations indicate key proteins involved in 
the SUMOylation pathway are differentially expressed during atherosclerotic plaque development 























Figure 5.2 The percentage of pSTAT5A positive cells is increased in both stable and unstable human 
plaques. 
Quantification and representative images of immunohistochemistry for pSTAT5A showing the 
percentage of pSTAT5A positive cells within non- diseased and atherosclerotic human coronary 
arteries defined as stable and unstable. Positive cells are stained brown and all nuclei are stained blue 
with haematoxylin. Percentage of positive cells was calculated within 10 random x 40 magnification 
fields. * indicates p<0.05, ** indicates p<0.01, ANOVA, Student-Newman-Keuls Multiple Comparisons 
Test, n=10. Scale bar represents 100 µm and applies to all panels. N-values represent number of 
patients with coronary arteries histologically defined as non-diseased, harbouring stable, or unstable 

























































Figure 5.3 The percentage of SUMO1 positive cells is increased in stable plaques and decreased in 
unstable human plaques. 
Quantification and representative images of immunohistochemistry for SUMO1 showing the 
percentage of SUMO1 positive cells within non- diseased and atherosclerotic human coronary arteries 
defined as stable and unstable. Positive cells are stained brown and all nuclei are stained blue with 
haematoxylin. Percentage of positive cells was calculated within 10 random x 40 magnification fields. 
* indicates p<0.05 and *** indicates p<0.001 compared to non-diseased, ### indicates p<0.001 
compared to stable plaques, ANOVA, Student-Newman-Keuls Multiple Comparisons Test, n=10. Scale 
bar represents 100 µm and applies to all panels. N-values represent number of patients with coronary 
arteries histologically defined as non-diseased, harbouring stable, or unstable plaques (n=10/group) 




























































Figure 5.4 The percentage of SUMO2/3 positive cells is increased in stable human plaques. 
Quantification and representative images of immunohistochemistry for SUMO2/3 showing the 
percentage of SUMO2/3 positive cells within non- diseased and atherosclerotic human coronary 
arteries defined as stable and unstable. Positive cells are stained brown and all nuclei are stained blue 
with haematoxylin. Percentage of positive cells was calculated within 10 random x 40 magnification 
fields. *** indicates p<0.001 compared to non-diseased and unstable plaques, ANOVA, Student-
Newman-Keuls Multiple Comparisons Test, n=10. Scale bar represents 100 µm and applies to all panels. 
N-values represent number of patients with coronary arteries histologically defined as non-diseased, 
























































Figure 5.5 The percentage of SENP3 positive cells is increased in both stable and unstable human 
plaques. 
Quantification and representative images of immunohistochemistry for SENP3 showing the 
percentage of SENP3 positive cells within non- diseased and atherosclerotic human coronary arteries 
defined as stable and unstable. Positive cells are stained brown and all nuclei are stained blue with 
haematoxylin. Percentage of positive cells was calculated within 10 random x 40 magnification fields. 
** indicates p<0.01 and * indicates p<0.05 compared to non-diseased arteries, ANOVA, Student-
Newman-Keuls Multiple Comparisons Test, n=10. Scale bar represents 100 µm and applies to all panels. 
N-values represent number of patients with coronary arteries histologically defined as non-diseased, 









































5.2.2 Topotecan reduces the ability of M-Mac and GM-Mac macrophages to uptake 
lipid and form foam cells 
Given the differential expression patterns of SUMO proteins, SENP3, and pSTAT5A (a key signalling 
molecule in GM-CSF macrophage polarisation), perturbation of SUMOylation in divergent macrophage 
subsets was explored. As discussed within the introduction, topotecan acts as a global SUMOylation 
inhibitor. Accordingly, to detect the effect of SUMOylation on the activity of different macrophage 
subsets, in the first instance a range of different doses of topotecan was administered to macrophages 
in order to identify the appropriate concentration of topotecan to modulate macrophage subsets 
without affecting cell viability (cytotoxicity). 
Results with topotecan treatment showed that 5 µM and 1 µM of topotecan caused a significant 
increase in the percentage of dying cells (65.1%, 295% respectively) for M-Mac, and (69.8%, 33.9% 
respectively) for GM-Mac (Figure 5.6) and therefore considered cytotoxic. However, 0.5 µM of 
topotecan did not significantly increase cell death numbers in the GM-Mac subset, but marginally 
remained significantly cytotoxic to the M-Mac subset (22.4%; p<0.05; Figure 5.6). Based on these 


















Figure 5.6 Effect of topotecan on M-Mac and GM-Mac cell viability 
Quantification of cell death in M-Mac and GM-Mac subsets derived from primary human macrophages 
and treated for 24 hours with increasing doses of topotecan, assessed by immunocytochemistry. Data 
presented as percentage of dead cells calculated within six random x 20 magnification fields. *** 
indicates p<0.001, ** indicates p<0.01, * indicates p<0.05 compared to respective unstimulated M-
Mac or GM-Mac control; ANOVA, Student-Newman-Keuls Multiple Comparisons Test, n=4. N-values 











































- ac  
µ  
topotecan 






- ac GM-Mac + 
5 µM 
topotecan 









Next, the selected dose of topotecan was assessed and validated for its ability to alter foam 
cell formation in the two different macrophage subsets derived from primary human 
macrophages. Human blood-derived monocytes were divided into two groups according to 
the period of time that the cells were incubated with colony stimulating factors. The first 
group were termed early macrophages, which were freshly isolated monocytes treated with 
M-CSF or GM-CSF for one day. The second group were classified as mature macrophages, 
which were freshly isolated monocytes treated with M-CSF or GM-CSF for 7 days. Finally, both 
groups were exposed to 10 µg/ml of Dil-oxLDL with and without 0.25 µM topotecan for 24 
hours. Cells were subjected to Oil Red O staining to visualize oxLDL accumulation (foam cell 
formation). Image analysis and subsequent quantification demonstrated that in early 
macrophages, 0.25 µM of topotecan induced a significant reduction in foam cell formation for 
both M-Mac and GM-Mac subsets (53.4%; p<0.05, and 48.5%; p<0.05 respectively; n=5; Figure 
5.7). Similar effects were observed in mature macrophages with topotecan treatment of both 



























Figure 5.7 Topotecan reduced the ability of early M-Mac and GM-Mac subsets derived from human 
PBMCs to accumulate oxLDL and form foam cells. 
Quantification and representative images showing the percentage of foam cells formed from human 
primary macrophages. Macrophages were incubated with Dil-oxLDL (10 µg/ml) with and without 
topotecan (0.25 µM) for 24 hours, after which cells were stained with Oil Red O to visualise oxLDL 
accumulation. Cells were counted within 10 random x 40 magnification fields. * indicates p<0.05, two 
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Figure 5.8 Topotecan reduced the ability of mature M-Mac and GM-Mac subsets derived from 
human PBMCs to accumulate oxLDL and form foam cells. 
Quantification and representative images showing the percentage of foam cells formed from human 
primary macrophages. Macrophages were incubated with Dil-oxLDL (10 µg/ml) with and without 
topotecan (0.25 µM) for 24 hours, after which cells were stained with Oil Red O to visualise oxLDL 
accumulation. Cells were counted within 10 random x 40 magnification fields. * indicates p<0.05, two 
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5.2.3 Topotecan regulates the mRNA expression of scavenger receptors MSR1 and 
CD36 as well as lipid transporters ABCA1 and ABCG1 in primary human 
macrophage subsets 
The previous results showed that topotecan (0.25 µM) was able to regulate foam cell 
formation in both M-Mac and GM-Mac subsets derived from primary human macrophages. 
As such, qPCR was performed to assess whether alterations in foam cell formation were 
associated with changes in the mRNA expression of key scavenger receptors and lipid 
tranporters that regulate cholesterol homeostasis, and to gain insight into potential 
mechanisms underlying the effect of topotecan on foam cell formation. Human blood-
derived monocytes were polarised to M-Mac and GM-Mac over 7 days and then treated with 
10 µg/ml of Dil-oxLDL with and without 0.25 µM of topotecan for 24 hours. Subsequent RT-
qPCR analysis was performed on RNA extracted from cells for gene expression of key 
lipoprotein-related scavenger receptors (MSR1, OLR1, MRC1, and CD36), and cholesterol 
efflux-related genes (NCOR1, PPARA, ABCG1, and ABCA1). The data revealed that although 
topotecan did not significantly affect the mRNA expression of MRC1, OLR1, or PPARA in M-
Macs (Figure 5.9), topotecan co-adminstration increased oxLDL-induced mRNA expression 
of the cholesterol efflux-related genes ABCA1, ABCG1, and NCOR1) in M-Macs (3.4-fold; 
p<0.05; 5.8-fold ; p<0.001; and 14.4-fold; p<0.001 respectively; n=5; Figure 5.9). Conversely, 
mRNA levels of the scavenger receptor MSR1 were downregulated by topotecan treatment 
of oxLDL stimulated M-Macs (2.4-fold; p<0.05; n=5; Figure 5.9). Whereas in GM-Macs, only 
the mRNA expression of the key lipoprotein-related scavenger receptor CD36 was 
suppressed by topotecan co-adminstration to oxLDL-exposed macrophages(1.7-fold; p<0.05; 
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Figure 5.9 Topotecan addition alters the mRNA expression of select key lipoprotein-related 
scavenger receptors and lipid transporters in M-Macs and GM-Macs derived from human PBMCs. 
Quantification of MSR1, CD36, OLR1, MRC1, ABCA1, ABCG1, and NCOR1 mRNA expression in M-Mac 
and GM-Mac subsets exposed to oxLDL (10 µg/ml) with and without topotecan (0.25 µM) for 24 hours 
and assessed by RT-qPCR. Data presented as fold change against M-Macs or GM-Macs exposed to 
oxLDL alone (mean ± SEM, *indicates p<0.05, and *** indicates p<0.001, two tailed, paired t-test, n=5). 
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5.2.4 Topotecan regulates the protein expression of scavenger receptors in primary 
human macrophages 
Next, validative studies were perfomred to determine if the changes observed at the mRNA 
level translated to differential protein expression, first focussing on the scavenger receptors 
MSR1 and CD36 in M-Mac and GM-Mac, respectively. In agreement, western blotting 
demonstrated that topotecan co-administration to oxLDL-exposed early and mature M-Macs 
significantly decreased protein expression of MSR1 (3-fold: p<0.001 and 1.6-fold: p<0.05 
respectively; n=5; Figure 5.10). Interestingly, a similar reduction in OLR1 protein levels was 
also detected (2-fold: p<0.05, and 1.7-fold; p<0.05 respectively; n=5; Figure 5.10), in 
discordance with mRNA levels which were unchanged, suggesting the involvement of a post-
transcriptional mechanism. In GM-Macs, topotecan co-administration significantly decreased 
protein expression of CD36 in both early and mature cells (1.5-fold: p<0.05, and 1.4-fold; 





























Figure 5.10 Topotecan reduced MSR1 and OLR1 protein levels in early and mature M-Macs derived 
from human PBMCs. 
Quantification and representative western blots for (A) MSR1 and (B) OLR1 protein expression in early 
and mature M-Macs treated with oxLDL (10 µg/ml) and with or without topotecan (0.25 µM). Stain 
free gel is shown as a loading control. Data presented as fold change (mean ± SEM, *indicates p<0.05, 
two tailed, paired t-test, n=5). N-values in macrophages derived from PBMCs represent the number 































































Figure 5.11 Topotecan significantly reduced the protein expression of scavenger receptors CD36 in 
GM-Macs derived from human blood monocytes. 
Quantification and representative western blots for CD36 protein expression in early and mature GM-
Macs treated with oxLDL (10 µg/ml) and with or without topotecan (0.25 µM). Stain free gel is shown 
as a loading control. Data presented as fold change (mean ± SEM, *indicates p<0.05, two tailed, paired 



























5.2.5 Topotecan increases the efferocytosis capacity of GM-CSF polarised 
macrophages 
As mentioned earlier, efferocytosis is a process in which macrophages can engulf dying cells 
to eliminate necrosis-associated inflammation. The results in Chapter 4 (Figure 4.17) 
demonstrated that GM-Macs display diminished efferocytosis capacity compared to their M-
Mac counterparts. Given that topotecan altered macrophage expression of scavenger 
receptors (which can also facilitate efferocytosis), the effect of topotecan on efferocytosis of 
pre-labelled (green fluorescent protein) apoptotic macrophages was assessed. Image analysis 
and associated quantification confirmed human PBMC-derived GM-Macs have reduced 
capacity compared to M-CSF controls, but is restored to comparable levels with administration 
of 0.25 µM topotecan (1.4-fold; p< 0.01; n=5; Figure 5.12). However, topotecan did not alter 




























Figure 5.12 Topotecan increased the efferocytosis capacity of GM-Macs 
Quantification and representative images showing the percentage of M-Mac and GM-Mac undergoing 
efferocytosis as determined by the positive uptake of exogenously added apototic macrophages 
(green), with and without co-incubation with topotecan (0.25 µM). Cells were counted within 10 
random x 40 magnification fields. ** indicates p<0.01, two tailed, paired t-test, n =5. Scale bar 
represents 200 µm and applies to all panels. N-values in macrophages derived from PBMCs represent 
























































5.2.6 Topotecan regulates the protein expression of pSTAT5A in primary human GM-
CSF polarised macrophages 
Considering the global SUMOylation inhibitor topotecan exerted profound effects on GM-Mac 
behaviour of foam cell formation and efferocytosis capacity, and differential expression patterns of 
SUMO proteins and pSTAT5A are associated with human coronary atherosclerotic plaque progression, 
the effect of topotecan on STAT5A phosphorylation was examined in GM-Macs. Human blood-derived 
monocytes were polarised to GM-Macs for 7 days and subsequently treated with 10 µg/ml of Dil-
oxLDL with and without 0.25 µM topotecan for 24 hours. Then, cells were assessed for differential 
protein expression by western blotting and fluorescent immunocytochemistry for pSTAT5A. 
Quantification of western blotting revealed that topotecan increased pSTAT5A protein levels in GM-
Macs exposed to oxLDL (3.5-fold; p<0.05; n=5; Figure 5.13). Topotecan upregulation of GM-Mac 














Figure 5.13 Topotecan increased pSTAT5A levels in GM-Macs co-incubated with oxLDL. 
Quantification and representative western blot for pSTAT5A expression for GM-Macs treated with 
oxLDL (10 µg/ml) and with or without topotecan (0.25 µM). Stain free gel is shown as a loading control. 
Data presented as fold change (mean ± SEM, * indicates P< 0.05. two tailed, paired t-test, n=5). N-
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Figure 5.14 Topotecan increased pSTAT5A expression in GM-Macs co-incubated with oxLDL. 
A: Quantification of cellular pSTAT5A protein expression in GM-Macs exposed to oxLDL (10 µg/ml) 
with and without topotecan (0.25 µM) for 24 hours, assessed by immunocytochemistry. Data 
presented as percentage of pSTAT5A positive cells calculated within 10 random x 40 magnification 
fields. ***indicates p<0.001; two tailed, paired t-test, n=4. N-values in macrophages derived from 
PBMCs represent the number of healthy donors. 
B: Representative images of immunocytochemistry for pSTAT5A within GM-Macs exposed to oxLDL 
(10 µg/ml) with and without topotecan (0.25 µM) for 24 hours. Positive cells are shown as green and 








































5.2.7 HODHBt increases STAT5A phosphorylation in primary human macrophages 
polarised with GM-CSF 
As topotecan acts as a global SUMOylation inhibitor, the observed effects on pSTAT5A levels maybe 
indirect. To explore if indeed STAT5 phosphorylation is directly regulated by SUMOylation, HODHBt 
was deployed. HODHBt is a SUMO:STAT5 interaction inhibitor, and therefore blocks STAT5-specific 
SUMOylation, resulting in increased STAT5 phosphorylation and associated activity. Human blood-
derived monocytes were polarised to GM-Macs for 7 days and subsequently treated with 10 µg/ml of 
Dil-oxLDL with or without 100 µM HODHBt for 24 hours. A recent study showed that addition of 100 
µM of HODHBt inhibited the SUMOylation of STAT5 (Bosque, Nilson et al. 2017). This protocol was 
used throughout this chapter to assess the effect of HODHBt on GM-Mac gene expression and 
behaviour. Then, cells were assessed for protein expression analysis by fluorescent 
immunocytochemistry for pSTAT5A. Image analysis and associated quantification demonstrated that 
HODHBt co-administration significantly increased protein expression of pSTAT5A (3.5-fold: p<0.05; 
n=5; Figure 5.15), to comparable levels as topotecan, demonstrating SUMOylation regulates STAT5A 




























Figure 5.15 HODHBt increased pSTAT5A expression in GM-Macs co-incubated with oxLDL. 
A: Quantification of cellular pSTAT5A protein expression in GM-Macs exposed to oxLDL (10 µg/ml) 
with and without HODHBt (100 µM) for 24 hours, assessed by immunocytochemistry. Data presented 
as percentage of pSTAT5A positive cells calculated within 10 random x 20 magnification fields. 
*indicates p<0.05; two tailed, paired t-test, n=4. N-values in macrophages derived from PBMCs 
represent the number of healthy donors. 
B: Representative images of immunocytochemistry for pSTAT5A within GM-Macs exposed to oxLDL 
(10 µg/ml) with and without HODHBt (100 µM) for 24 hours. Positive cells are shown as green and all 
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5.2.8 HODHBt decreases the F-actin content in GM-CSF polarised macrophage foam 
cells 
Results from the previous chapters demonstrated that perturbation of F-actin accumulation in GM-
Macs is associated with their shift towards an anti-inflammatory phenotype, as evidenced by 
increased expression of TGFBI and TIMP-3, alongside a concomitant decrease in MMP-12 (a STAT5 
regulated gene). Accordingly, the effect of blocking STAT5:SUMO interaction (and therefore increasing 
STAT5 phosphorylation) on F-actin accumulation was assessed in GM-Macs exposed to oxLDL 
alongside HODHBt. Image analysis and quantification of AlexaFluor 594-conjugated phalloidin 
fluorescent images demonstrated that GM-Macs exposed to oxLDL alongside treatment with HODHBt 
























Figure 5.16 HODHBt treatment reduced GM-Mac foam cell F-actin content. 
A: Quantification of F-actin content within GM-Macs exposed to oxLDL (10 µg/ml) with or without 
HODHBt (100 µM) for 24 hours, measured within 10 random x 20 magnification fields. ** indicates 
p<0.01; two tailed, paired t-test, n=5. N-values in macrophages derived from PBMCs represent the 
number of healthy donors. 
B: Representative images of F-actin within GM-Macs treated with oxLDL (10 µg/ml) with or without 
HODHBt (100 µM) for 24 hours, stained with AlexaFluor 594-conjugated phalloidin (red) alongside a 
























   









5.2.9 HODHBt increases the ability of GM-CSF polarised macrophages derived from 
human blood monocytes to accumulate lipid and form foam cells 
To assess if the effect of HODHBt on GM-Mac F-actin content is related to their ability to accumulate 
modified lipoproteins, the capacity of GM-Macs to form foam cells in the presence of HODHBt was 
assessed. Oil Red O staining of GM-Macs to visualise oxLDL accumulation (foam cell formation) was 
subjected to image analysis and quantification, which demonstrated that in GM-Macs, HODHBt 
induced a significant increase in foam cell formation (2.5-fold; p<0.01; n=5; Figure 5.17). These results 
indicate SUMOylation of STAT5 and resultant decreased phosphorylation/activity, blunts the capacity 













Figure 5.17 HODHBt increased the ability of GM-Macs to accumulate oxLDL and form foam cells. 
Quantification and representative images of foam cells formation in human GM-Macs after 24-hour 
incubation with oxLDL (10 µg/ml), plus or minus HODHBt (100 µM).Macrophages were stained with 
Oil Red O to visualise accumulation of oxLDL. Cells were counted within 10 random x 20 magnification 
fields. * indicates p<0.05, two tailed, paired t-test n=5. Scale bar represents 10 µm and applies to both 
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5.2.10 HODHBt upregulates OLR1 and MMP12 mRNA expression in GM-CSF polarised 
macrophages derived from human blood monocytes 
Given the heightened foam cell formation afforded by HODHBt treatment of GM-Macs, the 
effect of HODHBt on the expression of select scavenger receptors (OLR1, MSR1, and CD36), 
and lipid tranporters (PPARA, and NCOR1) were assessed to elucidate the effect of inhibiting 
STAT5 SUMOylation on foam cell formation. In addition, the expression of the STAT5-
responsive gene and cell marker of the GM-Mac susbet, MMP12, was also examined. 
Subsequent RT-qPCR analysis demonstrated that there was no significant change at the 
mRNA level of the scavenger receptors MSR1 and CD36, or the lipid transporters PPARA and 
NCOR1 (data not shown). However, HODHBt (100 µm) addition significantly increased the 
mRNA expression of OLR1 (2-fold; p<0.05; n=5; Figure 5.18) and MMP12 (5-fold; p<0.01; n=5; 









Figure 5.18 HODHBt addition upregulated the mRNA expression of OLR1 and MMP12 in GM-Mac 
foam cells. 
Quantification of OLR1 and MMP12 mRNA expression in GM-Macs exposed to oxLDL (10 µg/ml) with 
and without HODHBt (100 µM) for 24 hours and assessed by RT-qPCR. Data presented as fold change 
against untreated GM-Macs (mean ± SEM, *indicates p<0.05, ** indicates p<0.01, two tailed, paired 
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5.2.11 HODHBt upregulates OLR1 and MMP-12 protein expression in GM-CSF 
polarised macrophages derived from human blood monocytes 
Data revealed that GM-Macs exposed to oxLDL and treated with HODHBt (100 µM) 
significantly increased the protein levels of OLR1 (1.8-fold; p<0.01; n=5; Figure 5.19). Similarly, 
HODHBt administration significantly increased and the percentage of MMP-12 positive GM-
















Figure 5 19 HODHBt increased GM-Mac foam cell OLR1 protein expression. 
A: Quantification and representative images of OLR1 protein expression in GM-Macs exposed to oxLDL 
(10 µg/ml) with and without HODHBt (100 µM) for 24 hours, as assessed by immunocytochemistry. 
Positive cells are shown as green and all nuclei are stained blue with DAPI. Data presented as 
percentage of OLR1 positive cells calculated within 10 random x 20 magnification fields. **indicates 
p<0.01; two tailed, paired t-test, n=5. Scale bar represents 10 µm and applies to both panels. N-values 
in macrophages derived from PBMCs represent the number of healthy donors. 
B: Representative western blot for OLR1 expression of GM-Macs treated exposed to oxLDL (10 µg/ml) 
with and without HODHBt (100 µM) for 24 hours. Stain free gel is shown as a loading control. 
































Percentage of OLR1 positive cells
*
*
GM-Mac + oxLDL + HODHBt 
A 
B 31 kDa- 
31 kDa- 
OLR1 
Stain free gel 





















Figure 5 20 HODHBt increased GM-Mac MMP-12 protein expression. 
Quantification and representative images of MMP-12 protein expression in GM-Macs exposed to 
oxLDL (10 µg/ml) with and without HODHBt (100 µM) for 24 hours, as assessed by 
immunocytochemistry. Positive cells are shown as green and all nuclei are stained blue with DAPI. 
Data presented as percentage of MMP-12 positive cells calculated within 10 random x 40 
magnification fields. **indicates p<0.01; two tailed, paired t-test, n=5. Scale bar represents 10 µm and 
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5.2.12 HODHBt upregulates POU2F1 protein expression and increases its co-
localisation with pSTAT5A in GM-Mac foam cells 
Considering the elevated STAT5 phosphorylation afforded from HODHBt treatment in GM-
Macs (through blocking SUMOylation of STAT5) resulted in increased OLR1 expression, it is 
surprising that there are no predicted STAT5 binding sites observed within the promoter 
region of the human OLR1 gene (Figure 5.21). However, a previous study has shown that after 
phosphorylation, STAT5 can bind to POU2F1 (also known as OCT1) within the nucleus to form 
a complex that is necessary for the activation of target genes such as cyclin D1, in epithelial 
cells (Magné, Caron et al. 2003). Subsequent analysis of the predicted transcription factor 
binding sites within the human OLR1 promoter region identfied 12 POU2F1 (Oct-1) binding 
sites (Figure 5.21), greater than sites for any other transcription factor.Consequently, it was 
determined whether POU2F1 and pSTAT5A do indeed co-localise within human GM-Mac foam 
cells, and if treatment with HODHBt increases their co-expression. Dual-fluorescence 
immunocytochemistry and associated quantification confirmed the nuclear co-localisation of 
POU2F1 and pSTAT5A in GM-Mac foam cells (Figure 5.22), and demonstrated that HODHBt 
treatment significantly increased the co-expression of POU2F1 and pSTAT5A (1.5-fold; p<0.05 








Figure 5.21 Predicted transcription factor binding sites within the promoter of human OLR1.  
The thirteen predicting POU2F1 (Oct-1) binding sites within the promoter region of human OLR1 are 





















Figure 5 22 HODHBt increased GM-Mac foam cell co-expression of POU2F1 and pSTAT5A. 
Quantification and representative images of POU2F1 and pSTAT5A expression in GM-Macs exposed 
to oxLDL (10 µg/ml) with and without HODHBt (100 µM) for 24 hours, as assessed by dual-
immunocytochemistry. Cells positive for POU2F1 are shown as green, pSTAT5A positive cells are in 
red and all nuclei are stained blue with DAPI. Cells positive for POU2F1 and pSTAT5A appear as yellow 
within the merged images. Data presented as percentage of cells positive for POU2F1 and pSTAT5A 
calculated within 10 random x 40 magnification fields. **indicates p<0.01; two tailed, paired t-test, 
n=5. Scale bar represents 10 µm and applies to both panels. N-values in macrophages derived from 
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5.2.13 HODHBt heightens the efferocytosis capacity of GM-CSF polarised foam cell 
macrophages derived from human blood monocytes 
As mentioned earlier, efferocytosis is a process in which macrophages can uptake cells 
undergoing apoptosis to eliminate succeeding necrosis and associated inflammation. Earlier 
in this Chapter, global inhibition of SUMOylation (with topotecan) was shown to increase GM-
Mac efferocytosis (Figure 5.12). Therefore, to determine if SUMOylation specifically of STAT5 
modulates GM-Mac efferocytosis capacity, macrophages were subjected to an efferocytosis 
assay in the presence of HODHBt. Image analysis and associated quantification demonstrated 
that the low efferocytosis capacity of GM-Macs was significantly heightened after treatment 
with 100 µM of HODHBt (3.6-fold; p< 0.001; n=5; Figure 5.23), echoing the effect observed 
with topotecan. Interestingly, HODHBt did not alter the efferocytosis capacity of non-foam 
cell GM-Macs (Figure 5.23). A plausible explanation for this discrepancy is that SUMOylation 
of STAT5 and subsequent heightened efferocytosis in GM-Macs is induced as a result of oxLDL 























Figure 5.23 HODHBt increased the efferocytosis capacity of GM-Mac foam cells, but not non-foamy 
GM-Macs. 
Quantification and representative images showing the percentage of GM-Mac foam cells positive for 
the uptake of apototic macrophages (green) with and without HODHBt (100 µM) co-incubation for 24 
hours. Cells were counted within 10 random x 40 magnification fields. *** indicates p<0.001 compared 
to all groups; ANOVA, Student-Newman-Keuls Multiple Comparisons Test; n=5. Scale bar represents 
10 µm and applies to all panels. N-values in macrophages derived from PBMCs represent the number 
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5.2.14 Fasudil interferes with HODHBt-mediated efferocytosis of GM-CSF foam cell 
macrophages, but nifedipine is ineffective 
Efficient efferocytosis can be mediated by actin cytoskeleton and Ca+2 signalling-mediated 
mechanisms (Tajbakhsh, Rezaee et al. 2018) To assess if the enhanced efferocytosis capacity 
of GM-Mac foam cells provided by HODHBt treatment relies on the aformentioned 
mechanisms, fasudil and nifedipine were deployed to prevent actin polymerisaton and stress 
fibre formation, alongside the modulation of Ca+2 signalling, respectively. Image analysis and 
associated quantification demonstrated that GM-Mac foam cells co-incubated with fasudil (10 
µM) and HODHBt (100 µM) exhibited significantly reduced efferocytosis compared to GM-Mac 
foam cells treated with fasudil alone (2-fold; p< 0.01; n=4; Figure 5.24). However, the 
efferocytosis capacity of GM-Mac foam cells was unaffected by co-incubation with of 
nifedipine (10 nM) and HODHBt (100 µM) compared to nifedipine alone (Figure 5.25). These 
findings suggest that the heightened efferocytosis engendered in GM-Mac foam cells through 
sustained STAT5 phosphorylation (HODHBt blocking of STAT5 SUMOylation), is mediated 






















Figure 5.24 Fasudil co-incubation reduced the HODHBt-induced efferocytosis capacity of GM-Mac 
foam cells. 
Quantification and representative images showing the percentage of GM-Mac foam cells positive for 
the uptake of apototic macrophages (green) with and without co-incubation of fasudil (10 µM) and 
HODHBt (100 µM) for 24 hours. Cells were counted within 10 random x 20 magnification fields. * 
indicates p<0.05 vs GM-Mac + oxLDL, $ indicates p<0.05 vs GM-Mac + oxLDL + fasudil; ANOVA, 
Student-Newman-Keuls Multiple Comparisons Test; n=4. Scale bar represents 10 µm and applies to all 

































-   LDL 
 
GM-Mac + oxLDL 
+ fasudil 
GM-Mac + oxLDL 


















Figure 5.25 Nifedipine co-incubation did not alter the HODHBt-induced efferocytosis capacity of 
GM-Mac foam cells  
Quantification and representative images showing the percentage of GM-Mac foam cells positive for 
the uptake of apototic macrophages (green) with and without co-incubation of nifedipine (10 Nm) and 
HODHBt (100 µM) for 24 hours. Cells were counted within 10 random x 20 magnification fields. ** 
indicates p<0.01 compared to GM-Mac + oxLDL control; ANOVA, Student-Newman-Keuls Multiple 
Comparisons Test; n=4. Scale bar represents 10 µm and applies to all panels. N-values in macrophages 
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5.2.15 Fasudil alters GM-Mac foam cell membrane expression of OLR1 
Previous data presented within this chapter demonstrates that the mRNA and protein levels 
of the scavenger receptor OLR1 are increased in GM-Macs when treated with HODHBt (100 
µM), suggesting that HODHBt-amplified STAT5 activity (through blocking its SUMOylation) 
upregulates the expression of OLR1, and facilitates foam cell formation and efferocytosis 
capacity. Given that fasudil blocks the beneficial effect of HODHBt on efferocytosis in GM-Mac 
foam cells (Figure 5.24), while OLR1 expression is increased with HODHBt treatment (Figure 
5.19), the effect of fasudil on the augmented OLR1 expression within GM-Mac foam cells 
induced by HODHBt, was explored. Quantification of western blotting confirmed HODHBt 
treatment increased GM-Mac foam cell total OLR1 levels (1.8-fold; p<0.01; n=4; Figure 5.26), 
whereas fasudil had no effect in isolation or on co-incubation with HODHBt (Figure 5.26). 
Considering OLR1 traffics to the cell membrane to undertake the engulfment of modified 
lipoproteins and apoptotic bodies, cell fractionation was performed to allow assessment of 
cell membrane OLR1 protein levels. Quantification of western blotting revealed that, in line 
with total levels, membrane-localised expression of OLR1 was increased by HODHBt treatment 
of GM-Mac foam cells (2.1-fold; p<0.001; n=4; Figure 5.27). However, co-incubation of GM-
Mac foam cells with HODHBt and fasudil significantly decreased cell membrane protein 
expression of OLR1 (67 %; p<0.001; n=4; Figure 5.27), when compared to HODHBt alone. These 
findings indicate that while STAT5 upregulation of OLR1 is independent of F-actin cytoskeletal 
rearrangement, a competent actin cytoskeleton is necessary for OLR1 accumulation at the cell 





















Figure 5.26 Fasudil does not regulate total OLR1 protein levels in GM-Mac foam cells. 
Quantification and representative western blot for total cellular OLR1 expression in GM-Mac foam 
cells treated co-incubated with or without fasudil (10 µM) or HODHBt (100 µM) for 24 hours. Stain 
free gel is shown as a loading control. Data presented as fold change (mean ± SEM, ** indicates P< 
0.01 compared to GM-Mac + oxLDL, and GM-Mac + oxLDL + fasudil; ANOVA, Student-Newman-Keuls 
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Figure 5.27 Fasudil blunts HODHBt-mediated OLR1 membrane protein levels in GM-Mac foam cells. 
Quantification and representative western blot for OLR1 expression in the membrane fraction of GM-
Mac foam cells co-incubated with or without fasudil (10 µM) or HODHBt (100 µM) for 24 hours. Stain 
free gel is shown as a loading control. Data presented as fold change (mean ± SEM, *** indicates p< 
0.001 compared to GM-Mac + oxLDL, $ indicates p< 0.05 vs GM-Mac + oxLDL + HODHBt, $$$ indicates 
p< 0.001 vs GM-Mac + oxLDL + HODHBt. ANOVA, Student-Newman-Keuls Multiple Comparisons, n=4). 















































Previous studies have proposed that SUMOylation, a post-translational modification, may contribute 
an important role in the progression of atherosclerosis (Dehnavi, Sadeghi et al. 2019) . At a cellular 
level, SUMOylation can modulate the expression of numerous cytoskeletal proteins associated with 
the formation and function of actin filaments. Within macrophages, actin filaments can regulate their 
behaviour and function, including their migration, phagocytosis, and their transformation into foam 
cells, all processes associated with the development of atherosclerotic plaques. As such, the main goal 
of this chapter was to investigate the effect of SUMOylation on the properties of pro-inflammatory 
macrophages (GM-CSF polarised; GM-Mac), with particular focus on efferocytosis and foam cell 
formation given the results in the previous chapters. Furthermore, preliminary investigation into the 
signalling pathways regulated through SUMOylation were investigated, including their contribution to 
macrophage behaviour and relationship to the modulation of the actin cytoskeleton. 
 
5.3.1 Expression of SUMOylation pathway proteins in human atherosclerotic plaques 
Advanced human plaques with marked accumulation of foam cell macrophages are associated with 
heightened expression of GM-CSF levels which greatly exceeds the expression of M-CSF, favouring 
macrophage polarisation towards a more pro-inflammatory phenotype (Di Gregoli, Jenkins et al. 
2014). Furthermore, GM-CSF–directed macrophage polarisation has been associated with the 
development and progression of human atherosclerotic plaques, in part through promoting the 
protein levels of key deleterious proteases (such as MMP-12 and MMP-14) alongside suppressing 
TIMP-3 protein expression (Di Gregoli, Jenkins et al. 2014, Di Gregoli, Mohamad Anuar Nur et al. 2017, 
Di Gregoli, Somerville et al. 2020). Relatedly, STAT5 phosphorylation is significantly induced during 
GM-CSF-directed macrophage polarisation of macrophage, but not through M-CSF polarisation, and 
is therefore considered indicative of canonical GM-CSF–directed downstream signalling (Di Gregoli, 
Jenkins et al. 2014). In this chapter, it is shown that a high proportion of cells within the macrophage-
rich shoulder regions of human atherosclerotic plaques display STAT5 phosphorylation. This infers the 
accumulation of GM-polarised macrophages during plaque progression, as postulated by others 
(Waldo, Li et al. 2008) . Supporting modulation of the SUMOylation pathway during plaque formation, 
an increased percentage of cells expressing SUMO-1, -2, and -3 were detected in atherosclerotic 
compared to non-diseased coronary arteries. Interestingly, when assessing the foam cell macrophage-
rich intra-plaque regions where STAT5 phosphorylation was abundant, the proportion of cells 
expressing SUMO1, 2, and 3, were decreased in advanced unstable plaques compared to stable 




further investigation into the regulation of the SUMOylation pathway between macrophage subsets 




5.3.2 Effects of non-specific inhibition of SUMOylation on foam cell formation and 
efferocytosis in divergent macrophage subsets 
Findings presented within this thesis so far reveal that GM-CSF polarised macrophages display a 
heightened ability to uptake modified lipoproteins (oxLDL) and form foam cells in comparison to M-
CSF polarised macrophages, which is related to differences in their actin cytoskeleton. As such, it is 
proposed that the actin cytoskeleton may modulate endocytosis and phagocytosis of modified 
lipoproteins, and other related processes such as the efferocytosis of apoptotic bodies. However, the 
mechanisms underlying the disparities in function between GM-Mac and M-Mac subsets have yet to 
be fully elucidated. SUMOylation is a recently identified epigenetic/post-translational mechanism 
which has been suggested to regulate macrophage function during atherosclerosis (Dehnavi, Sadeghi 
et al. 2019). Accordingly, the effect of blocking SUMOylation on macrophage function was assessed 
within this chapter, utilising the broad-spectrum SUMOylation inhibitor topotecan. Topotecan was 
originally identified as a DNA topoisomerase inhibitor, and therefore can induce cell death and 
underlies it use as a chemotherapeutic agent. However, a non-cytotoxic concentration of topotecan 
was used in this chapter (0.25 µM) which suppressed foam cell formation in both pro- (GM-Mac) and 
anti-inflammatory macrophages (M-Mac) during different stages of maturation, implying a regulatory 
role for SUMOylation in macrophage foam cell formation. In support, a recent study demonstrated 
that a DNA topoisomerase II inhibitor (etoposide) was able to inhibit macrophage foam cell formation 
through enhancing reverse cholesterol transport via LXR-dependent upregulation of ABCA1 
expression  (de la Llera-Moya, Rothblat et al. 1992). Although the mechanism through which etoposide 
regulated LXR activity was not explored (and therefore not attributed to affecting SUMOylation, 
probably as SUMOylation was a poorly defined mechanism when this study was published), an 
ancillary study demonstrated that etoposide suppressed atherosclerotic plaque development in 
cholesterol-fed rabbits (de la Llera-Moya, Rothblat et al. 1992). However, another study has shown 
that treatment of mice with topotecan induced a significant lowering in serum HDL levels which was 
associated with a marked increase in cholesterol and triglyceride levels, effects expected to promote 




was not addressed in this study but highlighted that topotecan could modulate lipoprotein transport 
independent of chemotherapeutic mechanisms.  
As macrophage expression of scavenger receptors is essential for their phagocytosis of materials 
including modified lipoproteins, perhaps the aforementioned effects of topotecan on lipid profiles is 
in part through SUMOylation-dependent regulation of macrophage cholesterol transport? Associated 
assessment presented within this chapter show indeed that topotecan can downregulate the 
expression of select scavenger receptors in GM-Mac (CD36) and M-Mac subsets (MSR1 and OLR1) in 
the presence of oxLDL. In support, it was previously reported that administration of the topoisomerase 
inhibitor teniposide to Apoe KO mice fed a high cholesterol diet, reduced intra-plaque lipid 
accumulation within aortic root lesions, indicating suppressed foam cell accumulation, attributable to 
down regulation of LDLR and scavenger receptor class B type 1 (SRB1) expression alongside 
upregulation of the cholesterol efflux genes (Liu, Zeng et al. 2018). Collectively, these findings suggest 
a regulatory role of SUMOylation on the behaviour of different macrophage subsets with relevance to 
atherosclerosis, such as the repressed expression of scavenger receptors and ensuing oxLDL 
accumulation/foam cell formation.  
As mentioned previously, alongside the uptake of modified lipoproteins, efficient reverse transport 
including cholesterol efflux from macrophages ensures that modified lipoproteins do not adversely 
accumulate within cells. Considering the decreased foam cell formation observed within M-CSF or 
GM-CSF polarised macrophages with topotecan co-incubation, it is plausible that cholesterol efflux-
associated genes/proteins are dysregulated in addition to the observed increased scavenger receptor 
expression, and that regulation of SUMOylation reverses the deleterious effects. Indeed, the mRNA 
expression for select efflux regulators such as NCOR1, ABCA1, and ABCG1, were upregulated by the 
addition of topotecan (0.25 µM). This observation is supported by two previous studies which 
reported that addition of the topoisomerase II inhibitors etoposide or teniposide upregulated 
macrophage expression of ABCA1 and ABCG1 (Zhang, Jiang et al. 2013, Liu, Zeng et al. 2018). 
Accordingly, in the context of atherosclerosis SUMOylation would appear a detrimental process as 
addition of the global SUMOylation inhibitor topotecan to M-CSF polarised (M-Mac) or GM-CSF 
directed (GM-Mac) macrophage subsets, suppressed foam cell formation. These findings would 
support further studies to evaluate the potential athero-protective effects of topotecan However, the 
SUMOylation of individual proteins may impart beneficial effects on macrophages and other intra-
plaque cells (such as endothelial cells or VSMCs), as suggested previously (Dehnavi, Sadeghi et al. 
2019) , which would caution the therapeutic use of broad spectrum SUMOylation inhibitors for the 




Similar to the mechanism of oxLDL uptake, efferocytosis is a process in which immune cells, such as 
macrophages, can engulf apoptotic cell debris and remove dying cells, and is essential to prevent non-
resolving inflammatory diseases, such as atherosclerosis (Yurdagul, Doran et al. 2017). The findings in 
this chapter demonstrated that although GM-CSF polarised macrophages have impaired efferocytosis 
capacity compared to M-CSF polarised macrophages, blocking SUMOylation with topotecan restored 
their efferocytosis potential to comparable levels as that detected by M-CSF polarised macrophages. 
A previous study reported that similar to topotecan, the topoisomerase inhibitor teniposide imparted 
anti-inflammatory effects during cancer immunotherapy, which were associated with increased 
clearance of apoptotic cancer cells (efferocytosis) (Wang, Chen et al. 2019). Restoration of 
efferocytosis has been shown to prevent the progression of atherosclerotic plaques in mouse models, 
as it limits ensuing inflammation and prevents expansion of the necrotic/lipid-rich core (Schrijvers 
Dorien, De Meyer Guido et al. 2005). As such, the above findings provide further evidence that 
inhibition of SUMOylation could be a possible strategy to resolve atherosclerosis, limiting both 
macrophage foam cell formation while also promoting the clearance of apoptotic cells. 
However, the preliminary investigation of human coronary plaques within this thesis demonstrated a 
decreased proportion of cells positive for SUMO proteins within the foam cell macrophage-rich 
regions of histologically characterised unstable plaques compared to stable lesions. This would infer 
that SUMOylation is suppressed within advanced clinically-relevant plaques and argue against 
blocking SUMOylation to prevent plaque progression. Given that foam cell macrophages in unstable 
plaques display characteristics associated with the GM-Mac subset alongside an abundance of GM-
CSF and STAT5 phosphorylation, it is possible SUMOylation of STAT5 plays a role in atherosclerosis. 
Interestingly, our findings revealed that although STAT5 phosphorylation was detected in GM-CSF 
polarised foam cell macrophages, treatment with topotecan markedly increased pSTAT5 levels and its 
nuclear localisation. This novel observation suggests a prominent role of SUMOylation in the 
regulation of STAT5 signalling down-stream of GM-CSF induced polarisation of macrophages. 
Accordingly, a selective STAT5-SUMO protein-protein interaction inhibitor which blocks SUMOylation 
of phosphorylated STAT5 was deployed, named HODHBt. Specifically, HODHBt inhibits the binding of 
SUMO2/3 to STAT5 and subsequently maintains the phosphorylation and activation of STAT5, and its 
retention within the nucleus and subsequent interaction with STAT5 transcription factor binding sites 






5.3.3 Specific inhibition of STAT5 SUMOylation on foam cell formation and 
efferocytosis GM-CSF polarised macrophages  
In this study, and in line with proposed action of HODHBt, an increased number of GM-CSF polarised 
foam cell macrophages displayed STAT5 phosphorylation with heightened nuclear localisation after 
treatment with HODHBt, confirming SUMOylation of STAT5 occurs in GM-Macs. Pertinent to 
atherosclerosis and supporting the propositions suggested from the human coronary plaque 
investigations detailed within this chapter, suppressing STAT5 SUMOylation with HODHBt augmented 
foam cell formation in GM-Macs. Therefore, in opposition to broad-spectrum inhibition of 
SUMOylation, specifically retarding the SUMOylation of STAT5 (consequently sustaining STAT5 
phosphorylation and associated STAT5-dependent gene upregulation) would potentially accelerate 
atherosclerosis. Although the role of STAT5 signalling has not been directly assessed during 
atherosclerotic plaque formation and progression, some indirect evidence exists. For example, 
inhibition of JAK2 activity, a critical node between GM-CSF/STAT5 signalling, suppressed aortic 
atherosclerosis in Apoe KO mice, which was associated with reduced STAT5 phosphorylation in 
monocytes/macrophages (Tang, Liu et al. 2020). A previous study reported the relation between 
overproduction of GM-CSF and persistence of STAT5 phosphorylation (Litherland, Grebe et al. 2005), 
an association highlighted earlier in human advanced coronary atherosclerotic plaques. It has also 
been demonstrated that the presence of persistent levels of phosphorylated STAT5 is linked to other 
chronic inflammatory responses such as in thyroid autoimmune diseases (Litherland, Xie et al. 2005). 
Interestingly, it was shown that the effect of persistent STAT5 phosphorylation eventually becomes 
independent to GM-CSF levels (Litherland, Xie et al. 2005), perhaps through loss of STAT5 
SUMOylation. Accordingly, application of HODHBt to GM-Mac foam cells results in persistent STAT5 
phosphorylation, which may replicate the effect of GM-CSF overproduction.  
As shown earlier in this thesis, GM-CSF induces the polarisation of macrophages towards a pro-
inflammatory phenotype, and that GM-Mac are more able to accumulate lipid and form foam cells. 
As previously mentioned, GM-CSF polarised macrophages have reduced F-actin content, and the 
findings in this chapter showed that HODHBt administration further diminished the F-actin content in 
GM-CSF polarised foam cell macrophages, indicating that the cells additionally increase their GM-Mac 
properties, potentially as a result of sustained STAT5 phosphorylation. This proposition is supported 
by the increased expression of MMP-12 detected in GM-CSF polarised macrophages with HODHBt 
treatment. One of the potential mechanisms underlying the effect of heightened STAT5 
phosphorylation afforded by HODHBt on GM-Mac foam cell formation is modulation of OLR1 




treatment. Previous studies have confirmed OLR1 as a major scavenger receptor highly expressed in 
GM-Mac compared to its counterpart M-Mac (Di Gregoli and Johnson 2012).  
However, assessment of the transcription factor binding sites within the human OLR promoter 
revealed no STAT5 DNA-binding sites. Interestingly a previous study reported that upon 
phosphorylation and translocation to the nucleus, STAT5 can bind to POU2F1 (also known as OCT1) to 
form a stable complex and upregulate gene expression of cyclin D1 (Magné, Caron et al. 2003). Further 
assessment of the human OLR1 promoter revealed multiple POU2F1 DNA-binding sites, the most for 
any transcription factor, suggesting STAT5/POU2F1 complexes drive the upregulation of OLR1 in GM-
CSF-polarised foam cell macrophages. In agreement, data within this chapter demonstrated that co-
expression of nuclear pSTAT5 and POU2F1 are significantly increased in GM-CSF polarised 
macrophages with HODHBt treatment. This original finding indicates that STAT5-mediated 
transcription of OLR1 and subsequent foam cell formation in GM-Macs is in part dependent on 
POU2F1, although further investigations are needed to confirm this interaction. 
 
Previous data in this chapter demonstrated that global inhibition of SUMOylation with topotecan 
heightened the efferocytosis capacity of GM-Macs. However, suppression of STAT5 specific 
SUMOylation with HODHBt did not affect efferocytosis capacity in GM-Macs, but efferocytosis was 
augmented in GM-CSF-polarised foam cells. The disparate effect of HODHBt treatment on 
efferocytosis between macrophages and foam cell macrophages suggest oxLDL uptake and foam cell 
formation may regulate SUMOylation of STAT5 and subsequent heightened efferocytosis in GM-Macs. 
Accordingly, to understand the mechanism underlying the increased efferocytosis  observed in GM-
Mac foam cells afforded through HODHBt-dependent augmented STAT5 activity, two potential 
mechanisms were proposed; regulation reliant on Ca+2 signalling, or actin cytoskeleton rearrangement 
(Tajbakhsh, Rezaee et al. 2018). Nifedipine and fasudil were deployed respectively to interrogate the 
involvement of these processes. Previous study reported that calcium channel blocker (diltiazem) 
significantly inhibits the expression and activity of LOX-1 and results in decreasing the apoptosis of 
VSMCs with high glucose levels (Rudijanto 2010). Results revealed that fasudil attenuated the 
efferocytosis capacity of HODHBt treated GM-CSF polarised foam cell macrophages, whereas 
nifedipine was ineffective. These findings suggest that upregulated efferocytosis in GM-CSF polarised 
foam cell macrophages afforded through sustained STAT5 activity with HODHBt, is dependent on 
modulation of the actin cytoskeleton. These observations are similar to those seen for oxLDL 
accumulation and foam cell formation in GM-Macs, which are considered to be OLR1-mediated due 
to the aligned changes in expression of this scavenger receptor. Intriguingly, OLR1 has been shown to 




(Moriwaki, Kume et al. 1998), and consequently OLR1 can promote efferocytosis through recognition 
of PS-presenting apoptotic bodies (Chen, Masaki et al. 2002, Murphy, Tacon et al. 2005). Considering 
fasudil blocked HODHBt-mediated efferocytosis in GM-Mac foam cells, while OLR1 expression was 
increased with HODHBt treatment (Figure 5.18), effects on the actin cytoskeleton may alter OLR1 
expression within GM-Mac foam cells with sustained STAT5 activity. Indeed, fasudil administration 
significantly downregulated GM-Mac foam cell membrane expression of OLR1, without affecting total 
cellular levels. Collectively, these findings suggest that inhibition of STAT5 SUMOylation and 
subsequent STAT5-mediated upregulation of OLR1 is independent of F-actin cytoskeletal 
rearrangement. However, a competent actin cytoskeleton is required for OLR1 accumulation at the 
cell membrane and associated efferocytosis capacity, and perhaps oxLDL engulfment. 
In conclusion, HODHBt, which blocks SUMOylation of phosphorylated STAT5 and subsequently 
maintains the phosphorylation and activation of STAT5, augmented foam cell formation in GM-Macs, 
diminished the F-actin content with the cells, and heightened the efferocytosis capacity in GM-CSF 
polarised foam cells. However, fasudil co-incubation attenuated the efferocytosis capacity of HODHBt 
treated GM-CSF polarised foam cell macrophages and significantly downregulated cell membrane 
expression of OLR1, suggesting the requirement of actin cytoskeleton for the accumulation of OLR1 at 





















Atherosclerosis is a chronic inflammatory disease affecting medium- and large-sized arteries, and is 
characterised by the presence of heterogenous populations of macrophages (Stout and Suttles 2004). 
Different growth factors and cytokines have been proposed as key effectors of macrophage 
polarisation towards pro- and anti-inflammatory subsets, with the caveat that most studies are 
performed in vitro. However, M-CSF and GM-CSF have been shown to promote distinct macrophage 
subsets which are not only characterised by differential expression of specific genes, but also display 
discrete morphologies (Waldo, Li et al. 2008). Moreover, multiple studies have inferred that GM-CSF 
polarised macrophages, also termed GM-Mac, preferentially populate advanced atherosclerotic 
plaques and associate with their progression, through the deployment of protein markers specific for 
the GM-Mac subset (Waldo, Li et al. 2008, Di Gregoli, Jenkins et al. 2014, Di Gregoli, Mohamad Anuar 
Nur et al. 2017, Di Gregoli, Somerville et al. 2020). Considering the contrasting morphologies between 
the M-Mac and GM-Mac subsets, it is salient to reflect that the actin cytoskeleton is central to 
modulating the shape of cells (Karp 2010). Accordingly, in this thesis changes in the actin cytoskeleton 
between different macrophage phenotypes were explored, alongside examining the effects of actin 
perturbing drugs (such as fasudil and pravastatin) on macrophage subset gene expression and 
associated behaviour. With the aim that actin perturbing drugs could be deployed therapeutically to 
modulate macrophage subset function and hence suppress the progression of atherosclerosis. 
ROCK exists as two isoforms (ROCK1 and ROCK2) and is the first down-stream kinase activated by RhoA, 
a member of the Rho family of small GTPases. ROCK1/2 and RhoA are well-characterised regulators of 
the actin cytoskeleton and have also been ascribed a role in atherogenesis. In support of this 
proposition, administration of a ROCK1/2 inhibitor (Y-27632) to Ldlr-deficient mice inhibited the 
formation of atherosclerotic plaques within the aortic sinus and thoracic aorta, which was associated 
with reduced ROCK1/2 activity (Mallat, Gojova et al. 2003). Similarly, ROCK1/2 inhibition in Apoe-
deficient mice through delivery of fasudil suppressed atherosclerotic plaque formation within the 
brachiocephalic and common carotid arteries (Wu, Xu et al. 2009). Furthermore, the same study 
demonstrated that delayed administration of fasudil could retard progression of established plaques, 
which was associated with limiting intra-plaque macrophage accumulation (Wu, Xu et al. 2009). Taken 
together, these studies strongly suggest that modulation of the actin cytoskeleton in macrophages 
through inhibition of ROCK1/2 maybe exploited for targeting atherosclerosis therapeutically. However, 
fasudil administration to Apoe-deficient mice co-infused with Ang II (to induce vascular inflammation 
and aortic aneurysm formation), had no effect on carotid artery and aortic arch atherosclerotic lesion 
area (Wang, Martin-McNulty et al. 2005).  
Considering it is now well accepted that macrophages display marked heterogeneity with divergent 




macrophage subsets. Accordingly, both fasudil and pravastatin were deployed in this thesis as 
ROCK1/2 inhibitors, albeit acting through different mechanisms, to assess the effects of actin 
cytoskeleton modulation on the behaviour of different macrophage subsets. The results show that 
both fasudil and pravastatin alter the morphology of M-CSF or GM-CSF polarised macrophages (M-
Mac and GM-Mac, respectively) which was associated with reduced F-actin accumulation. 
Consequently, changes in cell shape are usually associated with alterations in cell behaviour, which 
may also include macrophage polarisation. Indeed, pravastatin or fasudil administration to GM-Macs 
decreased the expression of MMP-12 (a robust marker of the GM-Mac subset), while the levels of 
TGFβ (an anti-inflammatory marker) was increased, suggesting that pravastatin (and by inference 
actin depolymerisation) favours macrophage polarisation towards an anti-inflammatory phenotype. 
In support, a previous study reported that macrophages within atherosclerotic aortic aneurysms of 
patients receiving atorvastatin or simvastatin therapy shifted towards an anti-inflammatory 
phenotype, compared to lesions from placebo-treated individuals (van der Meij, Koning et al. 2013). 
This suggests that modulation of the actin cytoskeleton (via fasudil or pravastatin) influences 
macrophage phenotype, and may also exert direct or indirect effects on their behaviour. 
Macrophages within atherosclerotic plaques are able to uptake oxLDL via scavenger receptors and 
thereupon transform into macrophage foam cells, a process which is considered central to the 
development and progression of atherosclerosis (Glass and Witztum 2001). As mentioned previously, 
administration of ROCK1/2 inhibitors to atherosclerotic mice influences disease development and 
progression, an effect attributed to diminished macrophage foam cell formation (Mallat, Gojova et al. 
2003, Wu, Xu et al. 2009). In agreement, bone marrow-restricted deficiency of ROCK1 blunted 
macrophage phagocytic capacity and associated foam cell formation, translating in vivo to reduced 
development of aortic atherosclerosis (Wang, Liu et al. 2008). Likewise, loss of ROCK2 in bone marrow-
derived macrophages resulted in decreased foam cell formation and suppressed atherosclerotic 
plaque generation in Ldlr-knockout mice, ascribed to increased cholesterol efflux through 
upregulation of the PPARɣ/LXR/ABCA1 pathway (Zhou, Mei et al. 2012). Accordingly, the ROCK1/2 
signalling pathway, which is a central regulator of the actin cytoskeleton, promotes macrophage foam 
cell formation and atherosclerosis. However, if such effects are observed in all macrophages, such as 
disparate phenotypes, has not been discerned. 
As with previous observations, monocytes (THP-1 human monocytic cell line) and macrophages readily 
accumulated oxLDL and transformed into foam cells, and in agreement with recent evidence, 
demonstrated that monocytes are able to accumulate modified lipoproteins (Mosig, Rennert et al. 
2008, Mosig, Rennert et al. 2009). However, disparities were observed between M-CSF and GM-CSF-




foam cells after prolonged exposure to oxLDL, compared to M-CSF treated monocytes. This novel 
observation is aligned with those from Mosig and colleagues, who demonstrated differential oxLDL 
accumulation between divergent monocyte subsets, retrieved from patients with familial 
hypercholesterolaemia (Mosig, Rennert et al. 2009). Monocyte uptake of modified lipoproteins 
require the modulation of their actin cytoskeleton via the regulation of RhoA activity (Jackson, 
Weinrich et al. 2016). In agreement our study showed that the administration of fasudil reduced the 
GM-CSF-treated monocyte oxLDL accumulation. Similarly, GM-CSF polarised macrophages 
accumulated more oxLDL compared to M-CSF polarised macrophages derived from either THP-1 cells 
or human PBMCs, which was reduced with the administration of fasudil or pravastatin, mirroring the 
effects observed in monocytes. It is possible that the prolonged exposure of GM-CSF-stimulated 
monocytes to oxLDL induces their adhesion and accelerates their subsequent maturation into 
macrophages, which would require actin cytoskeleton rearrangement, and consequently promote 
oxLDL uptake – in part explaining the observed effects of fasudil co-administration. Indeed, previous 
evidence suggests select monocyte subsets mature into macrophages in response to oxLDL, which is 
then rapidly taken up by the cell (Mosig, Rennert et al. 2009). 
Fasudil or pravastatin suppressed oxLDL accumulation and foam cell formation in GM-CSF polarised 
macrophages which accompanied with altered expression of key scavenger receptors and 
genes/proteins associated with cholesterol efflux. Our findings showed that the protein expression of 
two key scavenger receptors, OLR1 and CD36, were decreased in GM-CSF polarised macrophages with 
co-incubation of fasudil or pravastatin, implying a role for the modulation of the actin cytoskeleton 
during macrophage foam cell formation. Conversely, while ABCG1, NCOR1, and PPARα protein levels 
were not changed by exposure to oxLDL, they were significantly increased by co-incubation with 
fasudil or pravastatin, indeed suggesting enhanced cholesterol efflux ability. Congruent findings 
reported PPARα protects macrophages from foam cell formation (Li, Binder et al. 2004, Srivastava 
2011). A study on isolated peritoneal macrophages from type 2 diabetic mice showed that 
downregulation of the expression of ABCG1 resulted in 2-fold increase in the accumulation of 
esterified cholesterol and subsequently increased foam cell formation in macrophages (Mauldin, 
Srinivasan et al. 2006). Another study on myeloid cell-specific NCOR1 knockout mice showed that 
deficiency of the expression of NCOR1 in macrophages increased the ability of macrophages to uptake 
oxLDL and form foam cells due to the upregulation in the expression of CD36 which was associated 
with the progression of atherosclerosis (Oppi, Stein et al. 2019). Collectively, the above findings 
suggest that perturbation of actin cytoskeleton reorganisation blunts GM-CSF-polarised macrophage 




Comparable to phagocytosis and uptake of modified lipoproteins, efficient efferocytosis is associated 
with alterations of the cell membrane through rearrangement of cells actin cytoskeleton. Defective 
efferocytosis is related to atherosclerotic plaque progression through necrotic/lipid core expansion 
and perpetuating a pro-inflammatory environment (Thorp and Tabas 2009). In line with attributing a 
deleterious role to GM-CSF polarised macrophages during plaque advancement and instability, GM-
Macs displayed decreased efferocytosis capacity compared to M-Macs. However, impaired 
efferocytosis by GM-CSF polarised macrophages was restored to M-Mac levels through co-incubation 
with either fasudil or pravastatin. Although these novel observations are the first to demonstrate 
divergent efferocytosis capacities between macrophage subsets which can be modulated by actin-
perturbing drugs, there is supporting evidence for the RhoA/ROCK pathway regulating macrophage 
efferocytosis. For example, lovastatin increased the efferocytosis capacity of macrophages in both in 
vitro and in vivo studies by inactivating the RhoA signalling pathway (Morimoto, Janssen et al. 2006). 
Relatedly, administration of a ROCK inhibitor (Y-27632) to a macrophage cell line increased their 
engulfment of apoptotic bodies (Tosello-Trampont, Nakada-Tsukui et al. 2004). Moreover, directly 
suppressing RhoA activity with a dominant negative approach also promoted macrophage clearance 
of apoptotic cells (Nakaya, Tanaka et al. 2006).  
In advanced human plaques, with marked localised accumulation of foam cell macrophages, the 
expression of GM-CSF is heightened, favouring the polarisation of macrophages towards a pro-
inflammatory phenotype (Di Gregoli, Jenkins et al. 2014). In line with this proposition, we 
demonstrated that STAT5 phosphorylation (an indicator of GM-CSF-induced signalling) was abundant 
within the foam cell macrophage-rich shoulder regions of human advanced atherosclerotic plaques. 
Recent evidence has suggested that SUMOylation and phosphorylation of STAT5 act antagonistically 
to each other (Krämer and Moriggl 2012), and that blocking SUMOylation of STAT5 potentiates its 
phosphorylation and translocation to the nucleus to drive gene expression (Bosque, Nilson et al. 2017). 
Interestingly, SUMOylation can also regulate actin polymerisation and other key processes related to 
the organisation and remodelling of the cytoskeleton (Alonso, Greenlee et al. 2015). As such, 
SUMOylation may represent a novel mechanism of GM-Mac responses related to their actin 
cytoskeleton and accumulation of modified lipoproteins. Supporting this proposition, further analysis 
of human plaques revealed increased expression of SUMO-1, -2, and -3 compared to non-diseased 
coronary arteries inferring the SUMOylation pathway is modulated during plaque formation. 
Importantly however, the percentage of SUMO-1, -2, and -3 positive cells within foam cell 
macrophage-rich regions of advanced unstable plaques, was decreased compared to stable lesions, 
suggesting that SUMOylation is reduced in foam cell macrophages during the progression of 




macrophages would be expected to suppress atherosclerotic plaque progression, while conversely, 
inhibition of the SUMOylation could accelerate atherosclerosis. 
The studies within this thesis using human PBMC-derived macrophages suggested that in the context 
of atherosclerosis, the SUMOylation pathway is deleterious as pan-SUMOylation inhibition (with 
topotecan) blunted foam cell formation in both M-CSF (M-Mac) or GM-CSF directed (GM-Mac) 
macrophage subsets. The blocking of SUMOylation was associated with decreased expression of 
important scavenger receptors that mediate oxLDL uptake, including CD36, MSR1, and OLR1. 
Conversely, levels of the key cholesterol efflux genes/proteins ABCA1, ABCG1, and NCOR1 were 
elevated by inhibition of SUMOylation. These dual effects would be expected to perturb macrophage 
foam cell formation, in keeping with the effect observed when blocking SUMOylation. These findings 
would support further studies to evaluate the potential athero-protective effects of topotecan-
induced pan-SUMOylation inhibition. However, the SUMOylation of individual proteins may also 
impart beneficial effects on macrophages and other intra-plaque cells (such as endothelial cells or 
VSMCs), as suggested previously (Dehnavi, Sadeghi et al. 2019), while the mechanism-of-action of 
topotecan as a topoisomerase I inhibitor also induces apoptosis of proliferating cells. These 
considerations would caution the therapeutic use of broad spectrum SUMOylation inhibitors for the 
treatment of atherosclerosis. To circumvent these potential caveats, focussing on key proteins or 
pathways dominant in GM-CSF-polarised macrophages may reveal specific SUMOylation targets that 
give rise to athero-protective effects.  
Relatedly and surprisingly, phosphorylation levels of STAT5 were increased within GM-Macs after 
topotecan administration, suggesting that SUMOylation dampens the activity of STAT5 and down-
stream target gene expression. To confirm this proposition, HODHBt, a selective STAT5-SUMO protein-
protein interaction inhibitor which blocks SUMOylation of phosphorylated STAT5 resulting in 
sustained pSTAT5 transcriptional activity was deployed. As expected, specifically blocking 
SUMOylation of STAT5 in GM-Macs resulted in heightened levels of STAT5 phosphorylation alongside 
retaining its accumulation within the nucleus, which translated to increased expression of MMP-12. 
However, in opposition to the effects observed with suppressing global-SUMOylation, this observation 
would imply that SUMOylation of STAT5 is a protective mechanism, as evidenced by the elevation in 
MMP-12 levels when SUMOylation of STAT5 is suppressed. Supporting a beneficial role for 
SUMOylation of STAT5 in GM-Macs, oxLDL-induced foam cell formation was increased in GM-Macs 
through suppression of STAT5 SUMOylation with HODHBt. Therefore, these findings suggest that loss 
of STAT5-targetted SUMOylation results in sustained STAT5 activation and signalling, subsequently 
augmenting the pro-inflammatory and pro-atherosclerotic phenotype of GM-Macs through 




The enhanced foam cell formation afforded from perturbing STAT5 SUMOylation was associated with 
increased expression (both mRNA and protein level) of OLR1, providing a potential mechanism for 
augmented oxLDL accumulation within HODHBt-treated GM-Macs. However, no STAT5 DNA-binding 
sites could be identified within the OLR1 promoter region, arguing against STAT5 directly regulating 
OLR1 expression. The most prevalent predicted binding sites were for POU2F1 (also known as OCT1), 
a transcription factor shown to upregulate macrophage OLR1 expression and therefore promote 
subsequent foam cell formation (Hu, Hui et al. 2020). Moreover, activated STAT5 can bind to POU2F1 
to transactivate target gene expression (Magné, Caron et al. 2003), raising the intriguing possibility 
that STAT5/POU2F1 complexes drive the upregulation of OLR1 in GM-CSF-polarised foam cell 
macrophages. In support, augmented pSTAT5 and POU2F1 co-localisation was detected within the 
nuclei of GM-CSF polarised macrophages after suppression of STAT5 SUMOylation. This novel finding 
implies that STAT5-mediated transcription of OLR1 and subsequent enhanced efferocytosis and foam 
cell formation in GM-Macs, is in part dependent on POU2F1, and moderated by the sustained STAT5 
activity afforded from blocking its SUMOylation. However, these original observations require further 
investigation and validation to confirm this interaction, including assessing the effects of GM-CSF 
polarisation and early foam cell formation on the expression levels of POU2F1. 
It has also been previously shown that OLR1 is able to bind phosphatidylserine (PS), and can therefore 
recognise PS-presenting apoptotic cells and promote efferocytosis (Moriwaki, Kume et al. 1998). 
Although, blocking SUMOylation of STAT5 in GM-Macs did not affect their efferocytosis capacity, it 
was significantly increased in GM-Mac foam cells. This observation suggests that the uptake of oxLDL 
and the formation of foam cells in GM-Macs may regulate the expression of SUMO proteins (or their 
inhibitors) and associated SUMOylation of STAT5, and therefore increase their efferocytosis capacity 
through upregulation of OLR1. Indeed, in Chapter 4 it was reported that OLR1 expression was 
increased in GM-Macs during foam cell formation, an effect which was interestingly suppressed by 
the actin-perturbing drugs fasudil or pravastatin. Connectedly, the inhibition of STAT5 SUMOylation 
decreased the F-actin content within GM-Macs, implying depolymerisation of F-actin and re-
organisation of the cytoskeleton are STAT5-dependent. Moreover, as fasudil was able to attenuate 
the increased efferocytosis observed in HODHBt-treated GM-Macs, this indicates that the enhanced 
efferocytosis capacity in GM-CSF polarised macrophage foam cells is dependent on the modulation of 
the actin cytoskeleton. It must be noted however, that efferocytosis is commonly considered an 
athero-protective process due to its function of clearing apoptotic cells and limiting ensuing pro-
inflammatory secondary necrosis. Conversely, enhanced efferocytosis may also impart detrimental 
effects, particularly in advanced plaques where foam cell macrophages are abundant. Indeed, it has 




perpetuates foam cell formation due to the breakdown and release of neutral lipids from the cell 
membrane of apoptotic cells, particularly within pro-inflammatory macrophage subsets (Ford, 
Zeboudj et al. 2019). This evidence would align with a detrimental role for GM-CSF polarised 
macrophages during atherosclerotic plaque progression. 
Accordingly, oxLDL uptake and foam cell formation may suppress SUMOylation of STAT5 and 
subsequently augment efferocytosis in GM-Macs, through a mechanism dependent upon actin 
cytoskeleton remodelling and the expression of OLR1. Interestingly, blunting remodelling of the actin 
cytoskeleton with fasudil had no effect on total OLR1 protein levels in GM-Mac foam cells treated with 
HODHBt but did markedly reduce membrane expression. Therefore, suggesting that actin 
cytoskeleton remodelling is necessary for translocation of OLR1 to the cell membrane and the 
associated heightened efferocytosis capacity detected in GM-Mac foam cells that display 
SUMOylation-dependent sustained STAT5 activity. Accordingly, these connected novel regulatory 
mechanisms (as summarised in Figure 6.1) support and underpin the proposed deleterious role of GM-
CSF polarised macrophages in atherosclerotic plaque progression and instability. It can be proposed 
that; 1) increased GM-CSF within advanced atherosclerotic plaques favours macrophage polarisation 
towards a pro-inflammatory phenotype with associated increased expression of scavenger receptors; 
2) subsequent increased uptake of oxLDL and early foam cell formation suppresses the SUMOylation 
pathway, specifically of STAT5 (the main transcription factor in GM-CSF signalling), enhancing STAT5 
activation and target gene upregulation; 3) increased expression of OLR1 and its translocation to the 
membrane facilitates enhanced oxLDL uptake and efferocytosis of neighbouring apoptotic 
macrophages, perpetuating foam cell size and propensity to die; 4) STAT5 directly or indirectly 
regulates remodelling of the actin cytoskeleton to facilitate OLR1 membrane translocation alongside 
phagocytosis and efferocytosis mechanisms.  
In conclusion, modulation of the actin cytoskeleton (via fasudil or pravastatin) influences macrophage 
phenotype and may also exert direct or indirect effects on their behaviour such as polaristion. 
Furthermore, perturbation of actin cytoskeleton reorganisation blunts GM-Macs foam cell formation 
through suppressed oxLDL uptake and augmented cholesterol efflux. Moreover, foam cell 
macrophage-rich intra-plaque regions in advanced unstable plaques shows increased STAT5 
phosphorylation and decreased SUMO1, 2, 3 expression implying SUMOylation is reduced. 
Accordingly, regulation of SUMOylation pathway especially with regard to GM-CSF/STAT5 pathway 
(via HODHBt or perhaps due to the uptake of oxLDL and foam cell formation) suppresses SUMOylation 
of STAT5 and activates STAT5 via phosphorylation. Phosphorylated STAT5 with POU2F1 forms a stable 
complex and upregulates target genes such as MMP-12 and OLR1. Increased expression of OLR1 and 




indirectly by STAT5) facilitates efferocytosis and enhanced oxLDL uptake (Figure 6.1). However, 
perturbation of actin cytoskeleton reorganisation (via fasudil) blunts the translocation of OLR1 to the 
membrane. Taken together, actin cytoskeleton regulates the inflammatory phenotype of 
macrophages, including the novel regulation by STAT5 SUMOylation, suggesting that targeting actin 
cytoskeleton remodelling in GM-CSF polarised macrophages, may have therapeutic potential for 













Figure 6.1 Schematic representation of our finding in GM-CSF polarised macrophages. 
STAT5 signalling pathway is activated in pro-inflammatory macrophages (GM-Macs). Activation of 
STAT5 occurs via phosphorylation. Phosphorylated STAT5 enters the nucleus and binds to POU2F1 to 
form a stable complex that can activate target genes including MMP12 and OLR1. OLR1 requires the 
rearrangements of actin cytoskeleton (regulated directly or indirectly by STAT5) for its translocation 
and accumulation at the cell membrane, which is associated with efferocytosis capacity, and perhaps 
oxLDL engulfment. SUMOylation and phosphorylation of STAT5 act antagonistically. Accordingly, 
inhibition of SUMOylation of STAT5 (via HODHBt or perhaps due to the uptake of oxLDL and foam cell 
formation) retain the activation and phosphorylation of STAT5.  
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There are several limitations associated with the findings presented in this thesis that are addressed 
throughout. However, some salient caveats are discussed here. For example, fasudil and pravastatin 
were used to modulate the actin cytoskeleton within different macrophage subsets. Although both 
fasudil and pravastatin can serve as actin perturbing drugs due to their capacity to modulate 
Rho/ROCK activity, they also affect other related and unrelated (in the case of pravastatin) signalling 
pathways. As such, in future experiments it would be sensible to deploy more direct F-actin filament 
disrupting reagents, such as cytochalasin D and latrunculin B, alongside adoption of an F-actin 
filament-stabilising reagent such as, jasplakinolide to validate the findings made in this study.  
Although the bulk of studies within Chapter 5 were performed in human PBMC-derived 
monocyte/macrophages, some of the initial findings in Chapters 3 and 4 were only undertaken in 
macrophages differentiated from THP-1 cells, a human monocytic cell line. Therefore, these studies 
would benefit from validation in human PBMC- derived macrophages. 
Throughout this thesis, F-actin content and associated quantification was performed using 
fluorescently-conjugated phalloidin labelling, but the expression of monomeric G-actin was not 
assessed. The formation of the actin cytoskeleton and its remodelling is regulated by the 
polymerisation and depolymerisation of F-actin and is best interrogated through the assessment of 
both F-actin and G-actin content within cells. Therefore, future experiments would ideally also 
examine G-actin content and quantify the G-actin/F-actin ratio between the different macrophage 
subsets. 
In Chapter 3, it is suggested that in comparison to GM-Macs, the anti-inflammatory M-Macs display 
enhanced TGFβ-mediated signalling through increased SMAD3 phosphorylation, which is dependent 
upon Rho/ROCK activity, and by inference, remodelling of the actin cytoskeleton. This proposition 
warrants further investigation as it may explain the relationship between F-actin cytoskeleton 
alteration during differential macrophage polarisation and associated anti- and pro-inflammaotry 
actions, such as TGFβ-mediated signalling. 
In this thesis, the majority of the studies were conducted in vitro, which while facilitating extensive 
experimentation, is far removed from the in vivo pathophysiological relevant setting. The investigation 
of the key findings in an animal model of atherosclerosis (such as the high fat-fed Apoe-deficient 





6.2 Future work 
 
Due to restrictions in time and available funding, the work proposed below could not be performed 
during this PhD but would form salient future work. 
Chapter 3. In chapter 3 we demonstrated that co-incubation of GM-CSF polarised macrophages with 
fasudil (10 µM) and pravastatin (5 µM) did not change the mRNA expression of MMP12. On the other 
hand, the protein expression of MMP-12 was significantly decreased, suggesting the involvement of 
posttranscriptional modification. This finding would benefit from further investigation to evaluate the 
posttranscriptional mechanisms underlying this discrepancy, such as identification and assessment of 
microRNA-regulation of MMP-12 in GM-CSF polarised macrophages. 
In this study we demonstarted that fasudil adminstration to M-Macs blunted TGFβ signalling (as 
evidenced by reduced pSMAD3 and TGFBI expression), which could not be rescued through the 
addition of recombinant TGFβ. Fasudil did not alter the mRNA or protein expression of any TGFβ 
receptors in M-Macs, or their responsiveness to TGFβ, as shown through assessment of pSMAD3 after 
deployment of a TGFβ neutralising antibody. Therefore, it can be proposed that the inhibitory effect 
of fasudil on the TGFβ signalling pathway within M-Macs is in between TGFβ receptor activation and 
phosphorylation of SMAD3, or upon another pathway/mechanism that modulates SMAD3 levels 
and/or phosphorylation and subsequnet down-stream signalling. These aspects would benefit from 
further investigation.  
Chapter 4. In Chapter 4 we demonstrated that addition of oxLDL to GM-CSF polarised macrophages 
significantly increased the expression of efflux genes ABCG1, NCOR1, and PPARA at mRNA level, an 
effect which was unaffected by co-incubation with fasudil, but suppressed with the addition of 
pravastatin for ABCG1 and NCOR1 levels. Discrepant observations were observed at the protein level, 
with oxLDL exerting no change in the expression of ABCG1, NCOR1, and PPARα, while co-incubation 
with fasudil or pravastatin significantly increased their protein expression. Suggesting that fasudil and 
pravastatin enhance cholesterol efflux proteins (and therefore mechanism) in GM-CSF polarised 
macrophages through a post-transcriptional mechanism that needs further investigation.  
Some similar discrepancies were observed between the mRNA and protein levels of CD36 and OLR1, 
similarly suggesting the involvement of a posttranscriptional mechanism which warrants additional 
examination.  
Chapter 5. In Chapter 5 we demonstrated that co-incubation of GM-CSF polarised macrophages with 




cooperation of POU2F1 in STAT5 in transactivation of OLR1 gene expression. However, further 
investigation and experimentation is needed to confirm and validate these findings. This could include 
CHIP assays alongside determination if POU2F1 silencing/knockdown reduces STAT5 associated 
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